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Abstract 
 
Cardiac patches comprised of embryonic stem cell derived cardiomyocytes (ESC-CMs) 
attached to biodegradable polymeric substrates were developed for patients suffering 
from heart attacks. Cardiomyocytes were derived from mouse and human embryonic 
stem cell (ESC). Thermoplastic elastomeric (TPE) block co-polymers poly(ethylene 
terephthalate)/dilionic acid  (PET/DLA), a relatively slow degrading biomaterial, served 
as substrates to deliver cardiomyocytes and to further support the myocardium after an 
infarct. Additionally, titanium dioxide (TiO2) nanoparticles (NPs) (mean size 23 nm), 
were incorporated in the PET/DLA polymer in a concentration of 0.2wt%. Results 
showed TiO2 NPs to effect polymer mechanical properties, increasing material stiffness 
and tensile strength. The surface roughness and hydrophilicity of the biomaterial also 
increased upon addition of TiO2 NPs. It was found that 0.2wt% TiO2 NP addition 
enhanced cellular adhesion, spread and proliferation. A fibroblastic cell line, used to test 
proliferation, proliferated on both biomaterials with and without pre-gelatin coating. 
Lactate dehydrogenase (LDH) release into culture media, used as a marker of cell death 
did not differ significantly between biomaterials and tissue culture plastic (TCP). The 
cytotoxicity of TiO2 NPs on adult cardiomyocytes, hESC-CMs and fibroblasts was also 
investigated at various concentrations (0-150 ppm) chosen based on their relevance for 
the intended application of the biomaterial. At 10 ppm the particles had no significant 
acute effect on cardiac contractility of either adult rat heart cells or hESC-CM. 
However, functional activity was significantly reduced, in terms of beating rate, over 
longer culture periods (4h). Further improvements were carried out to enhance the 
properties of the patch. The investigation included: i) lactide addition to the polymer to 
increase polymer degradation rate and ii) topographical surface changes introduced by a 
phase separation micromoulding technique (PSµM). Newly developed biomaterial was 
faster degrading (as measured by biomaterial %weight loss) and simultaneously 
encouraged fibroblast proliferation. Finally the biomaterials have been investigated ex 
vivo and in vivo by collaborators at NHLI (Imperial College London). The results have 
confirmed that the developed biomaterials in conjunction with cardiomyocytes from 
ESCs are promising for applications in myocardial tissue engineering (MTE) strategies 
with no adverse effect on cardiac functionality detected. 
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1 Introduction 
 
1.1 Background 
 
Heart attack (also known as myocardial infarction (MI)), is one of the major causes of 
death world wide, which occurs when a blood vessel in the coronary artery is blocked, 
diminishing nutrients and oxygen supply and causing ischemia with eventual cell death 
to the affected part of the myocardium. The inability of mature cardiac cells to divide to 
repair the damaged tissue, leads to scar tissue formation which has different electrical 
properties to that of the uninjured heart. This coupled with the lack of effective 
treatment eventually leads to heart failure. At end stage, organ transplant is the only 
option. However, due to shortage in donors, many patients die while waiting on the 
shortlist. Therefore, other alternatives are sought with cell therapy being a viable option.  
 
Attempts to regenerate the lost tissue via cardiac stem cells either resident in the heart, 
or recruited to the heart from bone marrow have been attempted without success. To 
repair the damaged tissue with contractile cells from skeletal muscle or with cardiac 
cells formed from bone marrow cells and embryonic stem cells (ESCs) have been 
considered. The current method of introducing these cells into the heart is via injection 
of cells into either the coronary circulation or directly into the heart muscle. The lack of 
knowledge on the best method of delivery of cells to the desired site without cell loss 
has encouraged scientists to explore alternative approaches such as tissue engineering 
(TE).  
 
Cardiac TE attempts to repair or regenerate a damaged section of the heart. It involves 
the synthesis of a biocompatible scaffold or patch combined with cells. The main 
function of the biomaterial is to act as the cell’s transport vehicle, to ensure cells are 
delivered to the scarred tissue while the cells integrate with the heart muscle, forming 
new myocardial tissue.  Biomaterials research is a broad subject area in which material 
scientists and engineers are constantly looking for improved candidates suitable for TE. 
So far, both synthetic (e.g. poly-co-glycolic acid (PLGA)) and natural polymers 
(including collagen and alginate) have been proposed for cardiac TE. Although no 
tissue engineered cardiac system has been approved for clinical use. 
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1.2 Aims and objectives 
 
The overall aim of the investigation is to develop an optimized ‘cardiac patch’ for 
myocardial tissue engineering (MTE). To achieve this, an attempt has been made to 
synthesize a suitable substrate made from a biocompatible polymeric material to 
‘deliver’ human embryonic stem cell derived cardiomyocytes (hESC-CM) to the desired 
site of the heart, by stitching the patch onto the infarct region and to restrict ventricular 
enlargement, which occurs following a myocardial infarct.  
 
The specific objectives of the investigation include: 
 
- Develop and characterize two different polymeric materials poly(ethylene 
terephthalate)/dilionic acid (PET/DLA) and PET/DLA-0.2wt%TiO2. Their 
biocompatibility, surface morphology and mechanical properties are of main 
interest. 
- Generate mouse embryonic stem cell derived cardiomyocytes (mESC-CMs) and 
human embryonic stem cell derived cardiomyocytes (hESC-CMs) and quantify 
the percentage obtained. 
- Investigate the cell-biomaterial interactions in terms of ESC-CM adhesion and 
spread, viability, contractile functions. Furthermore, the proliferation and cell 
death of fibroblasts on the polymeric substrates was also investigated. 
- Determine the toxicity effect of the TiO2 NPs on hESC-CMs, adult 
cardiomyocytes and fibroblasts. 
- Further enhance the biomaterials by introducing surface topographical changes 
to encourage cell alignment and ESC-CM maturation. 
- Develop a novel polymer with increased degradation rate by introducing lactide 
groups. 
- Evaluate the ex-vivo and in-vivo performance of the developed patches by well 
established ex-vivo models (collaborating with Dr. Hikaru Ishii (Imperial 
College London, National Heart and Lung Institute (NHLI)). 
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2 Literature review 
2.1 The heart 
2.1.1 Anatomy and physiology 
 
The heart, blood and blood vessels together make up the cardiovascular system. The 
heart is also known as the body’s pump as its main function is to circulate blood around 
the whole body at each beat by repeated rhythmic contractions. The heart is considered 
as two separate pumps; the right pump pumps blood to the lung (pulmonary circulation) 
while the left pump circulates blood around the whole body (peripheral circulation). 
Figure 2.1 illustrates the heart’s anatomy. 
 
 
Figure 2.1 Illustrating anatomy of the heart (www.info.med.yale.edu, accessed 2006) 
 
 
Both the right and left side of the heart consist of two chambers, an atrium and a 
ventricle. The atria forces blood into the ventricles and the ventricles propel the blood 
either through pulmonary or peripheral circulation. As each chamber contracts, a 
volume of blood is forced into the ventricles and out of the heart to re-circulate, causing 
consistent pressure changes in the heart. Four valves, two atrioventricular and two semi-
lunar valves, ensure a one-way blood flow system by opening to let blood through and 
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then closing preventing backflow of blood during contraction and relaxation (Guyton & 
Hall 2000). In adult the human’s heart dimension is about 12cm in length, 6cm thick 
and approximately 9cm wide at its broadest point (Tortora & Grabowski 2002); where 
as the rat’s heart is approximately 1.5cm in length and 0.5cm wide.   
 
A membrane called the pericardium, surrounds and protects the heart. The epicardium, 
myocardium and endocardium all make up the heart wall. The epicardium is comprised 
of connective tissue and is the protective layer. Cardiac tissue muscle, known as the 
myocardium, found in the middle layer makes the bulk of the heart and is responsible 
for the pumping action. A thin layer of endothelium and connective tissue makes up the 
innermost endocardium, providing smooth chamber lining and heart valve covers 
(Guyton & Hall 2000). Figure 2.2 illustrates the cell layers found in the heart. 
  
 
Figure 2.2 Illustrating the muscle layers found in the heart (ww.nicksnowden.net, 
accessed 2006) 
 
Nutrients and oxygen in the circulation are unable to diffuse quickly enough to the 
myocardium to supply all the cells that make up the heart wall. Figure 2.1 also shows 
the coronary arteries that branch from the aorta to supply the myocardium with the 
required nutrients. The heart’s extracellular matrix (ECM) is mainly dominated by 
collagen type I and III, the former existing in the form of fibers resisting deformation 
and the latter being more flexible. Collagen is important in the make up of the ECM, 
contributing to its elasticity and hence mechanical properties (Bendall et al. 2002).  
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2.1.2. Basic features of cardiac muscle 
 
Heart  muscle cells, also known as cardiomyocytes, together with fibroblasts, smooth 
muscle cells, endothelial cells, macrophages and other leukocytotic cells all contribute 
to the organ’s framework (Wu et al. 2006). However, cardiomyocytes, 70% of which 
are ventricular cells, are the cells responsible for contraction. Other heart cells include 
atrial, pacemaker and purkinje fiber cells. The latter two are concerned with the 
generation and propagation of hearts electrical activity, respectively (Opie 1991).  
 
Similar to skeletal muscle, cardiac muscle is striated. Cardiac tissue often looks like a 
continuous three-dimensional cytoplasmic network due to the longitudinal splitting at 
the ends of the fibers which branch out and abut onto similar branches of adjacent cells. 
Skeletal muscle typically has many nuclei, whereas each cardiac muscle exhibits one 
centrally located nucleus, although the odd cardiac cell may have several nuclei 
(Guyton & Hall 2000). Their contraction also differs, where cardiac muscle is 
involuntary, brought about by sarcomeric proteins, actin and myosin, it is not 
consciously controlled. Cardiomyocyte contractions are initiated by inherent 
mechanisms, although the contractions are modulated by external autonomic and 
hormonal stimuli. Intercalated discs found in cardiac cells, containing desmosomes and 
gap junctional proteins e.g. connexin43, provide anchorage for the myofibrils and allow 
extremely rapid spread of contractile stimuli (conduction) from one cell to another 
(Young et al. 2006), permitting heart cells to work in synchronization as they are able to 
contract simultaneously.  
 
2.1.3. Heart failure 
 
Cardiovascular disease (CVD) is a major health problem and the leading cause of death 
in the western world. In the United Kingdom, CVD accounts for 238,000 deaths, 
comprising 39% of all deaths per annum (www.bhf.org.uk). Heart attacks, or MI are the 
main cause of death in patients with CVD. According to the British Heart Foundation 
(BHF), approximately 30% of the 270,000 patients suffering from heart attacks each 
year die before reaching the hospital (www.bhf.org.uk). In the remaining patients who 
survive their initial acute event, the damage sustained causes inefficiency in heart’s 
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pump action, forcing heart to work harder. This overload on heart mucle may eventually 
lead to the development of heart failure (HF).  
 
The most common causes of MI are coronary artery disease and hypertension (high 
blood pressure), a significant reduction in coronary blood supply to an area of the heart 
over a sustained period will cause oxygen and nutrient deprivation (ischaemia) and 
eventual cell death to that part. The dead tissue is replaced by a non-contractile fibrous 
scar tissue which is incompatible with the rest of the healthy heart, because the 
myocardium is a terminally differentiated tissue i.e. it is unable to divide to produce 
new cells to compensate the cell loss that occurs during MI. Hence HF ensues. For these 
reasons there is much interest in developing new methods to repair and regenerate an 
infracted area of the myocardium. Figure 2.3 shows a schematic diagram representing 
the damaged area after a heart attack due to a blocked coronary artery. 
 
 
 
Figure 2.3 Illustrating the damage caused by MI (www.heartpoint.com, accessed 2006) 
 
 
Currently, the standard conservative treatment for patients suffering from mild MI is by 
pharmacological therapy using diuretics in an attempt to reduce the heart’s work load 
and protect the heart from toxic humoral factors that become overactive during heart 
failure, these medications include catecholamines (β-blockers) angiotensin-converting 
enzyme (ACE inhibitors) and aldosterone (spironolactone) (Chen et al. 2008).  Patients 
with more serious symptoms and limitations in activity receive more interventional 
therapy such as implantation of pacing devices to control electrical/mechanical 
asynchrony. However, both drug and pacing devices do not control the inevitable 
progression to end stage HF. At end stage, organ transplant is the only option; owing to 
Infarcted area 
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the shortage in donors (Akins 2002), many patients die whilst waiting on the shortlist. 
Therefore, other alternatives are sought with cell therapy being a viable option.  
 
HF develops also in other situations in which damage occurs to any part of heart’s 
intricate structures. This includes disease of the heart valves, the electrical conduction 
system of the heart, or external pressure around the heart due to constriction of the 
pericardial sac in which the heart is sited. 
 
2.2 Cardiac regeneration and repair via cellular cardiomyoplasty 
 
Repair and regeneration of infarcted myocardium has been extensively studied with 
cellular cardiomyoplasty, the injection of cells either directly into or around infarct 
region or intravenously. A number of cell sources have been explored, these can be 
categorized as angiogenesis-stimulating cells (e.g. endothelial progenitor cells (Urbich 
& Dimmeler 2004) and fibroblasts (Weber, Sun, & Katwa 1997)), somatic muscle cells 
(e.g. skeletal muscle (Taylor et al. 1998)) or stem cells (e.g. bone marrow (Orlic et al. 
2001a) ESCs (Klug et al. 1996)). Table 2.1 summarizes the cell sources explored for 
cell transplantation, which are also reviewed in more detail below. In general, all cell 
sources explored have had mixed results. Many hurdles still face clinical application of 
the autologous cell therapy strategies including the ideal cell type, cell dose, optimal 
timing for cell transplantation and mode of delivery to optimize cell retention within the 
myocardium. Long-term survival and terminal differentiation post-implantation is yet to 
be determined (Al Attar, Razak, & Scorsin 2002). Whether cells are injected directly 
into the infarct or adjacent myocardium by thoractomy, or delivered via coronary 
circulation, the need for surgery or the inevitable cell loss after implantation by injection, 
respectively, raises doubt about cell transplantation. 
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Table 2.1 Cell sources considered for cell transplantation (Jawad et al. 2008a) 
 
CM= cardiomyocytes and CPCs= cardiac progenitor cells 
 
2.2.1 Somatic muscle cells 
2.2.1.1 Skeletal myoblasts  
Progenitor satellite cells found in undamaged muscle tissue are often quiescent. Upon 
muscle injury, these cells have the ability to become active, self-renew and differentiate  
permitting muscle regeneration (in vivo) (Al Attar, Razak, & Scorsin 2002). Despite 
their non-cardiac origin, their ability to contract and continuously repair the damaged 
muscle made these cells an attractive alternative to primary cardiomyocytes. They have 
been shown as being easily cultured, able to maintain their undifferentiated state whilst 
being multiplied to sufficient clinical numbers and recognized in vitro. Due to their 
auotologous nature there was further interest in these as they obviate the need for 
additional immunosuppressants and therefore were the first cell types to reach clinical 
application. Initially, these cells were introduced into the infarcted region with hope 
they will transform to a more cardiac phenotype and repair the infarcted region, 
however this has been proven otherwise (Hassink et al. 2003). The results of studies 
Cell source General advantages General disadvantages 
Skeletal myoblasts 
Autologous, contractile, 
easily cultured and 
expanded in vitro 
Inability to transdifferentiate into CM, preventing 
electrical coupling causing arrhythmias. 
Progenitor cells 
mobilized from bone 
marrow 
 
Autologous 
 
Results are not reproducible, cell route from bone 
marrow to infarct and bone marrow cell 
transdifferentiation to CM is questionable. 
Bone marrow stem 
cells 
 
Easily accessible and 
autologous 
Mixed results achieved. Limited evidence on 
transdifferentiation. Possible formation of other 
tissue types 
Bone marrow 
derived 
cardiomyocytes 
 
Autologous 
 
Results of differentiating bone marrow into CM in 
vitro is difficult to reproduce 
 
Embryonic stem cell 
derived 
cardiomyocytes 
 
Remain in culture for 
unlimited periods 
Immunological and ethical constraints. 
Teratoma formation 
Spermatogonial 
derived 
cardiomyocytes 
 
Authentic cardiomyocyte 
phenotype 
Evidence of expandability and reproducibility at an 
early stage 
Primary 
cardiomyocytes 
True morphological 
representation and 
preserve cardiac function 
in vitro 
Do not survive in culture longer than 48hrs (adult 
ventricular cells) and 1 wk (neonatal myocytes). 
dedifferentiate in culture. Unable to proliferate and 
self renew. Human source problematic   
Cardiac Progenitor 
Cells (CPCs) 
Potential autologous 
source. 
Evidence of expandability and reproducibility at an 
early stage 
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attempting to restore cardiac function have been mixed, with some being successful 
(Chiu, Zibaitis, & Kao 1995;Hutcheson et al. 2000;Menasche et al. 2001;Taylor et al. 
1998) and somewhat encouraging clinical trials have been reported (Menasche et al. 
2001), while others reporting no sign of physiological improvements and/or cardiac 
differentiation (Murry et al. 1996;Scorsin, Hagege, & Marotte 1997;Scorsin, Hagege, & 
Marotte 2000).  
 
Key obstacles for the use of these cells for myocardial regeneration are their apparent 
inability to transdifferentiate into cardiomyocytes and remain committed only to further 
mature as myoblasts. Hence, their electromechanical properties remain different, 
preventing electrical coupling with native cardiomyocytes, creating a pro-arrhythmic 
substrate as the impulse cannot propagate evenly across the myocardium and 
transplanted cells. Patients require pacemakers or defibrillators to ensure synchronous 
beating and to treat any dangerous heart rhythms (arrhythmias) which may be triggered. 
This reflects the absence of gap junctional protein connexin43 expression in skeletal 
myoblasts. Introduction of connexin43 by genetic modification has not been successful 
because it has been shown to affect cell life span (Reinecke et al. 2004). However, 
despite these drawbacks, it has been suggested that fibrin glue and skeletal myoblasts 
together can preserve cardiac function when injected into a myocardial infarcted region 
(Christman et al. 2004a). 
 
2.2.1.2 Primary (foetal or neonatal) cardiomyocytes 
 
The first cell types to be investigated for cell transplantation were cardiomyocytes, as 
they are the cells that contribute to the majority of the cells that make up the heart. The 
use of isolated adult and neonatal cardiomyocytes has been pivotal for our 
understanding of many aspects of cardiac cell biology, electro-physiology and 
pharmacology (Menasche & Desnos 2002). The main advantage of isolated adult 
cardiomyocytes is their true electrophysiological, morphological and contractile 
representation and perseveration of cardiac function in vitro. Adult ventricular and atrial 
cardiomyocytes are isolated from both human (Harding et al. 2006) and animal hearts. 
Unfortunately, their clinical application is not ideal, for a number of reasons. Firstly, it 
has been difficult to demonstrate survival of adult cardiomyocytes in culture without 
losing their characteristic features for more than 48 hours (h). They are also reported to 
dedifferentiate in-culture, with their phenotype eventually verging on the neonatal 
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cardiomyocyte phenotype, which is less structured (Harding et al. 2006). Furthermore, 
adult cardiomyocytes provide limited supply in culture as they lack the ability to 
differentiate, proliferate and self-renew and therefore are best suited as a 
pharmacological model.  
 
Rat neonatal cardiac myocytes are easy to prepare in large quantities, last longer in 
culture (1 week) and can be genetically modified which enable their tracking in 
experimental animals following cell transplantation. Many studies have reported the 
success of engrafting cardiac myocytes into diseased hearts in experimental animals: 
some reporting these cardiomyocytes survive and improve cardiac function for up to 6 
months (Muller-Ehmsen et al. 2002); some reported improved left ventricular (LV) 
function (Scorsin, Hagege, & Marotte 1997) and reduced left ventricular remodelling 
(Etzion et al. 2001b) following MI. Several different mechanisms have been thought to 
contribute to improved cardiac function post cardiomyocyte implantation; the ability of 
the transplanted cardiomyocytes to directly contribute to the native hearts contractile 
function and the possible secretion of growth factors from transplanted cardiomyocytes 
may induce angiogenesis and support native cardiomyocytes in the infracted region 
possibly activating residential progenitor cells (Chen et al. 2008). Despite the fact that 
isolated cardiomyocytes have the ideal characteristics for cardiac repair, in that they are 
contractile and able to electrically couple with host myocardium, these cells will not be 
autologous in nature if ever taken to clinical trials and immunosuppressants will be 
needed; therefore implanting isolated  cardiomyocytes into infarcted hearts it is not a 
realistic approach for humans. For this reason, much research has focused on 
developing cardiomyocytes from ESCs (Kehat et al. 2001;Klug et al. 1996) (section 
2.2.2.4) and more recently induced pluripotent stem cells (iPSCs) (section 2.2.2.5) as 
these cells do not produce an immune response in the host (Takahashi et al. 
2007;Takahashi & Yamanaka 2006).  
 
2.2.2 Stem cells 
 
Unspecialized cells with the potential to self renew for indefinite periods and 
differentiate along multiple cell lineages are called stem cells. They are able to develop 
into mature cells with specialized functions and characteristic shapes of specific cell 
types found in the body, for example skin, nerve and heart cells, depending on their 
differentiation methods (Bongso & Richards 2004).  Due to their ability to self-renew 
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throughout life, proliferative capacity for unlimited numbers in vitro and broad 
differentiation profile, stem cells are the ideal cell source for tissue regeneration.   
 
Depending on their origin, they are referred to either as adult stem cells, ESCs, foetal 
stem cells or cord blood stem cells, with the former two being of interest in this review. 
Stem cells can be further categorized in terms of their ability to develop; figure 2.4 
illustrates the stem cell hierarchy (Wobus & Boheler 2005). 
 
Totipotent cells are able to differentiate into embryonic cell types as they are developed 
by the fusion of a sperm cell and an egg. ESCs are formed from early embryos, having 
the ability to differentiate into every cell type in the body derived from the three germ 
layers (ectoderm, mesoderm and endoderm), and are therefore referred to as pluripotent. 
Adult stem cells, which reside in tissues/organs, are referred to as multipotent as they 
have the capacity to differentiate into a restricted number of cell lineages. Examples of 
adult stem cells include hematopoietic and mesenchymal stem cells of the bone marrow, 
liver, brain and cardiac stem cells. Finally, unipotent stem cells (e.g. skin cells) are 
similar to non-stem cells, in that they have the ability to differentiate into one specific 
cell type, however they are able to self-renew. 
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Figure 2.4 A schematic illustration of the stem cell hierarchy in terms of potency, 
adapted from (Wobus & Boheler 2005) (ICM = inner cell mass, ESC = embryonic stem 
cell, PGC = primordial germ cells, EGC = embryonic germ cell).  
 
2.2.2.1 Cardiac stem cells resident in the heart 
 
Traditionally the heart has always been thought to have no regenerative capability, with 
cardiomyocytes viewed as terminally differentiated cells that were unable to regenerate. 
Recently, the paradigm has been challenged with the notion that there are resident 
cardiac progenitor cells in the heart that are capable of giving rise to new 
cardiomyocytes upon muscle injury. Anversa and co-workers have described a group of 
cells resident in adult hearts with markers such as Lin-, c-Kit+ (stem cell marker), Ki-67 
(proliferation marker) (Beltrami et al. 2001;Beltrami et al. 2003;Smits et al. 2005) and 
early cardiac transcription markers like GATA-4 and Nkx2.5, referred to as cardiac 
progenitor stem cells. However, their low population and the limited evidence for 
In vivo 
In vitro 
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myocardial regeneration hinders their immediate use in clinical trials, even though these 
cells have been shown to have the ability to differentiate into cardiomyocytes and 
vascular cells when isolated from human myocardium (Messina et al. 2004; Smits et al. 
2005). However, their origin is still unclear and hypotheses include that these cells may 
home to the heart from either the bone marrow, or alternatively they may reside in the 
heart from fetal life. They may contribute to cell turnover and heart repair on a small 
scale through normal life i.e. ageing, but this capacity is overwhelmed by the injury to 
the myocardium from acquired heart diseases such as MI.  
 
2.2.2.2 Cord blood stem cells 
 
Cord blood stem cells are multipotent cells that are derived from the blood of the 
placenta and umbilical cord after birth and have been suggested as a possible cell source 
for myocardial regeneration (Chen et al. 2008). Advantages of this cell source include 
the possibility of growing these cells in an unlimited supply without any ethical issues 
hindering their applicability. Furthermore, when harvesting these cells neither the 
mother nor infant are affected, these cells are available in significantly large quantities 
and more importantly they have shown to have a low rejection rate therefore there is a 
possibility that immunosuppressant is not prerequisite, this maybe due to their immature 
immunogenicity. Despite the above listed advantages, the mechanism for myocardial 
repair is still unknown and requires further investigations (Yu et al. 2008). Recently, 
Ghodsizad et al. (2009) achieved functional improvement and prevention of scar 
formation in an infarcted porcine heart using cord blood stem cells 8 weeks post 
infarction. However, further investigations are required for long term studies.  
 
2.2.2.3 Regeneration by the bone marrow stem cells 
Progenitor cell mobilization from bone marrow: 
Cytokines, such as granulocyte-colony stimulating factor (G-CSF) and stem cell factor 
(SCF), are known to stimulate progenitor cell release from the bone marrow.  After 
mobilization, i.e. releasing a pool of stem cells into the peripheral circulation, it has 
been hypothesised that these undifferentiated stem cells may home to the infarcted 
region of the heart. Much debate exists as to whether this phenomenon occurs in 
humans, and if so whether the homing bone marrow cells have any capacity to 
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differentiate into cardiomyocytes, contributing to myocardial regeneration (Smits et al. 
2005). This has been investigated further, with some reports on an improvement in 
infarcted area and cardiac function (Orlic et al. 2001b) while others reported G-SCF and 
SCF having no effect on the infarct size but encouraged vessel formation (Noral et al. 
2003). Quaini and coworkers (Quaini et al. 2002) reported that 9% of cells express 
stem-cell antigens, however, this percentage has not been observed by others, 0.016% 
(Smits et al. 2005). 
 
Debate exists as to whether bone marrow progenitor cells do indeed migrate to the 
infarcted region in the adult human. If they do, then further questions arise: what 
fraction of cells is lost whilst in the blood circulation, what is the fate of the mobilized 
cells, and do these cells differentiate into cardiomyocytes? Most experiments have been 
carried out using young healthy mice (Kawada et al. 2004), and applicability to the 
human clinical situation is limited. 
Bone marrow stem cell injection: 
Over the years, much attention has been focused on bone marrow as a source of stem 
cells for cell therapy. It contains two components, stroma and hematopoietic, the former 
producing mesenchymal stem cells while the latter is involved with new blood cell 
(both red and white) formation. Advantages of bone marrow stem cells include their 
relatively easy access, their autologous nature. Moreover, Wang et al reported their 
ability to differentiate into cardiomyocytes in vivo (Hassink et al. 2003;Wang et al. 
2000) but this has been difficult to reproduce by others. 
 
Jackson  et al. (Jackson et al. 2001) demonstrated a 26% survival rate of mice that had 
been injected with hematopoietic stem cells into their circulation following MI. Results 
suggested that the transplanted stem cells responded to signals in the infarcted region of 
the myocardium, causing them to migrate to the damaged area (cell homing) and 
differentiate into the cells required for cardiac repair, contributing to neovascularization. 
Orlic et al. (Orlic et al. 2001a; Orlic 2002) used florescence-activated cell sorting 
technique to select Lin–c-kit+ bone marrow cells from mice; cells were then injected 
directly into the infarcted area, creating new cardiomyocytes, smooth muscle cells and 
vascular endothelium forming de novo myocardium with living tissue nine days after 
cell transplantation. Results were promising as the regenerated myocardium occupied 
68% of the infarcted area and the mice that received cell transplantation survived in 
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greater numbers in comparison to the mice that did not. Analysis of the region 
surrounding the damaged tissue suggests that the stem cells responded to signals in the 
infarcted area causing them to multiply into “specialized” cardiomyocytes (Orlic et al. 
2001a). In another study, bone marrow stem cells were shown to be capable of 
developing vascular endothelial cells when transplanted into rat hearts, forming new 
blood vessels in the damaged area (Kocher et al. 2001). 
 
These findings have only been demonstrated in rodent models, with young animals 
receiving young healthy bone marrow. Reproduction of these findings by others groups 
has been unsuccessful (Balsam et al. 2004; Murry et al. 2004; Nygren et al. 2004), and 
publication bias towards positive studies may skew the true extent of bone marrow 
progenitor cells to regenerate the infarcted myocardium. However, in elderly patients 
with cardiac disease the bone marrow has greatly reduced function (Heeschen et al. 
2004) and similarly for older rats in comparison with younger ones (Lehrke et al. 2006). 
Therefore, the likelihood of clinically significant reparative or regenerative qualities of 
their own bone marrow progenitor cells is minimal.  
 
The current dogma is that bone marrow stem cells do not transdifferentiate into 
contractile cardiomyocytes. This brought about suggestions that the marginal 
improvements (e.g. LV ejection fraction) in clinical trials maybe be due to other factors, 
such as increased cytokine release and/or formation of more blood vessels. The latter 
could provide significant benefit as angiogenesis would supply more oxygen and 
nutrients to support native cells in ischaemic tissue (Takahashi et al. 2006). Critical 
issues to be addressed include the possible formation of non-muscle tissue types, i.e. 
bone and cartilage (known to be formed from bone marrow stem cells) and the need for 
more long-term studies. Recently, Rosenzweig (Rosenzweig 2006) reported on the 
mixed results achieved from bone marrow stem cells transplantation into patients with 
infarcted hearts; with Schachinger et al (Schachinger et al. 2006) reporting the best 
evidence so far on the success of bone marrow stem cells.  However, other trials 
suggesting mild or no improvement lessens the excitement for bone marrow stem cells 
use for therapeutics (Rosenzweig 2006). 
 
Bone marrow derived cardiomyocytes: 
An alternative method for obtaining cardiomyocytes is by culturing the bone marrow 
stem cells in vitro, for example treating them with 5-azacytidine, to differentiate these 
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cells into cardiomyocytes and introduced into the injured heart. Fukuda et al. (Fukuda 
2001), Makino et al. (Makino et al. 1999) and Tomita et al. (Hassink et al. 2003) have 
reported differentiated myogenic cells from bone marrow stem cells to improve 
myocardial function. This work, however, has been difficult to reproduce.  
 
2.2.2.4 Embryonic stem cell derived cardiomyocytes (ESC-CMs) 
 
For all the above limitations listed, the idea of using ESCs for both research and 
therapeutics is being more accepted, despite the ethical complications (Polak & Bishop 
2006). Mouse ESCs (mESCs) were isolated from the inner cell mass of  a mouse 
blastocyst-stage embryos just over two decades ago (Evans & Kaufman 1981;Gardner 
1983) (figure 2.5). However, derivation of human ESCs (hESCs) is more recent and 
was first reported in 1998 by Thomson et al. (Thomson et al. 1998) opening a new era 
in therapeutics. This is promising since ESCs have the potential to be propagated in 
culture for unlimited periods without karyotypic changes allowing good supply of cells 
for potential use. Furthermore, they are able to differentiate into all cell types in the 
body, because all three primary germ layers that arise during embryo development, 
ectoderm, endoderm and mesoderm (Bradley et al. 1984), are developed during ESC 
differentiation in vitro. The outermost layer, ectoderm, forms the epidermis and nervous 
system, while the endoderm layer forms the gastrointestinal and respiratory tracts as 
well as the endocrine glands. Cardiac tissue, blood, bone, cartilage, endothelial and 
mesenchymal cells are formed from the mesoderm layer (Van Laake 2005).  
 
As well as ESCs, two other different types of pluripotent stem cell lines from 
mammalian embryos are possible, embryonic carcinoma (EC) and embryonic germ 
(EG) cells. The defining feature of ESCs that distinguishes them from the other two is 
the fact that when reincorporated into normal embryonic development, i.e. a host 
blastocyst, they have the full potential to develop along all lineages of the embryo 
proper. EC cells are derived from undifferentiated embryonic components of germ cell 
tumors, whereas EG cells are derived from primordial germ cells in the genital ridge 
(Boheler 2002), making ESCs more attractive for TE applications. Figure 2.5 illustrates 
the origin of these three different stem cells. 
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Figure 2.5 Illustrating the differentiation time scale of ESCs, adapted from (Boheler 
2002).  
 
Despite immunological and ethical constraints, cardiomyocytes derived from ESCs 
represent an expanding field in cell therapy and TE (Harding et al. 2006;Kumar 2005). 
The differentiation of ESC into all cardiac cell types (pacemaker, atrial-, nodal-, 
purkinje-like and ventricular- cells) has been well characterized in many laboratories 
(Ali et al. 2004; Harding et al. 2006; Kehat et al. 2001; Kehat et al. 2004; Mummery 
2002; Mummery 2003). Initially, the cardiomyocytes formed at the early stages 
(neonatal) resemble pacemaker cells. It is not until later on during the differentiation 
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process that atrial-, nodal-, purkinje-like and ventricular- cells are developed (Laake, 
Hoof, & Mummery 2005; Wobus et al. 1997).  The rate at which cardiac expression 
factors are expressed also occurs during different differentiation stages, with cardiac 
specific myosin heavy chain ((MHC), a protein specific to cardiomyocytes) occurring in 
mature cardiomyocytes (Laake, Hoof, & Mummery 2005). 
 
Klug et al. (Klug et al. 1996) were the first to demonstrate the potential use of ESC-
CMs for cardiac repair, by treating dystrophic mice hearts (non-injured) with mESC-
CMs. After a seven week follow up post mESC-CM transplantation, cardiac MHC 
labeled cardiomyocytes were found to have formed stable cardiac grafts. Furthermore, 
Min et al. (Min 2002) demonstrated that ESC-CMs can survive in the cardiomyocyte 
phenotype in vivo, and repair myocardial damage in animal models, showing ESC is a 
good source for producing cardiomyocytes that can be used for heart repair. 
Interestingly, the transplantation of undifferentiated mESCs, treated with specific 
growth factors (TGFβ- or BMP2) (Behfar et al. 2002) or cardiac-committed cells 
(Menrad et al. 2005) into infarcted hearts was successful in that cells were integrated 
and myocardial function was improved; however, others reported cell rejection and 
teratoma development (Leor et al. 2005). With much research successfully reporting the 
potential of mESC-CM (Caspi & Gepstein 2006b; Guo et al. 2006; Messina et al. 2004; 
Min 2002; Mummery 2002; Sachinidis, Fleischmann, & Kolossov 2003; Stojkovic et al. 
2005; Wei 2005), hESC-CM are now receiving much attention for their possibilities for 
cell therapy (Laflamme et al. 2005). To date, researchers have established 
characteristics of many aspects of the cardiac phenotype of the hESC-CMs, confirming 
the presence of cardiac-specific structural genes, proteins and transcription factors. Also 
identified were calcium transients, action potentials, extracellular electrical activity, 
cardiac structures, such as intercalated discs and sarcomeric organization (Caspi & 
Gepstein 2006b; Dai et al. 2007; Kehat et al. 2001; Kehat et al. 2004; Mummery 2003; 
Xu et al. 2002), providing further proof of successful cardiomyogenesis from hESCs. 
More recently, electromechanical integration of hESC-CMs with the host myocardium 
both in vitro and in vivo has demonstrated successfully the potential use of hESC-CMs 
in cell therapy. Laflamme et al. (Laflamme et al. 2007) reported the formation of human 
cardiac tissue in athymic rat hearts by injecting an enriched population of hESC-CMs 
by the fourth week, further proving their capability to proliferate suggesting a sufficient 
cell dose will form a cardiac graft in the desired scarred region.  
  
43 
Leor et al. (Leor et al. 2005) compared undifferentiated hESCs and differentiated hESC-
CMs and showed that both can survive when transplanted into either normal or infarcted 
hearts of nude rats. However neither type contributed to new myocardium formation 
and some possible teratoma formation was observed. They also reported the importance 
of eliminating undifferentiated cells prior to transplantation. Table 2.2 highlights key 
investigations of successful ESC-CMs used in cell transplantation in experimental 
infarction models (Foldes, Harding, & Ali 2008). Although van Laake (2008) (Van 
Laake et al. 2008) reported green fluorescent protein (GFP) tagged hESC-CMs survived 
four weeks after cell transplantation and that cardiac function improved with 
preservation in LV remodeling, these cells were not detected three months post 
transplantation.  
 
Table 2.2 Summary of ESC based cell transplantation studies in experimental MI 
models, adapted from Foldes, Harding, & Ali 2008. 
 
 
Number of  
cells injected Model 
Injection 
time after 
infarction 
Follow-up 
duration LV function Used control 
mESC 
(cardiac-
committed) 
5 x 107 sheep 14 days 4 weeks EF ↑ medium 
mESC-CM 5 x 105 rat 7 days 4 weeks FS ↑ medium 
mESC-CM 0.03-0.1 x 106 mouse 0 days 3-4 weeks EF ↑, EDV ↓ 
BMCs, 
fibroblasts and 
medium 
hESC-CM 
outgrowth 0.1 mm
2
 rat 7-10 days 2-4 weeks FS ↑ medium 
hESC-CM 106 mouse 0 days 12 weeks EF ↑ (4 wks) 
    ↔ (12wks) 
hESC-derived 
non-myocytes 
 
hESC-CM 107 rat 4 days 4 weeks FS ↑, EDV ↓ 
hESC-derived 
non- myocytes 
and  saline 
 
hESC-CM 1.5 x 106 rat 7-10 days 4 weeks FS ↑, EDV ↓ 
hESC-derived 
non-myocytes 
and saline 
BMCs=bone marrow cells; EDV=end-diastolic volume; EF=ejection fraction; FS=fractional shortening. 
 
State of the art of ESC-CM for myocardial regeneration 
The predominant opinion today is that the infarcted heart requires a supply of new 
contractile cardiomyocytes to improve and regenerate the diseased non-contractile 
region. The lack in evidence in improved myocardial function with somatic cells and 
adult stem cells, as described above, has led experts to strongly favor ESCs due to two 
main attractive reasons, firstly their obvious ability to differentiate, ex vivo, into 
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cardiomyocytes (Kehat et al. 2001; Klug et al. 1996) and secondly their capacity for 
unlimited expansion in vitro (Foldes, Harding, & Ali 2008; Zandstra et al. 2003).  Other 
advantages of ESCs as potential sources for cardiomyocytes include their ability to 
differentiate into many different cell lineages for specific applications, such as various 
specialized cardiomyocytes (e.g. atrial, ventricular, pacemaker cells) as well as 
angiogenesis-inducing cells (e.g. endothelial progenitor cells) (Oyamada et al. 2008). 
ESCs can also serve as cellular delivery vehicles for different therapeutic procedures, 
namely gene therapy, for example ESCs may be ‘loaded’ with various drugs and 
growth- or angiogenic- promoting factors that will be secreted locally upon 
transplantation to manipulate the diseased myocardium towards a desirable healthier 
environment (Caspi & Gepstein 2006a). However this approach is beyond the scope of 
this review, more detail maybe found in Caspi & Gepstein 2006a.  
Issues and concerns regarding hESCs for myocardial regeneration 
Several issues still remain regarding the use of ESC derived cells in human disease, 
hence hampering the application of ESC-CM in myocardial regeneration. There is much 
concern regarding the origin of ESC lines (ethical issues), the products and components 
used to differentiate into specialized cells (xenogenic concern), the enrichment of 
differentiated cardiomyocytes before transplantation (uncontrolled tumour formation) 
and finally the immunogenicity. Other concerns for cellular cardiomyoplasty, both 
somatic and stem cells, include the sufficient cell dose of cardiomyocytes, the time of 
cell transplantation post-infarction and the method of cell delivery are matters that are 
yet to be determined. Table 2.3 below summarizes the challenges and requirements 
researchers face today before the possible clinical application of ESC-CMs. Certain 
concerns are further discussed in this section. However, induced pluripotent stem (iPS) 
cell lines derived from patient fibroblasts are very promising (see section 2.2.2.5). 
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Table 2.3 The challenges and requirements for clinical application of ESC-CMs in 
myocardial regeneration. Adapted from (Foldes, Harding, & Ali 2008). 
 
  
Proliferative issues Large scale ESC culture 
 
Control of cell and tissue growth, different cardiac subtypes 
 Tumour formation. Use of tumourgenicity assays 
 
Purification of the culture from contaminating cells 
 
Clinical problems when cells need to be genetically modified 
Experimental studies Use of suitable large animal models 
 Control of graft size in infarction models 
 Inducible but no spontaneous cellular contractility 
Xenogenic conditions Xeno-, DMSO- and serum-free conditions for maintenance 
 Defined matrix components 
 Recombinant enzymes for passaging 
Immunogenicity Allogeneic nature of the cells. Immune rejection and suppression 
Other Ethical and legal issues 
 Biodistribution and safety issues  
 Clinical trial issues 
 
  
Ethical concerns. Since the origin of hESCs is from human blastocyst, this causes 
controversy regarding their acceptance hence hindering their progress into clinical trials. 
Currently, the laws on the use of hESCs in the UK are relaxed compared to the US law, 
where only 60 hESC lines are funded for research (www.cnn.com/2006). Attempts to 
derive ESCs from single blastomers without interfering with the embryo’s development 
(Chung et al. 2008; Klimanskaya et al. 2006) may help overcome the ethical issues 
concerning ESCs and more recently, the development of human induced iPS cells from 
adult skin fibroblasts, without any involvement of an embryo (Takahashi et al. 2007). 
However, the use of retroviruses to insure iPS cells have ESCs properties adds further 
complications. If the ethical issue regarding destruction of an embryo is overcome, the 
laws on ESC research will be liberal world-wide and more funding will be available for 
researchers to draw closer the possibility of using ESCs as a possible cell source in 
regenerative medicine.   
 
Xenogenic conditions.  Currently hESC differentiation towards cardiomyocytes 
involves the use of animal products which may cause complications upon 
transplantation. In fact, the entire procedure used for maintenance and induction of 
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differentiation of hESCs involves animal components and coculture with mouse 
fibroblasts. Many ESC lines that have been harvested from human embryos by 
immunosurgery, were established earlier on MEFs as feeder cells and  in media 
containing animal products, e.g. fetal bovine serum (FBS), although in recent years 
improvements have been made: (a) human fibroblast feeder cells can replace MEFs 
(Lee et al. 2005b) (b) hESCs can be grown in the absence of MEFs (under feeder-free 
conditions (Xu et al. 2001). However, the system is still not completely devoid of 
materials of animal origin.  For instance, when grown under non-feeder conditions, cells 
need to be grown on Matrigel coated surfaces: this is an ECM, which is rich in laminin, 
type IV collagen and some growth factors but it is obtained from a mouse fibrosarcoma 
cell line. Although serum has been removed from culture media, its replacement, i.e. 
knockout serum replacement (KOSR) still contains components of animal origin 
(Foldes, Harding, & Ali 2008; Mummery 2003). To increase cell number, ESCs are 
sub-cultured/ passaged a number of times until enough cells are obtained; the enzymes 
used to lift undifferentiated and differentiated hESCs are collagenase (made from a 
bacteria found in wounds, Clostridium histolyticum) and trypsin (contains porcine 
components). Furthermore, harvested cells are frozen in a mixture containing 10% 
hazardous dimethyl sulfoxide (DMSO), a cryprotectant. Thus, progress towards an 
animal-free procedure is essential to making hESCs acceptable for clinical trials. 
Although a method for culturing hESCs in feeder-free conditions with human 
component containing medium (Ludwig et al. 2006) and others have reported the 
differentiation of hESCs using serum free conditions and fibroblasts of human origin 
(Lee et al. 2005a;Lee et al. 2004), more research is required for a complete xenogenic-
free protocol. 
 
Teratoma formation and immunogenicity. Although the differentiation of ESCs into 
cardiomyocytes has been around well over a decade (Klug et al. 1996), no defined 
protocol has been developed to form a high yield of cardiomyocytes; the common 
method adopted of inducing differentiation via embryoid body (EB) formation, gives 1-
3% and less than 1% of ESC-CMs in mESC and hESC cultures, respectively (Kehat et 
al. 2001; Ling-Ling et al. 2006; Xu et al. 2002). Although the specific cell dose required 
to repair the scarred tissue is still unknown considerably fewer cardiomyocytes are 
obtained relative to what is required for ischemic regeneration. Recently, alternative 
methods to increase the yield of ESC-CM have been reported, for example treating 
ESCs with medium containing activin A, bone morphongenetic proteins (BMPs) and 
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other factors which enhance cardiomyogenesis from cells in the embryo (Yao et al. 
2006). However, this is beyond the scope of this review. Another important issue that 
needs to be addressed once yield has increased is the development of strategies to 
identify and exclude any undifferentiated hESCs that might escape differentiation from 
the differentiated cell population, either prior to cell transplantation or after implantation 
to prevent clinical complications and teratoma formation (Balsam et al. 2004; 
Nussbaum et al. 2007). Finally, immunogenicity is a major concern for allogenic cell 
transplantation, and there is generally the need for immunosuppressant’s to prevent cell 
rejection.  
 
2.2.2.5 Induced pluripotent stem (iPS) cells 
 
In 2006 Takahashi and Yamanaka were the first to report the possibility of 
reprogramming already differentiated mouse embryonic fibroblasts (MEFs) and adult 
mouse tail-tip fibroblasts to an ‘embryonic-like’ state. These cells were induced to 
generate pluripotent stem cells by introducing transcription factors such as Oct3/4 and 
Sox2 (Takahashi & Yamanaka 2006). iPS cells have been reported to express ESC cell 
marker genes and exhibit both growth and morphological properties of ESCs. This 
research was further studied and iPS cells were later reported to have been induced from 
human fibroblasts (Takahashi et al. 2007). Since there are issues regarding the use of 
human embryos to form ESCs, the development of iPS cells has introduced a new 
revolutionary era in research for tissue regeneration as the differentiated cells (made 
from the patients own cells) developed will be patient-specific.    
 
2.2.3 Cell delivery routes 
 
Important drawbacks of cell therapy include the lack of sufficient published data on the 
optimal timing for cellular transplantation, ideal number of cells required for 
transplantation as well as their long-term survival and terminal differentiation post-
implantation, this has been critically reviewed in the literature (Al Attar, Razak, & 
Scorsin 2002). Moreover, cell delivery technique is of major concern. The two different 
routes proposed for cell delivery to the damaged area are injection of cells directly into 
the infarcted region (Orlic et al. 2001a) or via coronary circulation (Jackson et al. 2001). 
Both routes have advantages and disadvantages. Directly injecting cells into the 
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infarcted area ensures the delivery of cells directly to damaged area, but is hampered by 
significant cell loss after needle withdrawal from the myocardium. Cell implantation 
can be achieved via open chest surgery (thoracotomy),  which carries risks associated 
with surgical operations, or percutaneously via needle injection from a catheter directed 
to the inner surface of the ventricle (endocardial injection). At present, the preferred 
method of introducing cells is by injection into the coronary vessels with the hope that 
they will home to the infarcted area. In an attempt to increase contact time of cells with 
the myocardium, blood flow in coronary vessels can be temporarily occluded by 
angioplasty balloon inflation. This technique is also inefficient at cell delivery, with 
only a small fraction of the delivered cells being retained in the heart (<5%) (Grossman 
et al. 2002; Hofmann et al. 2005). However, the best route for cell delivery is still to be 
determined, and in particular to minimize cell loss. With this major obstacle, MTE has 
been suggested as a method of delivery, i.e. delivery of a pre-formed cardiac patch or 
scaffold (Zimmermann et al. 2000; Zimmermann 2002; Zimmermann, Melnychenko, & 
Eschenhagen 2004). Table 2.4 lists other suggested alternatives to heart transplant 
which have been carried out in an attempt to regenerate the scarred tissue after MI. 
These approaches will be further discussed in section 2.3, with great focus on the cell 
types used and TE approach. 
 
Table 2.4 Summary of the advantages and disadvantages of myocardial tissue 
regeneration approaches (Jawad et al. 2007)  
Approach Advantages Disadvantages 
 
Cellular cardiomyoplasty 
(injection of cells only, either 
directly or intravenously) 
Minimally invasive surgery if 
injection is intravenously. 
Lack of knowledge as to how cells 
contribute to regeneration or repair. 
Much concern revolved about direct 
injection only affecting endocardium 
and not epicardium. Concern 
regarding cell loss. 
In-situ engineering 
(injection of cells and an 
injectable biomaterial 
Biomaterial acts as a 
supporting matrix while cells 
will simultaneously regenerate 
infarction. 
Involves open chest surgery and this 
suggestion is at infancy. 
Injection of a biomaterial 
alone 
Matrix for homing autologous 
progenitor cells. 
 
Immunogenicity; as only natural 
polymers have been suggested. 
Left ventricular restraints 
(‘Wrapping’ the ventricles 
with a biopolymer) 
 
Doesn’t involve cell injection. Prevents remodelling, but does not 
repair or regenerate damaged area. 
Tissue engineering Ensures cells are delivered to 
desired area with minimal cell 
loss. 
Involves open chest surgery and 
more work is required to determine 
suitable cell type and material. 
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2.3 Tissue Engineering (TE) 
 
By broad definition, TE is a process known today for the reconstruction of tissue 
equivalents by combining biomaterials and living cells, used together in repair, 
maintenance, replacement and augmentation of tissue or organs.  TE involves both 
principles in engineering and biological sciences and it has been used in many different 
applications, from repairing abdominal wall (Drewa et al. 2005), to regenerating various 
soft tissue types such as vascular grafts and blood vessels (Jones 1979) as well as the 
repair of hard tissue (bone) (Persidis 1999). The concept of TE has been around for two 
decades; Charles Vacanti (Vacanti 2006) refers to Fra Angeliac’s famous painting 
“Healing of Justinian” as one of the first historical reference to TE. Figure 2.6 illustrates 
the famous painting where Saint Brothers are transplanting a homograft limb onto a 
wounded soldier. In 1933 the first TE procedure was reported, when tumor cells were 
wrapped in a polymer membrane and implanted into a pig (Habib et al. 2005). 
 
Figure 2.6 Fra Angelica’s “Healing of Justinian” painting illustrating the 
transplantation of a homograft limb onto a wounded soldier (www.scientist.com, 
accessed 2008) 
 
Figure 2.7 illustrates the various stages involved in the field of TE. It is an 
interdisciplinary field, bringing together the work of material scientists, biologists and 
clinicians to form an engineered cell/biomaterial construct (ex-vivo or in-situ), 
eventually implanted into the injured site by clinicians. 
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Figure 2.7 Various steps involved in TE (www.myweb.uiowa, accessed 2006) 
 
 
The contribution of materials science and engineering is to fabricate and process 
biomaterials for the scaffold, to guide tissue development and to develop a paradigm to 
assess the functional capacity of generated tissue (Bonassa & Vacanti 1998). MTE, a 
specific subgroup of TE dedicated to myocardial tissue, is an exciting novel therapeutic 
concept (Etzion et al. 2001a) and is currently receiving much attention in the field of 
regenerative medicine as an alternative to current treatments for heart disease (Giraud et 
al. 2007). The basic MTE paradigm is to seed cells capable of forming cardiomyocytes 
onto a biocompatible material in vitro, followed by implantation of the construct on or 
in the infarcted region of the failing heart. The grafted tissue will in turn direct new 
tissue formation as the cells integrate with the native tissue while the scaffold degrades 
over time (Shin, Jo, & Mikos 2003). For tissue regeneration to be successful, it is 
essential to generate appropriate numbers of cells which will not only maintain the 
specific biological functions but also to differentiate to the correct phenotype. Some of 
the crucial cell functions include interacting with neighbouring cells/tissue, producing 
ECM in the correct organization as well as secreting signalling molecules.  
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2.4 Biomaterials in soft TE 
 
A biomaterial is a nonviable material used in a medical device, intended to interact with 
biological systems (Williams, 1987; Ratner et al. 2004). Biomaterials play a key role in 
most TE strategies. Polymers are the largest class of engineered biomaterials used today 
in the biomedical field. As well as their use in cardiovascular implants they are 
legendary in their use as implants and medical devices. The different types and classes 
of polymeric materials used in the TE field are without doubt enormous, and the 
complete review of the whole field is beyond the scope of this section. Polymers, both 
natural and synthetic, are the broadest and most widely developed biomaterials used for 
tissue reconstruction. Synthetic polymers in particular are available in a wide variety of 
compositions, properties and most importantly they can be readily fabricated into 
complex structures. Table 2.5 lists the advantages and disadvantages of some of the 
natural and synthetic polymers currently being suggested for soft TE. Further details 
and examples of specific natural and synthetic polymers used in MTE are discussed in 
section 2.6. 
 
Table 2.5 A summary of the advantages and disadvantages of polymers suggested for 
TE applications (Chen et al. 2008)  
Biomaterials Positive Negative 
Naturally occurring biomaerials Excellent biocompatibility 
Biodegradable 
Poor processibility 
Poor mechanical properties 
 Bioresorbable Immunogenicity 
  Disease transfection 
   
Bulk biodegradable synthetic 
polymers 
Good biocompatibility 
Biodegradable 
Inflammatory caused by acid 
degradation products 
Poly(lactic acid) 
Poly(glycolic acid) 
Poly(lactic-co-glycolic acid) 
Bioresorbable 
Off-the-shelf availability 
Good processibility 
Accelerated degradation rates 
cause collapse of scaffolds 
Poly(propylene fumarate) Good ductility  
   
Surface bioerodible synthetic 
polymers 
Good biocompatibility 
Good processibility 
Cannot be completely replaced by 
new tissue 
Poly(ortho esters) 
Poly(phosphazene) 
Retain mechanical integrity 
during degradation 
Concern with long term effect 
Poly(anhydrides) Enhanced tissue ingrowth 
into porous scaffold 
 
 Off-the-shelf availability  
   
Nondegradable synthetic 
polymers 
No foreign body reactions 
Off-the-shelf availability 
Second surgery is required 
 Good processibility 
Tailorable mechanical 
properties 
Concern associated with long term 
effects if they have to stay in host 
for a lifetime 
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2.4.1 Natural polymers in soft TE 
 
The aim of soft TE is to either replace or help regenerate the natural ECM. Since the 
ECM comprises of structural proteins (collagen type I and III and elastin), adhesive 
proteins (laminin, collagen IV and VI) as well as anti-adhesive proteins, enzymes and 
proteoglycans, much work is being focused on developing biomaterials based on natural 
polymers such as collagen and its derivatives, fibrinogen, alginate and 
polyhydroxyalkanoates (Chen & Wu 2005; Philip, Keshavarz, & Roy 2007). Although 
the aim of natural polymers is to provide a natural substrate to facilitate cell attachment, 
proliferation and maintain cells in their differentiated state without causing an 
inflammatory response in vivo; their rapid degradation kinetics, weak mechanical 
properties, inconsistent material properties between various batches and 
immunogenicity (associated with the introduction of foreign collagen in vivo) are major 
drawbacks hindering their success in TE (Chen et al. 2008; Jawad et al. 2008a; 
Zimmermann et al. 2000). Table 2.6 lists some of the naturally occurring polymers used 
in TE.  
 
Table 2.6 List of some naturally occurring polymers used in TE applications (Atala & 
Lanza 2002) 
Polymer Source Main application fields 
Collagen Tendons and ligaments Multi-applications, including cardiac tissue 
engineering 
Collagen-GAG- 
   (alginate) copolymers 
 Artificial skin grafts for skin replacement 
Albumin In blood Transporting protein, used as coating to form 
a thromboresistant surface 
Hyaluronic acid In the ECM of all higher 
animals 
An important starting material for 
preparation of new biocompatible and 
biodegradable polymers that have 
applications in drug delivery and tissue 
engineering , including cardiac tissue 
engineering 
Fibrinogen-fibrin Purified from plasma in 
blood 
Multi-applications, including cardiac tissue 
engineering 
gelatin Extracted from the collagen 
inside animals’ connective 
tissue 
Multi-applications, including cardiac tissue 
engineering 
Chitosan Shells of shrimp and crabs Multi-applications, including cardiac tissue 
engineering 
MatrigelTM (gelatinous 
   protein mixture) 
Mouse tumor cells Myocardial tissue regeneration 
Alginate Abundant in the walls of 
brown algae 
Multi-applications, including cardiac tissue 
engineering 
Polyhydroxyalkanoates By fermentation Cardiovascular and bone tissue engineering 
  GAG = collagen and glycosaminoglycan 
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2.4.2 Synthetic polymers in soft TE 
 
Since naturally occurring polymers raise concerns, synthetic polymers were sought to 
be an alternative and have generally been accepted as more suitable substrates for TE 
applications due to their predictable and reproducible mechanical and physical 
properties, biocompatibility and controlled biodegradation rate. Moreover they can be 
manufactured with great precision and can be made available as ‘off the shelf’ products. 
However, synthetic polymers also have their drawbacks; they are foreign materials to 
cells therefore may cause inflammatory response when implanted and maybe difficult 
for some synthetic biomaterials to integrate with native tissue, albeit they allow native 
cells to form an ECM which eventually replaces the synthetic biomaterials (Chen et al. 
2008). The development of synthetic polymers has lead to an astonishing success rate 
for soft tissue implants, due to the fact that polymers can be tailor-made to match the 
properties of soft tissues (El-Fray 2003b). Polymers used for tissue reconstruction must 
be biocompatible, have a degradation rate equivalent to the healing rate of the tissue 
they intend to support and possess similar mechanical properties for optimal recovery. 
Currently there is no universal material suitable for all TE applications; in each case, the 
advantages and disadvantages must be weighed out before deciding on an appropriate 
biomaterial for the intended TE application.  
 
One of the first polymeric materials used for heart TE was based on hydrolytically 
degradable biocompatible polyesters composed of polylactic acid (PLA), polyglycolic 
acid (PGA) and their copolymer polylactic-co-glycolic acid (PLGA) (Torres et al. 
2006;Zammaretti & Jaconi 2004). The ability to tailor their mechanical properties, 
define their morphology  and control their degradation kinetics by altering copolymer 
ratio, to better suit the tissue it intends to replace, are attractive features of these 
synthetic polymers (Giraud et al. 2007). A furthermore, the natural metabolites of PGA 
and PLA and their copolymers, glycolic and lactic acid, make these polymers more 
appealing as the human body is naturally able to completely remove monomeric 
compounds of lactic and glycolic acids (Misra & Boccaccini 2007), although it has been 
reported that these by-products increase acidic concentration in the body, causing 
inflammatory response which in turn damages local tissue. Further disadvantage of 
these polymers is their bulk degradation kinetics which causes sudden loss of 
mechanical properties of the construct (Giraud et al. 2007).  Moreover, experimental 
trials have confirmed that the elastic properties of the biomaterial must match the elastic 
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properties of the native heart to prevent the cells detaching from the bioengineered 
construct (McDevitt et al. 2002). Therefore other polymers have been developed for 
cardiac TE, as reviewed recently (Chen et al. 2008;Jawad et al. 2008a). 
 
It has also been found that many factors, such as water absorption and polarity, hinder 
the medical suitability of polymeric biomaterials. Water uptake may cause other ions, 
low molecular weight polymer molecules and polymer additives to be taken up, leading 
to unwanted biodegradation and toxic responses. To overcome these problems 
(elasticity, water absorption and polarity), thermoplastic elastomers (TPEs), specifically, 
nanostructured multiblock (segmented) copolymers, multiblock polyurethanes for 
example, have been recognized as key polymers in the medical field being among the 
most bio- and blood-compatible materials known today (El-Fray 2003a). This class of 
polymers relevant for the present study is discussed in further detail in section 2.5.  
2.4.3 Nanomaterials in TE 
 
Polymer nanocomposites for soft TE applications are a rapidly evolving class of 
relatively new functional and structural materials (Jog 2006). They are polymer 
composites that contain a particular class of fillers such as nanoparticles (NPs), 
nanotubes or nanoclays. This new group of composite biomaterials for TE scaffolds is 
of great interest to scientists because of their benefits compared to the properties of the 
base polymer alone. Advantages include a significant improvement in mechanical 
properties (El-Fray & Boccaccini 2005;Liu et al. 2008) as well as enhanced cellular 
adhesion (Bacakova et al. 2007;Webster & Smith 2005) and higher cytocompatibility 
than composites containing conventional micrometer particles (Mei et al. 2007;Webster 
2003;Webster & Smith 2005). Generally, these polymers are defined as two phase 
materials, where the polymer or copolymer is the matrix phase and the second phase is 
dominated by the dispersed inorganic NPs in the matrix. Examples of possible nano 
sized materials used as second phase include NPs such as TiO2 (El-Fray & Boccaccini 
2005), copper NPs (Chen et al. 2006) alumina (Gutwein & Webster 2002), 
hydroxyapatite (Kim et al. 2007), carbon nanotubes (Abarrategi et al. 2008), bioactive 
glass (Liu et al. 2008) or layered silicates such as clay (Jog 2006).   
 
Bionanomaterials, which are defined in the 1-100nm range, have been used to create 
materials that have novel physical/chemical properties and functions based on their 
advantageous, miniscule size. These materials can be considered “next generation” 
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biomaterials which are designed to increase functions of cells leading to efficient tissue 
regeneration (Hench & Polak 2002). A new approach to the design of TE scaffolds is 
thus to simulate the nanometre surface roughness found in natural tissues in synthetic 
formulations as well as to mimic the mechanical properties of the native tissue they 
intend to replace. However, despite the increasing interest and application of 
nanomaterials, there is a serious lack of information concerning the impact of 
manufactured nanomaterials on human health and environment. This is due to the fact 
that NPs are small enough to penetrate through the smallest capillaries throughout the 
body and could pass through biological cellular membranes, in turn affecting the 
physiology of any cell in an animal’s body (Brooking, Davis, & Illum 2001). This 
consideration is of importance for stem cells, where the effect of NPs on their potential 
for self-renewal and differentiation is unknown. With many advantages reported on the 
success of NPs, little is known about the effect of these particles on biological 
applications, specifically those involving heart and bone regeneration despite the fact 
that the ECM of the bone and heart are nanostructured materials. Data available from 
toxicity studies of NPs, in particular on ESCs, are limited (Braydich-Stolle et al. 2005).  
 
There is an increasing interest in polymers containing bioactive and bioinert ceramic 
phases for TE applications. These composites offer variability in both surface 
morphology and mechanical properties. Considering that the ECM (including proteins) 
of natural human tissue is at the nanometre range, previous investigators (Webster 
1999) focused their research on mimicking the surface roughness in natural tissue. 
Webster et al. (1999) compared osteoblast adhesion on conventional micro- and nano- 
phase ceramics and found cellular adhesion on nanophase titania (32 nm grain size) 
significantly greater than on conventional titania with a grain size of 2.12 µm. More 
recently, Gerhardt et al. (2007) demonstrated that mimicking the surface and structure 
of living tissue incorporating TiO2 NPs in biopolymers positively influenced the cellular 
behaviour.  
 
Many studies have recently reported on the success of TiO2 NPs in bone TE 
applications (Boccaccini et al. 2005;Boccaccini & Blaker 2006;Gerhardt 
2007;Nakayama 2007;Wei 2008) with much focus on the topography of the 
biomaterials to improve the bone-implant interface and to further enhance cellular 
adhesion and spread. Moreover, the incorporation of TiO2 NPs has been shown to 
improve the mechanical properties of biomaterials, for bone TE applications this was 
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vital so as to eliminate elastic modulus mismatch and stress shielding effects, where 
incorporations in poly(D,L lactide acid) (PDLLA) as high as 20 wt% (Wei 2008) and 30 
wt% (Gerhardt 2007) TiO2 NPs were investigated. TiO2 NPs have been also 
incorporated into PLGA (Torres 2007) and PDLLA (Nakayama 2007) matrices. More 
relevant to this investigation, TiO2 NPs have been incorporated into TPE; multiblock 
poly(aliphatic/aromatic-ester)s containing phthalic acid sequences, PET or 
poly(butylene terephthalate) (PBT) and a dimer fatty acid (DFA), to increase bioactivity 
and enhance mechanical properties to tailor the biomaterials suitability for soft and hard 
TE as well as other biomedical applications (El-Fray & Boccaccini 2005).  
 
TiO2 NPs are commonly used in air and water remediation as well as in various 
products designed for direct human use because TiO2 NPs under illumination are strong 
oxidizing agents resulting in free radicals that are capable of reacting with organic and 
biological molecules (Sayes 2006). Therefore, they are effective in deactivating 
pollutants and killing microorganisims.  Because NPs are defined as particles ranging 
between 0 and 100 nm in size, one major concern for the use of NPs is that the human 
body, via inhalation, can potentially easily take them up. This can pose a serious risk on 
organs in the human body that are sensitive to oxidative stress damage (e.g. the brain, 
heart and the immune system) and may cause diseases such as Parkinson’s and 
Alzheimer’s disease. Moreover, oxidative stress is strongly linked to worsening 
conditions for MI, for example, it may disrupt membrane-bound enzymes and in turn 
increase membrane permeability causing cardiac arrhythmias (Kukin & Fuster 2002). 
Although studies have reported the effect of TiO2 NPs on brain microaglia (Long 2006), 
liver (Hussain 2005), bone-like osteosarcoma (Gerhardt 2007) and lung cells (Warheit 
2007b), no studies have reported on the cardiotoxicity of TiO2 NP in cultures. In a study 
by Polonchuk et al. (2000) seeded adult rat cardiomyocytes onto sol-gel derived titania 
coated substrates (commercially available glass cover slips with a roughness of 
approximately 10 nm and titania ceramic discs with roughness of approximately 900 
nm) and showed that TiO2 ceramics mimicking cell surface topography can promote 
cell growth, spreading and maintained adult cardiomyocytes phenotype in long-term 
primary cultures (Polonchuk et al. 2000).   
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2.4.4 Topography in TE 
 
As mentioned earlier the cardiac ECM is comprised of structural, adhesive and anti-
adhesive proteins, as well as enzymes and proteoglycans. All these components in the 
ECM are in the nanometer range giving the ECM its nanotopography feature. It is thus 
of importance for tissue engineers to mimic this topography when considering different 
biomaterials for cardiac TE. One of the current challenges in TE is to develop more 
suitable methods for the fabrication of scaffolds of defined architecture to guide cell 
growth and proliferation. Mimicking the heart’s ECM is a much studied research topic 
in cell physiology but many questions remain unanswered, such as the fact that 
arrangement of cardiac myocytes, as found in vivo, is usually lacking in the in vitro 
models as well as the significant detachment seen between the biomaterial and the cells 
(McDevitt et al. 2002). In the particular case of TE based on using a polymer substrate 
(e.g. a pre-formed patch), it is vital to not only ensure that cells attach to the polymeric 
surface but to know also that once the polymer undergoes mechanical stretching for 
example, as it would in vivo, the cells do not detach. The common approach is to coat 
the biomaterials with collagen to keep cells attached. Silicone coated with collagen has 
been used to keep cells attached, however, upon repeated mechanical deformation 
significant problems with the detachment of the collagen layer from silicone occurred 
(Ikada 1994). Alternative methods to modify polymeric surfaces for TE include electron 
beam lithography, photolithography, chemical etching and polymer demixing (Norman 
& Desai 2006). The use of nanotechnology for TE is at early stages and where 
techniques are still being refined, there is the need for simpler model systems to gain an 
insight into cellular responses to their nano-environment.   
 
One must obviously consider also the effect of micro-topography, since most structures 
in the human body are in the micron to millimeter size range. Cardiomyocytes prefer to 
terminate on vertical structures with a subsequent increase in cell height, a more 
representative of in vivo behavior (McDevitt et al. 2002). By creating topographic 
features corresponding to cellular dimensions, ranging between 10 and 50 µm, cells also 
seem to exhibit a more in vivo-like cellular morphology (Deutsch et al. 2006). Research 
is ongoing to identify which topography is more suited and compatible for cardiac cells, 
as well as many other cell types; to grow, proliferate, and most importantly eventually 
recreate tissue architecture at the cellular and sub-cellular level in a reproducible 
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manner, maintaining optimum cardiomyocyte lifespan. The aspect of topography and its 
influence on cell attachment and maturation is of interest in the present research project. 
2.5 PET/DLA block copolymers 
2.5.1 Elastomers 
Elastomers are amorphous polymers existing above their glass transition temperature 
(Tg), giving them their key feature of considerable segmental motion. The term 
“elastomer” is used to designate natural or synthetic materials with rubber like 
properties (El-Fray 2003a). Elastomers are usually either thermosets which require 
vulcanization or thermoplastics. This project is mainly concerned with thermoplastics as 
they have the advantage of being, biocompatible and recyclable since they are able to go 
through many melt/freeze cycles with no significant chemical change; they have the 
ability to withstand strong deformation forces without rupturing and once the 
deformational force is removed they return to their original size and shape (El-Fray 
2003c). 
 
There are many commercially available elastomers currently used in the medical field, 
examples include, PVC used to make gloves and tubes and naphthalene-plasticized 
resins which are fabricated into porous vascular graft prosthesis. The list is ongoing. 
However, the most widely used polymers in the medical field are the biocompatible 
silicone elastomers, due to their very strong and mobile bonds of their Si-O-Si backbone. 
They are mainly used in applications such as air/blood filter membranes or even contact 
lenses, where mechanical properties are of little importance, as their high tear resistance 
and gas permeability outperform their mechanical properties (El-Fray 2003b).  
2.5.2 Thermoplastic Elastomers (TPEs) 
TPEs  have been used widely since they were first introduced in the 1960’s. A unique 
characteristic of TPEs is that they are processed as thermoplastics, yet they possess 
physical properties of rubbers, such as resilience, softness and flexibility. Unlike other 
elastomers, TPEs do not need to undergo the slow and irreversible thermosetting 
vulcanization procedure (which takes place upon heating), to improve their physical 
properties. The transition from a thermoplastic elastomeric melt to a rubber-like solid 
one is rapid and reversible and takes place upon cooling (Holden 2005). This reversible 
transition does cause some setbacks and limitations to the application of the TPEs. 
Applications where compression set and resistance to deformation at high temperatures 
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is of importance, conventional vulcanized rubbers are used, for example in areas such as 
automobile tyres. However, thermoplastic materials are a significant and growing 
branch of the polymeric market, an estimated 1.3 million tons were consumed in the 
year 2000 (Holden & Krischeldorf 2004). 
 
Most TPEs are multiphase compositions; these phases are either chemically bonded by 
block or graft copolymerization. At least one phase consists of a rigid nanoscale domain 
(hard segments) at room temperature which becomes fluid upon heating; which is 
covalently bonded to another phase consisting of a softer material that is rubber-like 
material at room temperature (soft segments). The A-B-A structure represents a simple 
block copolymer, where A is a hard phase and B is the elastomer. It is the unique 
combination of the hard and soft segments that gives thermoplastics the important 
property of having the elasticity of vulcanized rubbers. Thermoplastic copolymers 
consist of different types of segments that alternate along the macromolecule, with each 
segment having its own characteristic properties, such as melting temperature (Tm), Tg 
and differing mechanical properties. The immiscibility between hard and soft segments, 
due to difference in structure and molecular weight, is an important characteristic of 
multiblock copolymers. With the former segment possessing high elastic modulus and 
Tg, making up the crystalline spherules found in the amorphous matrix of the latter soft 
segment. The soft segment provides the elastomeric properties of the polymer. 
 
TPEs can be subdivided into three categories; microphase-separated block copolymers, 
dynamically vulcanized rubbers and nanostructured multiblock copolymers (El-Fray 
2003a). Microphase block copolymers of polystyrene (block A) and polydienes (block 
B) and their derivatives are the largest commercially produced TPEs, an example of this 
is poly(styrene-block-elastomer-block-styrene) (S-B-S). However, where load-bearing 
applications are of importance, it is the dynamically vulcanized TPEs that are of interest. 
In this sub-category of TPEs, the vulcanized elastomer particles are dispersed in melt 
processable plastic matrices. Nanostructured multiblock copolymers have become in 
recent years one of the key material groups for research in the medical field with several 
formulations being commercially available. An example is polyurethane-elastomer, 
which is commercially available as Pellthane® or Estane® used in heart valves as well 
as cardiac assist devices (Han et al. 2006). Polyester-elastomer, commercially available 
as Polyactive®, is another example of useful multiblock copolymer which is currently 
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used in the reconstruction of tympanic membrane and skin (El-Fray 2003b;Pouliot 
2004;Waris et al. 2008). 
 
Poly(ethylene terephthalate) (PET) and poly(butylene terephthalate) (PBT) are aromatic 
polyesters commonly used as biomaterials as they exhibit excellent thermal and 
mechanical properties as well as inducing weak inflammatory response in vivo. 
However, despite their biocompatibility, their relative stability under physiological 
conditions remains a major setback (Deschamps et al. 2006a;Deschamps et al. 2006b). 
There is a still ongoing effort to accelerate the degradation rate of these aromatic 
polyesters by preparing aliphatic/aromatic polyesters, with the aliphatic compound 
being, for example, poly(ethylene glycol) (PEG) or a fatty acid. Commercially available 
Polyactive®, a family of copolymers based on PEG and PBT, has been used extensively 
as a degradable material in medicine. The desirability of using segmented block 
copolymers is the ability to modify its physical and mechanical properties to suit each 
application by varying the copolymer composition, i.e. the ratio of the hard and soft 
segments, making the copolymer available to a wide range of applications. Polyactive® 
has been used for human fibroblasts substrate (Fromstein 2002) where a weight ratio of 
55/45 of PEG/PBT was used, respectively (van Dorp et al. 2006), while other groups 
have suggested its use in orthopedic and dental applications (Sakkers et al. 2006b), 
where stiffer materials are needed.   
 
The combination of segments, hard and soft, has been a topic frequently investigated 
(El-Fray & Slonecki 1999), where various polymer blocks have been suggested for 
different applications. Poly(ester-ether) (PEE) is another example of these types of 
block copolymers, where PBT (Sakkers et al. 2006a) or poly(butylene isophthalate) 
(PBI) are the hard segments and poly(oxytetramethylene) (PTMO) is the soft segment. 
It is commonly used in mechanical, automotive industries and medical devices (El-Fray 
& Slonecki 1999;El-Fray & Slonecki 1995). Unfavorable aspects of PTMO include the 
ability to undergo photodegredation, oxidative degradation or hydrolysis at elevated 
temperatures and has lead researchers to find alternative soft segments (El-Fray & 
Slonecki 1999). In 1974, PTMO was replaced with an aliphatic amorphous block, DFA 
(El-Fray 2003c), as the soft segment.  This substitution produces a high degree of 
hydrogenation contributing to excellent oxidation resistance, hence resulting in a more 
stable block copolymer. 
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Monomers from fatty acids and their dimers obtained from refined natural carbon (C18-
C22) unsaturated fatty acids such as erucic acid dimer, bile acid dimer, ricinoleic acid 
and other fatty acids have been successfully used for the preparation of different 
polymer formulations. Industrial DFA (El-Fray & Boccaccini 2005) containing a C36 
aliphatic group is another type of amorphous fatty acid with hydrophobic properties; it 
can be produced from renewable resources as a cheap and abundant material and is a 
resultant from dimerization products of linoleic acid. These are widely used monomers 
for many different polymer formulations as the soft segment of a copolymer 
contributing to important properties such as; high impact strength and flexibility, 
resistance to temperature, UV and oxidative degradation. However, the key property of 
DFA monomers is their excellent elastic recovery after tensile loading (El-Fray 2003b).  
 
The initial focus of this project will be mainly concerned with the 
poly(aliphatic/aromatic-ester) nanostructured multiblock copolymer made of PET and 
DLA (from here on abbreviated as PET/DLA) randomly arranged along the 
macromolecule backbone. This material was first developed by Professor M El-Fray in 
Technical University of Szczecin, Poland, for soft tissue reconstruction (El-Fray 2003b). 
The polymer is synthesized in a two-stage process; transesterification followed by 
polycondensation in the melt. Further details on the processing of PET/DLA are 
documented in chapter 3, section 3.4.  
2.6 Myocardial Tissue Engineering (MTE) 
 
The term cardiac TE is a very broad and general description that is sometimes used. It 
can involve the TE of heart valves and sometimes the TE for other heart constituents. 
However, in this section an extensive review about MTE is documented. Firstly, the key 
requirements for successful MTE are listed. This is followed by highlighting the most 
common methods used to fabricate MTE constructs. Finally, key findings in MTE are 
discussed. Figure  2.8 highlights the fundamental components for a successful MTE 
construct before implantation. Briefly, a scaffold/patch is made from a biomaterial 
(natural or synthetic polymer). A selection of cells (cardiac or non-cardiac) is expanded 
in vitro, with additional growth factors.  Cells, with or without growth factors, are 
seeded onto the scaffold to form the MTE construct and mechanical, electrical and 
morphological properties are optimized. This construct is eventually sutured onto the 
infarcted region (Jawad et al. 2008a). 
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Figure 2.8 Schematic diagram illustrating the principle of TE for myocardial 
regeneration (Jawad et al. 2008a).  
2.6.1 Requirements for MTE constructs 
 
Although many biomaterials have been suggested for various TE purposes, all 
constructs share the following basic requirements: 
• Biocompatible. The biomaterial must not be rejected or induce an 
inflammatory response in vivo.  
• Mechanical integrity. The biomaterial must enable handling during 
transplantation. More importantly, mechanical properties should match 
the host tissue it intends to replace and provide mechanical support 
during regeneration. 
• Biodegradable. The degradation rate of the biomaterial should match 
the regeneration rate of the host tissue and the degradation by-products 
must be non-toxic and readily removed from the body to avoid second 
surgery.  
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• Cell ‘friendly’. Enhance cell adhesion and survival both in vivo and in 
vitro. 
• Biomimetic. Replicate the ECM of the tissue it intends to replace. 
• Fabrication. The biomaterial must be easily accessible and designed 
with acceptable cost. 
Additional requirements for MTE constructs include: 
• The biomaterial should be able to withstand, or even contribute to the 
continuous stretching/relaxing motion of the myocardium that occurs at 
each heartbeat.  
• The biomaterial must encourage cell proliferation and differentiation into 
cardiomyocytes as well as supporting vascular cells. 
• Ideally, biomaterials could encourage cardiomyocyte alignment and 
maturation in vitro before implantation, improving the contractile 
properties of the graft.  
• The biomaterial must enable electrical integration of engineered graft 
with the native tissue to allow synchronised beating between the artificial 
construct and the heart. This requires matched excitability of host and 
grafted tissue, and support of electrical wave front propagation. 
• The biomaterial should encourage vascularisation of the construct, to 
support survival of grafted cells. 
• Identifications of a suitable cell source that will not provoke arrhythmia 
once introduced into the body. 
 
In terms of cardiac function itself, the physical characteristics of the material, in 
particular elastic behaviour, should lie in a range of values that are close enough to the 
natural myocardium so that they do not massively enhance diastolic stiffness (and hence 
impede relaxation).  It might be argued that a certain degree of support of the scar 
would be beneficial to prevent scar expansion and the consequent deleterious 
remodeling of the myocardium, and therefore stiffness slightly in excess of the scar 
itself would be acceptable. For systolic function, the material alone will confer no 
benefit other than, possibly, contributing to elastic recoil: the important point is that the 
shape, attachment method and stiffness should not physically hinder the full contraction 
of the ventricle.  If the material is combined with beating myocytes, then it should allow 
these cells to exert their contractile effect.  One desirable potential strategy is for the 
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material to support nascent new cardiomyocytes as they develop and integrate into the 
host and biodegrade when assimilation is complete.   
 
There is concern whether a dense ‘patch’ is useful. It has been frequently reported that 
for the cells to survive and carry out their full potential functions they must be 
embedded in a 3D scaffold containing pores. In this scenario, one must consider the 
required functions of the engineered construct. If the construct is to act solely as a 
“vehicle” to transport the cells into the patient, and then degrade in a short period (e.g. 
within 3 months), it is possible that a patch would be suitable (Ke et al. 2005). 
Alternatively, if the construct is to support the damaged area for a sustained period 
(simultaneously acting as a left ventricular (LV) restraint and a delivery vehicle for the 
cells), then it is vital that it ensures cell survival for the time they are in contact with the 
scaffold and slow degradation behaviour is required (Jawad et al. 2007).  
 
2.6.2 Left ventricular (LV) restraint devices 
 
Unlike TE, the attempt to restrain the LV remodeling and dilation caused by infarction 
using a polymeric material as a restraint does not require the incorporation of cells. 
Briefly, this has been suggested as either a ‘wrap’ for the ventricles (both ventricles 
(Schroder et al. 2006;Walsh 2006) or solely the left ventricle (Enomoto et al. 2005)) or 
as a suture in the region of infarction (Kelley et al. 1999). Results showed this approach 
to be controversial, with some reporting improved cardiac function by preserving LV 
geometry (Christman & Randall 2006;Kelley et al. 1999) and others reporting marginal 
improvements in suturing materials onto infarcted area in comparison to the 
improvements with sheep who received a wrap around the ventricles (Moainie et al. 
2002).  
 
A commercially available cardiac support device (CSD), the Acorn Cardiovascular Inc. 
(St. Paul, Minnesota), manufactured from a common very slow degrading PET has been 
used as a wrap around the cardiac ventricles to prevent deterioration of the left ventricle 
(Sabbah 2003;Walsh 2006). This has been clinically tried with a total of 300 patients on 
different occasions (Christman & Randall 2006), all reporting an improvement in LV 
end-diastolic volume. However, the lack of long-term studies and knowledge on the 
mechanism as to how the CSD improves cardiac function as well as the conflicting 
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results on the improvement of cardiac function (Christman & Randall 2006;Schroder et 
al. 2006) hinders the approval by the Food and Drug Administration (FDA). Table 2.4 
summarizes the advantages and disadvantages of different MTE approaches covered in 
this review. 
 
2.6.3 Methods adopted in MTE constructs 
 
Cardiac TE is still at its formative years. However, it is an emerging field that gives 
enormous hope for improving the treatment of heart diseases. Not only patients needing 
heart transplants will benefit from this approach, but some patients may only require 
smaller structures like pieces of muscle, valves or even vessels, will also appreciate the 
enormous possibilities offered by cardiac TE.  
 
The heart-lung machine was one of the first approaches to overcome heart disease, 
which was initially used by Miller and colleagues in Philadelphia, USA (Zammaretti & 
Jaconi 2004). Mitral valve replacement shortly followed, using either cadavers or fascia 
lata to surgically create the valve. Kwan-Gett and co-workers first introduced the 
artificial heart in 1969 (Zammaretti & Jaconi 2004). Eventually, in the mid-1990’s 
scientists started to apply gene delivery techniques, followed by cell transplantation 
approaches, as described in section 2.2. Initially, scientists looked at autologous tissues 
and cells, but new developments in the use of synthetic materials and cells is leading to 
innovative TE strategies for the heart (Zammaretti & Jaconi 2004). In this section, a 
brief insight is given on a series of techniques used to produce engineered constructs for 
MTE.  
2.6.3.1 Electrospinning 
Collagen is the main constituent of the ECM, and since TE constructs require an ECM-
like structure and topography to mimic the in vivo size and scale of the collagen fibrils 
in the ECM (section 2.4.4), electrospinning has been suggested for this purpose. 
Electrospinning, a process patented in 1934 by Formhals, is used to develop scaffolds, 
made from synthetic, natural or a combination of both, with sub-micron pores and nano-
topography surfaces (Pham, Sharma, & Mikos 2006). Electrospinning involves an 
electrically charged jet of polymer solution produced by a high voltage. A constant 
pressure generated by a metering pump causes the polymer mixture to flow from the 
pipette, at a constant rate, onto a collector screen which eventually dries/solidifies 
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leaving a polymer fibre (fibre diameter can range from 3nm to 5µm). This method is 
common in MTE and has been suggested for various biomaterials (see table 2.7). 
 
Figure 2.9 Schematic diagram showing electrospinning machine 
(http://www.che.vt.edu, accessed on 18/11/06) 
2.6.3.2 Bioreactors 
The general concept of a bioreactor is to encourage growth and development of 
biological cells or tissue on biomaterials as if under in vivo condition (Polak & 
Mantalaris 2008). The ability of producing a 3D myocardial tissue comprised of more 
than a few layers of muscle is the main advantage of using a bioreactor. Although the 
main purpose of using bioreactors is scientific research, further improvements in in vitro 
design and quality control may eventually allow their application for MTE. Several 
different bioreactors have been suggested for cardiac constructs. Static or mixed flask 
bioreactors where constructs are suspended in cultivation medium, rotating vessel 
bioreactors where constructs are suspended in medium that has a constant rotational 
flow and finally perfusion cartridge bioreactors where constructs are perfused at 
interstitial velocities, comparable to blood flow in native tissue (Vunjak-Novakovic, 
Radisic, & Obradovic 2006), the four types of bioreactors are illustrated in figure 2.9. 
 
 
 
Figure 2.10 Schematic illustrations on the four types of bioreactors used for MTE (a) 
static (b) mixed (c) rotating (d) perfusion bioreactors (Freed et al. 2006) 
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The main advantage of bioreactor systems used in MTE is the ability to cultivate cells 
on biomaterials producing contractile constructs of cell-polymer origin (Bursac et al. 
1999; Carrier et al. 1999; Carrier et al. 2001; Carrier et al. 2002; Kofidis et al. 2003b; 
Papadaki et al. 2001; Park et al. 2005). Researchers are constantly striving to design 
improved bioreactors to make it possible to grow 3D myocardial tissue comprised of 
more than a few layers of muscles. Many different geometries portraying various 
patterns of fluid dynamics have been suggested (Leor 2005).  
 
Currently, the limitation of bioreactors is their restricted ability to supply an adequate 
amount of nutrients to a tissue of thickness greater than approximately 100µm (some 
reports suggesting 80 µm, (Birla et al. 2005)), or less than 10 cell layers thick (Leor 
2005). This limitation causes weak cellular integrity, short duration of contractibility, as 
well as inhomogeneous seeding; as a result affecting tissue function and cellular 
viability (Vunjak-Novakovic, Radisic, & Obradovic 2006). Although the purpose of 
these bioartificial tissues is primarily for scientific studies, researchers also intend to 
improve their in-vitro designs and eventually use them for cardiac repair. Carrier et al. 
(Carrier et al. 2001) and Radisic et al. (Radisic et al. 2005; Radisic et al. 2006) 
demonstrated the importance of oxygen on engineered cardiac grafts to overcome the 
limitation of producing a 100µm thick new tissue. They found by increasing the oxygen 
concentration supply to the in-vitro construct, an improved engineered cardiac muscle 
was produced. They then went on to further improve the engineered cardiac muscle by 
allowing the medium to directly perfuse the construct (Carrier et al. 2002). Additional 
studies are required to evaluate the specific properties of these engineered constructs, 
including the mechanical behavior, biodegradability and eventually their in-vivo 
performance. Primary neonatal rat ventricular cells were cultured on PGA scaffolds by 
Bursac et al. (1999) (Bursac et al. 1999) using bioreactors to form cardiac muscle 
constructs. The polymer scaffold provided the 3D substrate for cell attachment and 
consequently tissue formation, whereas the bioreactor promotes mass transfer of 
nutrients and gases to the forming tissue. Within one week, cardiac myocytes were 
organized in multiple layers in a 3D configuration and this was used for in vitro impulse 
studies on a macroscopic (tissue) level, rather than on a cellular level. 
2.6.3.3 Cell sheeting (temperature-sensitive) 
This method was initially reported by Shimizu et al. in 2002 (Shimizu et al. 2002) and 
has been suggested for MTE. The concept of this method involves temperature-
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responsive dishes made from a specific polymer, poly(N-isopropylacrylamide) 
(PIPAAM), which is temperature sensitive. At 37°C the polymer is hydrophobic and 
cell adhesive, however, a 5°C reduction in temperature can cause the polymer to 
become non-cell adhesive as it hydrates and swells because its hydrophobic nature is 
now hydrophilic. Cardiomyocytes seeded onto the polymer will produce individual 
spontaneously beating myocardial tissue sheets. More recently, Miyahara et al., (2006) 
reported on the success of implanting a 100µm thick cardiac tissue, made from six 
monlayered mesenchymal stem cell sheets layered together and implanted onto the 
infarcted region, improving infarcted wall thickness (Miyahara et al. 2006).  
2.6.3.4 In-situ engineering  
Like TE, in situ engineering involves both biomaterials and cells. However, this is a 
‘scaffold-free’ approach in MTE. It involves the direct injection of the biomaterial and 
cell mixture into the infarcted region. Unlike prefabricated scaffolds used in MTE, the 
injectable natural polymers will readily bond to the native tissue, as they can be easily 
shaped or cast to the heart’s complex structure, simultaneously providing good support 
for the cells. Different polymers such as alginate (Leor et al. 2000), fibrin glue 
(Christman et al. 2004b), collagen (Dai et al. 2005) and Matrigel (Kofidis et al. 2005b) 
have been suggested for in situ engineering. Acellular alginate with bioactive molecules 
has also been suggested, with the hope that cardiac progenitor cells will home to the 
infarcted region (Leor 2005). More recently, biomaterials with peptides and growth 
factors (Iwakura et al. 2003), as well as ‘self-assembling’ peptide nanofibres (Davis et 
al. 2005) have been suggested. None of these strategies have in fact produced new 
myocardial tissue, and experience with injection of cells directly into the heart has 
suggested that there is a low limit on the amount of new material that can be introduced 
into either the dense and continually compressing myocardium or the stiff and avascular 
scar. 
2.6.4 Achievements in MTE 
Wide ranges of polymers, have been suggested for MTE (table 2.7), this section will 
give an insight to the types of biomaterials reported specifically for myocardial 
generation.  
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Table 2.7 Key examples of MTE approaches developed to date (Jawad et al. 2008a) 
 
Scaffold material Processing method Cell source 
 
Natural materials 
Collagen Commercially available 3D 
scaffold Acellular  
Collagen gel Bioreactor Neonatal rat CM  
Commercially available 
patches 
Fetal rat CM  
Fetal human CM  
Rat smooth muscle cells  
Rat skin fibroblasts 
Gelatin mesh (Gelafoam) 
Biostretch/bioreactor Fetal human CM  
Collagen + glycosaminoglycan (GAG) 2 cross-linking methods Bone marrow derived 
mesenchymal cells  
 
Collagen type I sponge + matrigel 
 
Bioreactor 
Undifferentiated mESCs  
mESCMs  
 
Sodium alginate 
 
Freeze-drying technique 
               Neonatal CM  
Fetal rat cardiac CM  
hESC-CM 
 
Synthetic materials 
Polyurethane Solvent cast and spin 
coating Neonatal rat CM  
Elastomeric 1,3-trimethylene 
carbonate (TMC) & D,L-lactide 
(DLLA) and copolymers 
Salt-leaching 
Rat cardiomyocytes cell 
(CRL-1446) line and human 
endothelial cells  
Vicryl mesh (Dermagraft, Smith and 
Nephew) Commercially available Human dermal fibroblasts  
poly(N-isopropylacrylamide) 
(PIPAAM) Cell sheeting Neonatal rat CM  
Neonatal mesenchymal cells  
 
Poly(ε-caprolactone) 
 
Electrospinning Neonatal rat CM  
Poly-glycolic acid (PGA) Commercially available mESC-CM  
non-woven poly(lactide)- and 
poly(glycolide)-based (PLGA) Electrospinning Primary rat CM  
Poly-co-caprolactone (PCL) Solvent casting and particle leaching 
Rat bone-marrow derived 
nuclear cells  
 
Combination of natural and synthetic materials 
Poly(ester urethane) urea and collagen 
type I Electrospinning 
 Aortic rat smooth muscle 
cells  
PCL mesh coated with collagen type I Electrospinning Isolated rat cardiomyocytes  
PGA, PLA, and PCL polymers with 
commercially available collagen 
sponge (Ultrfoam®) 
Three polymers mixed and 
pores achieved using gas-
forming method, followed 
by immersion in collagen 
Neonatal heart cells  
Collagen (type I and IV) and Matrigel 
matrix mixed with cells and seeded 
onto non-woven polymer mesh  
Materials mixed in circular 
moulds 
Multipotent bone marrow-
derived mesenchymal 
progenitor cells  
3D=three dimensional, CM=cardiomyocytes, mESC-CM=mouse embryonic stem cell derived 
cardiomyocytes, hESC-CM=human embryonic stem cell derived cardiomyocytes 
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2.6.4.1 MTE based on synthetic biomaterials 
This section will describe novel in vitro and in vivo methods proposed for growing 
cardiac tissue from synthetic biomaterials. Polyurethane, a degradable polymer 
renowned for its biocompatibility with soft and hard tissue, was investigated for its 
potential application in MTE (Alperin, Zandstra, & Woodhouse 2005;McDevitt et al. 
2002). Researchers demonstrated that the successive addition of spatially organized 
cardiomyocytes onto micro-contact laminin patterned lanes (15x10µm) on polyurethane 
films will produce a build up of a more 3D organized cardiomyocyte sheet  (McDevitt 
et al. 2002). A highly porous pre-coated laminin polyurethane scaffold was seeded with 
rat skeletal myoblasts and cultured in vitro for 15 days before implantation. Four weeks 
post implantation results showed no signs of transdifferentiation into cardiomyocytes, 
however cells did proliferate within the scaffold (Siepe et al. 2007). Interestingly, the 
group of Woodhouse generated a large amount of ESC-CMs in a bioreactor and seeded 
these cells onto polyurethane scaffolds. Immunostaining revealed connexin43 and 
sarcomeric myosin was evident and beating cardiomyocytes were observed 14 days 
after seeding (Fromstein et al. 2008).   
 
Pego et al. (Pego et al. 2003) investigated the in vivo implantation of elastomeric 1,3-
trimethylene carbonate (TMC) and D,L-lactide (DLLA) polymers and their copolymers 
made by salt-leaching technique with rat cardiomyocytes cultured on the surface. They 
found that the construct disappeared within 10 months and no severe tissue reaction was 
observed post implantation. They also showed that this copolymer has the ability to 
sustain the cyclic loading of the heart muscle under physiological conditions. 
 
Dermagraft® (Smith and Nephew, London, UK), a human tissue composed of human 
dermal fibroblasts, was cultured on Vicryl® mesh (90:10 poly(glycolide:lactide)) by 
Kellar et al. (Kellar et al. 2001) developing angiogenic patches. In-vivo implantation 
was successful as the patch stimulated angiogenesis within the region of cardiac 
infarction. They then went on to show that the patch does attenuate further loss of LV 
function, suggesting it maybe related to myocardial revascularization (Kellar et al. 
2005). This investigation illustrates the wide range of cells being tested to repair 
infarcted areas, where fibroblasts were used as opposed to cardiomyocytes. Iyer and 
Radisic (Iyer & Radisic 2006) reported a rather interesting new concept for MTE where 
they seeded three different types of cells (tri- culture), fibroblasts, endothelial and 
cardiomyocyte cells onto PEG discs. Spontaneous beating was observed in both the tri-
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culture samples and PEG samples solely with cardiomyocytes. Recently, a novel 
approach has been described for the generation of a 3D synchronously contracting 
engineered cardiac muscle derived from hESC-CMs, endothelial cells and embryonic 
fibroblasts seeded porous sponge (composed of 50% PLGA and 50% PLLA). The 
construct exhibited structural and functional properties typical to that of early cardiac 
tissue (Caspi et al. 2007). This approach is still at infancy, however it may serve as a 3D 
model of human cardiac tissue for in vitro studies.  
 
Many studies have illustrated the successful combination of cell sheeting and 
temperature responsive culture dishes in MTE as mentioned above (Sekine et al. 
2006;Sekiya et al. 2006;Shimizu et al. 2006).  Miyahara et al. (Miyahara et al. 2006) 
reported improvement in infarcted wall thickness due to implantation of mesenchymal 
stem cell mono-layers using this approach. The mono-layer was reported to have 
expanded in situ making the infarct region approximately 600 µm thickness, with few 
cardiomyocytes but mainly undifferentiated mesenchymal stem cells. Although the 
increase in wall thickness is greater than the commonly achieved 100 µm thick (Birla et 
al. 2005; Leor 2005) engineered tissue, the 600 µm thickness achieved by Miyahara et 
al. is still not thick enough for the human heart (Sabbah 2003). The caveats about the 
potential for the bone marrow derived mesenchymal stem cells becoming 
cardiomyocytes also hold for these cell sheets. More recently, Sekine et al. (2008) 
examined the effect of the transplanting an engineered 3D layered endothelial cell 
cocultured cardiomyocyte sheet on vascularization of infarcted rat hearts, based on the 
cell sheet-based TE approach. Their findings showed a significant increase in capillary 
formation and cardiac function improvements four weeks after transplantation (Sekine 
et al. 2008). 
 
With much research focusing on the biomimmetic aspects of TE several reports have 
been published on electrospinning being the optimal method to produce successful 
ECM like scaffolds in cardiac TE (Courtney et al. 2006;Ishii et al. 2006;Shin et al. 
2004;Stankus, Guan, & Wagner 2004;Zhong et al. 2005). Ishii et al. (Ishii et al. 2006) 
have cultured primary cardiomyocytes harvested from neonatal rats onto biodegradable 
electrospun nanofibrous poly(ε-caprolactone) meshes with an average fiber diameter of 
250 nm, using the cell layering technique (Shimizu et al. 2001). Results demonstrated 
that strongly beating cardiomyocytes attached well to the meshes throughout the 14-day 
experimental period. Histological and immunohistochemistry tests confirmed 
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morphological and electrical communications were established in constructs with up to 
5 layers of meshes, proving strong adherence between the individual layers and cells 
(Haraguchi et al. 2006). However, long-term studies are yet to determine the cells life-
span in-vitro as well as in-vivo. 
 
The above studies showed the role of fetal or neonatal cardiomyocytes in bioengineered 
constructs. However, as mentioned earlier, the inability or limited ability of these cells 
to proliferate (Wu et al. 2006) and the success of directly injecting ESCs (Sabbah 2003) 
into an infarcted area of the heart; have prompted novel approaches. For example, 
researchers (Ke et al. 2005) have investigated the effectiveness of grafting a 
commercially available PGA biodegradable patch with mESCs (in an undifferentiated 
state). The patch was then sutured on the hearts of rats that were MI induced, by ligation 
of the left coronary artery. Cardiac function and hemodynamics were evaluated eight 
weeks post patch implantation, showing a significant improvement in ventricular 
function and blood pressure with a survival rate of 82.1%. On the other hand, 46.2% of 
mice that did not receive the cardiac patch with ESCs died within eight weeks. Caspi 
and co-workers (2007) then reported the success of engineering a triple-cell-based 
culture 3D muscle construct consisting of hESC-CMs, human endothelial cells and 
embryonic fibroblasts cultured in a highly porous (93% porosity) PLGA (50% PLLA 
and 50% PLGA) biodegradable scaffold. The purpose of the tri-culture was to permit 
cell proliferation and enhance cardiomyocyte survival. Results demonstrated, for the 
first time, a 3D vascularized human engineered cardiac tissue with cardiac specific 
functional (synchronized beating within construct), molecular and ultrastructural 
properties (Caspi et al. 2007). The success of this novel approach of combining 
biomaterials and ESCs is still at infancy, however ongoing research will provide a more 
solid foundation to questions that need answering for advancement of the field. 
 
Poly-co-caprolactone PGCL seeded with bone marrow-derived mononuclear cell was 
recently suggested as a cardiac patch for rat myocardial infarcted hearts (Piao et al. 
2007), reporting reduced LV remodeling, preserved systolic function of the LV and 
some presence of MHC, indicating transdifferentiation of the bone marrow cells into 
cardiac cells. However, this study was carried out for four weeks only and the current 
dogma that bone marrow stem cells do not transdifferentiate in contractile 
cardiomyocytes suggests much more work is needed for this idea to be widely accepted. 
It has also been reported that the size and location of the infarct determines the success 
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of an engineered cardiac patch (Cui et al. 2005). The strategy was found to be more 
successful with smaller infarct sizes and when the infarct was anteriorly positioned to 
prevent unnecessary manipulation of heart during surgery. This study does provide 
information for researchers that are currently investigating the success of their 
engineered scaffolds or patches; however, one cannot control the size and position of 
infarcts that occur in humans. Furthermore, the soft elastomeric poly(glycerol sebacate) 
(PGS) (Chen 2008) and PET/DLA block copolymers (Jawad et al. 2008b) have been 
characterized for their potential application in MTE. More recently, 3D PGS scaffolds 
with an accordion-like honeycomb structure cultured with neonatal rat cardiomyocytes 
has been suggested for MTE by Engelmayr and co-workers (Engelmayr et al. 2008). 
Results showed the scaffold to have mechanical properties matching the native 
myocardium and encouraging ccardiomyocyte alignment (Engelmayr et al. 2008). 
2.6.4.2 MTE based on natural materials 
Zimmermann et al. (Zimmermann et al. 2000) have developed over the past years a 
novel technique to engineer a cardiac muscle construct, better known as the engineered 
heart tissue (EHT), with the combination of neonatal cardiomyocytes with an artificial 
ECM made mainly from collagen type I and Matrigel, in circular molds while being 
subjected to mechanical strain. 
 
The all natural EHT construct developed by Zimmerman et al. (Zimmermann et al. 
2000) has both advantages and disadvantages. Advantages include: EHT has been 
reported to contract for eight weeks in vivo, newly formed myocardium of ~450 µm 
thickness has been observed (Zimmermann et al. 2006), functional and morphological 
properties of differentiated heart muscle have been observed and heart muscle shape and 
size can be manipulated accordingly. Unfortunately, several disadvantages were found. 
For example, upon implantation, LV function was not improved according to 
echocardiography studies and the need for immunosuppression for the survival of the 
EHT in vivo (Zimmermann 2002). Recently, three modifications were implemented to 
the original EHT to improve in vivo performance; firstly culture took place under 
elevated ambient oxygen, secondly culture under auxotonic load (EHT contracts against 
load-adjusted coils) and finally culture medium was supplemented with insulin 
(Zimmermann et al. 2006). 28 days after implantation, electrical coupling to the native 
myocardium was observed as well as systolic wall thickening of the infarcted region. 
The results revealed that large contractile grafts maybe constructed in vitro, implanted 
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in vivo and eventually support infarcted myocardial muscle. As exciting as these results 
are, more questions need answering, such as the potential clinical use, suitable cell 
source, the immunogenicity of the EHTs and finally the graft size (Zimmermann et al. 
2006). It was recently reported that mixing heart cell populations in serum- and 
Matrigel- free conditions is possible and may reduce immunogenicity of the EHTs 
(Naito et al. 2006).   
 
Li et al. (Li et al. 1999;Li et al. 2000) seeded fetal rat ventricular cells onto 
commercially available 3-dimensional gelatin mesh (Gelafoam®), forming cardiac 
tissue that contracted spontaneously both in vitro and in vivo for five weeks after 
implantation onto rat myocardial scar tissue, forming junctions with the recipient heart. 
However, post implantation results showed no sign of cardiac function improvement.  
 
Zhong et al. (Zhong et al. 2005) developed a scaffold by electrospinning collagen and 
glycosaminoglycan (GAG), both abundant proteins in the ECM of the body; forming a 
nanofibrous scaffold reporting a favorable environment for cell proliferation upon the 
incorporation of collagen. Other studies reported successful combination of collagen 
and GAG, where bone-marrow derived mesenchymal stem cells were implanted into 
scaffolds and onto the infarcted region resulting in neovascularization on the infarcted 
region (Xiang et al. 2006). Kofidis et al. (Kofidis et al. 2002a) went on to design an 
experimental reactor with multiple chambers for the production of bioartificial tissue, 
where neonatal rat cardiomyocytes were inoculated into collagen ground matrix; 
obtaining a 8 mm graft, compared to 2 mm previously achieved (Carrier et al. 1999), to 
allow the ventricular wall to restore transmurally. More recently, Kofidis et al. (Kofidis 
et al. 2005a) combined undifferentiated mESCs with collagen type I matrix and reported 
the benefits of ESCs in a 3D collagen matrix when implanted in the infarcted area 
introduced by ligation of the left anterior descending artery in nude rat and surgically 
forming an intramural pouch. Stable intramyocardial grafts were observed without 
altering the myocardial geometry and increasing ventricular wall thickness (1.4 ± 0.1 
mm) as well as expressing gap junctional protein connexin43 in vivo. This study 
highlights the benefit of both the controversial ESCs and the continually questioned 
immunogenicity of collagen when used in TE. Recently, human mesenchymal stem 
cells were embedded into rat tail collagen (type I) matrix to engineer a cardiac patch 
(Simpson et al. 2007). After a four day culture period, cardiac patches with and without 
mesenchymal cells were applied directly onto the epicardial surface of the infarct. 
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Results for the patches with cells demonstrated an increase in cell engraftment along 
with improved cardiac function and reduced LV remodeling compared to the patches 
devoid of cells. This study highlights the benefits of TE for the delivery of cells 
showing that cells can be delivered efficiently allowing good cell engraftment and 
homogenous distribution directly onto infarcted regions.  
 
Ongoing studies are required in this area as there are many more aspects to be 
considered including endothelialization of the grafts inner surface as well as mechanical 
properties. Attempts have been made to improve the mechanical function of bioartificial 
tissues grown on natural polymers. For example Akhyari et al. (Akhyari et al. 2002), 
seeded heart cells on a gelatin based matrix scaffold (Gelfoam); cyclical mechanical 
stress was applied at a frequency of 80 cycles/min for 14 days using a bio-stretch 
apparatus, as described by Liu et al. (1999) (Liu et al. 1999). The important effect of 
mechanical stress during development of bioartificial tissue was portrayed, as the 
proliferation and distribution of cells improved upon incorporation of mechanical stress.  
 
Guo et al. (2006) (Guo et al. 2006) demonstrated that ESCs can be used for cell seeding 
in MTE. Cardiomyocytes derived from ESCs were mixed with type I collagen 
supplemented with Matrigel, and pipetted into circular casting moulds then incubated 
for 30-45mins to allow hardening of the mixture making the engineered cardiac tissue 
(ECT). After seven days in culture, the ECT was placed into a stretch device to undergo 
unidirectional cyclic stretch for an additional 7 days. However, this study is still at 
infancy and additional work is required to determine in-vivo suitability.  
 
Collagen hemostatic scaffold, also called tissue fleece, was first suggested for MTE by 
Kofidis et al. (Kofidis et al. 2003a); they developed a contractile bioartificial 
myocardial tissue from collagen tissue fleece and cardiomyocytes in vitro with 
homogenous cellular distribution. Gaballa et al. (Gaballa et al. 2006) reported a 
reduction in cardiac remodeling and increased neo-angiogenesis when grafted with 
acellular 3D collagen scaffold onto infarcted rat hearts (625 neo-vessel/cm2  from 75 
neo-vessel/cm2 in rats without scaffolds). Further neo-angiogenesis (978 neo-
vessel/cm2) was reported when rats implanted with collagen scaffold received 
subcutaneous injection of G-CSF, which has been reported to mobilize progenitor cells, 
for 5 days. Although the collagen scaffold is initially there to provide mechanical 
support and reduce remodeling, immunogenicity of the scaffold is still an obstacle. The 
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conflicting results as to whether granulocyte-colony simulating factor (G-CSF) does 
actually mobilize resident cells to home to the infarct region are still questionable 
(Noral et al. 2003;Orlic et al. 2001b;Quaini et al. 2002;Smits et al. 2005).  
 
Alginate, a natural biomaterial, is a negatively charged linear copolymer produced by 
brown seaweed, although certain bacteria also produce alginates. Figure 2.10 shows 
blocks of (1-4)-linked ß-D-mannuronate (M) and its C-5 epimer α-L-guluronate (G) 
residues, respectively, covalently linked together in different sequences. 
 
 
Figure 2.11 A schematic diagram illustrating the chemical structure of alginate. 
(http://www.lsbu.ac.uk, accessed on 18/11/06) 
 
Leor et al. (Leor et al. 2000) grew fetal rat cardiac cells within 3D porous sodium 
alginate scaffolds made by freeze drying technique (Shapiro & Cohen 1997). Biograft 
transplantation of the cardiac graft took place seven days post MI. Visual and 
histological examinations revealed intensive neovascularization from neighboring 
coronary network and limited myofibers embedded in collagen matrix. In conclusion, 
alginate scaffolds were shown to provide a supporting and conductive environment to 
encourage cardiac cell culturing as well as promising results for the regeneration and 
healing of the infarcted myocardium. The group of Leor et al. then went on to seed 
human ESCs on alginate scaffolds and found human ESCs to have no significant 
contribution to myocardial regeneration (Leor et al. 2005). However, because no 
experiments were carried out previously for alginate scaffolds without cell incorporation, 
it is yet to be determined whether it is the alginate alone or the combination of the two 
materials that encourages neovascularization. In 2002, Dar et al. (Dar et al. 2002) 
achieved 3D high density cardiac constructs with a uniform cellular distribution. This 
was carried out by applying a moderate centrifugal force during cell seeding which in 
turn permitted the loading of a large number of cells onto the 3D alginate scaffolds.  
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Robinson et al. (Robinson et al. 2005) have reported successful implantation of an 
engineered cardiac patch made from four layer multilaminate urinary bladder-derived 
ECM in the infarcted LV walls of pigs. Results from one week and one month revealed 
thrombus formation and inflammation. However, three months post-implantation 
revealed fibrocellular tissue with contractile cells and biodegradation of the matrix 
when compared to the implantation of polytetrafluoroethylene (PTFE) where necrosis 
and calcification was observed. Kochupura et al. (Kochupura et al. 2005) found that 
cardiomyocyte populations due to myocardial patch derived from ECM provided 
mechanical benefit in the myocardium, however this experiment was not carried out for 
infarcted hearts. Furthermore, a group in Japan has reported the development of a 
bioengineered cardiac patch constructed from acellular bovine pericardia and 
multilayered mesenchymal stem cells (Wei et al. 2008). Results demonstrated improved 
heart function and restored LV dilation in rats that received the bioengineered patch, 
which appeared to have integrated well with the host myocardium. 
 
More recently, mixing equal amounts of collagen and Matrigel (2 mg/mL) with rat 
skeletal muscle cells was carried out to develop an engineered biodegradable skeletal 
muscle graft which was sutured (with fibrin glue) on infarcted rat hearts. There was 
evidence of improved systolic heart function when compared to rat receiving fibrin glue 
alone and sham operated rats as well as evidence of myoblasts differentiated into 
randomly oriented myotubes. These results suggest that both natural polymers (collagen 
and Matrigel), skeletal myoblasts and fibrin glue (as the adhesive polymer) could be 
beneficial to infarcted hearts (Giraud et al. 2008). This approach is similar to the work 
of Eschenhagen and his colleagues (2002), where neonatal rat cardiomyocytes on 
collagen and Matrigel have been replaced here with skeletal muscle cells, however in 
this study the graft did not develop any contractile properties which is due to the lack of 
mechanical stretching that is required for the production of the contractile  EHT 
(Eschenhagen et al. 2002).  
2.6.4.3 Combination of natural and synthetic materials 
Collagen enhances cell attachment when used as a scaffold (Kofidis et al. 2002b;Kofidis 
et al. 2002a) or matrix (Kutschka et al. 2006). However, the mechanical properties of 
collagen are poor, being a disadvantage. Researchers have attempted to combine 
synthetic polymeric materials with collagen to engineer a suitable scaffold using the 
electrospinning technique, improving cellular adhesion while the mechanical properties 
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are better than those of pure collagen. An example of this was reported by Stankus et al. 
(Stankus, Guan, & Wagner 2004) with the combination of poly(ester urethane)urea with 
type I collagen. 
  
Cardiomyocytes from neonatal Lewis rats were cultured on electrospun, nanofibrous 
polycaprolactone (PCL) meshes coated with type I collagen to enhance cellular 
attachment, forming cardiac nanofibrous meshes (CNM) (Shin et al. 2004). Formation 
of contractile cardiac grafts in vitro was achieved. However, this approach is still at its 
infancy. The CNM consisted of a wire ring that acted as a passive load for the beating 
cells permitting contractions at natural frequency. Advantages of this electrospun 
method include topography similar to that of the ECM of the heart, collagen coating 
permitting cellular adhesion and scaffold contraction in synchronization with beating 
cells.  
 
Researchers have also attempted to combine polymeric materials with collagen using 
bioreactors to produce a potentially suitable engineered cardiac tissue. Biodegradable, 
hydrophobic PGA, poly(DL-lactide-co-caprolactone) and commercially available 
hydrophilic collagen sponge (Ultrafoam™) were mixed and made into a composite 
scaffold. Neonatal heart cells were seeded onto it, using bioreactor cartridges (Radisic et 
al. 2003). Improved cellularity as well as an increase in the presence of cardiac markers 
was observed.  
 
In 2002, Krupnick at al. (Krupnick et al. 2002) evaluated the transplantation of 
multipotent bone marrow-derived mesenchymal progenitor cells into infarcted syngenic 
rat hearts. Instead of directly injecting these cells in the infarcted region, they were 
seeded within a collagenous matrix made from collagen type I and IV and Matrigel. The 
mixture of cells and collagenous was then seeded onto a non-woven polymer mesh 
(PDLLA reinforced with PTFE) and implanted in vivo. Results were promising as 
minimal intra-cardiac inflammation occurred, cells retained fibroblastic shape and 
immunohistochemistry revealing activity at the junction of native myocardium and the 
engineered construct in three of the four rats implanted. Some transplanted cells stained 
for myosin indicating cell differentiation occurred. Cardiac function appeared to be 
normal with no arrhythmias occurring.    
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2.6.4.4 Natural materials used in situ engineered myocardial tissue 
Although TE has shown to have successful outcomes there is a need for further 
investigations until it will be clinically applied, due to the disadvantages mentioned and 
questions that remain unanswered. In situ engineering has also been suggested for 
myocardial repair; it involves the injection of a mixture of biomaterial and cells, as 
mentioned in section 2.6.3. The biomaterial will in some way act as a supporting matrix 
for the cells, which will attempt to repair or regenerate the infarcted region, depending 
on the cell type used.  
 
Recently, acellular alginate biomaterial has been implanted in situ with bioactive 
molecules into the infarcted heart with the hope that the reported ‘resident cardiac 
progenitor cells’ will home to the damaged region (Leor 2005). A further improvement 
on this was reported when a novel viscous absorbable calcium cross-linked alginate 
solution was developed and upon injection into infarcted rat hearts the alginate 
biomaterial undergoes phase transition into hydrogel. Histology results show 50% of 
scarred was replaced by connective tissue six weeks post injection. Furthermore, cardiac 
function improved and adverse remodeling was prevented. Fibrin glue has been reported 
to induce angiogenesis (Christman et al. 2004c;Thompson et al. 1992). Birla et al. (Birla 
et al. 2005) engineered a contractile 3D cardiac tissue in an exciting new method where 
neonatal cardiac myocytes seeded onto fibrin glue were cultured in vivo in silicone 
chambers while being in close proximity to a vascular pedicle, therefore having an 
intrinsic vascular supply. Within three weeks, the chamber was full with living tissue. 
This exciting methodology is a different approach for engineering 3D cardiac tissue in 
vivo.  
 
Christman et al. (Christman et al. 2004c) demonstrated the success of transplanting 
skeletal myoblasts in fibrin glue, a biopolymer formed by polymerization of fibrinogen 
monomers (Christman et al. 2005), via direct injection into the infarcted region, where 
infarct size decreased and fibrin glue increased arteriole density and cell survival in vivo. 
Injecting fibrin alone was reported to preserve cardiac function and reduce cardiac 
remodeling where LV geometry was unchanged (Christman et al. 2004a). Ryu et al. 
(Ryu et al. 2005) reported similar results with implantation of bone marrow 
mononuclear cells with and without fibrin matrix. The combination of the bone marrow 
mononuclear cells and fibrin matrix produced approximately 350 microvessels/mm2 
density in the infarcted region compared to 262 and 76 microvessels/mm2 achieved 
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without fibrin matrix and medium injection only, respectively. Implantation of both 
cells and matrix also produced microvessels with larger diameters, also indicting 
enhanced neovascularization. Injection of endothelial cells with fibrin glue also resulted 
in improved LV function, myocardial blood flow and neovascularization (Chekanov et 
al. 2003). 
 
Collagen has also been suggested as an injectable biopolymer, however with many 
conflicting results. Huang et al. (Huang et al. 2005) for example, reported the effect of 
three different biopolymers injected into the infarcted region separately, fibrin, collagen 
and Matrigel with endothelial cells. Results demonstrated increased capillary formation 
for all three biopolymers where collagen showed greater infiltration of myofibroblasts 
into the region in comparison to fibrin and Matrigel. Ischemic myocardium injected 
with progenitor cells in a collagen-based matrix was reported to significantly restore 
vascular supply in the region (Suuronen et al. 2006). However, Dai et al. (Dai et al. 
2005) reported a decrease in infarct wall thickness without neovascularization in the 
collagen implant, suggesting the improvement in LV function, increased scar thickness 
and remodeling maybe due to the decreased wall thickness. Introducing biomaterials is 
thus a vital factor in preserving cardiac function. On the other hand, it is yet to be 
determined why fibrin glue improves cardiac function, whether it maybe due to 
neovascularization or preserved LV geometry. More research is required as to whether 
collagen does induce neovascularization as some authors report it does (Huang et al. 
2005) but other authors report no signs of it (Dai et al. 2005). 
 
Thompson et al. (Thompson et al. 1992) injected a mixture of autologous bone marrow 
cells and collagen hydrogel into the anterior interventricular coronary vein via the 
coronary sinus using a composite catheter system (TransAcess), which consists of an 
ultrasonic tip to give guidance to allow the transvascular myocardial access via a 
sheathed extendable nitinol needle for the implantation of the collagen-cell suspension. 
Since injection was done only on uninjured hearts, it is difficult to claim whether this 
method of injection is feasible for injured hearts since inflammation and remodeling 
may obstruct percutaneous intermyocardial access. However, this study does provide 
advancements for minimally invasive surgical approaches.  
 
Implantation of bioartificial liquid made of Matrigel and murine endothelial ESCs into 
the ischemic myocardium of mice by Kofidis et al. (Kofidis et al. 2005b) improved 
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cardiac function as well as attenuated LV remodeling. Expression of gap junctional 
protein connexin43 at intercellular sites was observed, indicating possible connections 
with the native myocardium. Interestingly, Matrigel alone was effective in that cardiac 
function deterioration was inhibited two weeks after injury and LV thickness was 
retained throughout the experiment. Interestingly, Zhang at al. (Zhang et al. 2006) 
suggested injecting the EHT (Zimmermann et al. 2000), before it solidifies, into the 
injured region. Rats that were injected with similar EHT solution showed far better 
histological configuration and appeared to be more stable than the rats that only 
received injectable artificial matrix and neonatal cardiomyocytes. This study is at 
infancy and has obvious limitations such as the immunogenicity of the Matrigel and 
hindered transmural repair of the infarcted region.  
 
A different biomaterial was introduced by Davis et al. (Davis et al. 2005) where ‘self-
assembling’ peptide nanofibres were injected into the myocardium, creating 
microenvironments to recruit progenitor cells and induce vessel growth. 
Immunohistochemistry tests revealed that progenitor vascular cells and cells expressing 
endothelial markers were homed to the nanofibres. Separately, neonatal cardiomyocytes 
were injected with the peptides and they were reported to not only survive but also 
augment endogenous cell recruitment. However, implantation of Matrigel did not 
recruit endothelial cells until 28 days later, when some capillary formation was also 
observed. Interestingly, researchers have attempted to deliver injectable biomaterials 
along with growth factors. Gene-activated matrix composed of Pleiotrophin plasmid in 
commercially available fibrin glue was reported to increase neovascularization 
(Christman et al. 2005). Other studies reporting the success of injecting biomaterials 
with peptides and growth factors are those of Iwakura et al. (Iwakura et al. 2003) and 
Hsieh et al. (Hsieh et al. 2006). This approach is relatively new in the regeneration for 
myocardial tissue and has only been explored by limited number of researchers.  
 
2.7 Conclusion/closing remarks 
 
Great effort is being made toward the development of an ‘optimal’ MTE construct, 
however limitations to take this further into clinical trials are inevitable. The choice of 
biomaterial, cell source and suitable environment for cells to proliferate and 
differentiate in vitro before implantation remain obstacles in the field. Moreover, the 
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design of the construct remains a key issue. To add further complications, cardiac 
contractile and electrical properties need careful consideration when designing the 
construct; the MTE construct must enable electrical coupling between the cells on the 
construct as well as with the host myocardium to prevent arrhythmias. Proposed 
materials which use animal-derived products, such as Matrigel, add another layer of 
complication to the testing and approval process for clinical application.  There is no 
doubt about what type of cells need to be introduced into the infarcted region; 
cardiomyocytes have shown to help regeneration and improve cardiac function. 
However, the source of cardiomyocytes, i.e. whether those resident in the heart or 
derived from bone marrow, embryonic or spermatogonial stem cells, needs to be 
determined before constructs can be introduced into human hearts. Furthermore, the 
stage of development, i.e. whether immature cells could further proliferate in vivo or 
mature cardiomyocytes with the properties of adult myocytes remains to be determined. 
In addition the question remains whether cardiomyocytes alone should be introduced 
into the region or rather a multi-type culture consisting of cardiomyocytes, endothelial 
and fibroblastic cells to further enhance neovascularisation. Purification strategies for 
cardiomyocytes may be counterproductive for this reason. Moreover, whether the 
cellular constructs needs to be cultured in vitro over a period before introducing into the 
myocardium or implantation should occur immediately after cell seeding remains 
questionable. A further possibility is the initial implantation of an acellular construct 
into the diseased myocardium to allow impregnation of newly formed vessels and ECM 
on the scaffold to provide a suitable environment for the implanted cells that will follow. 
Attachment of the material is another challenge, given the strong and repetitive forces 
generated during myocardial contraction. Compressive forces upon constructs placed 
within the muscle, or stretching of suture sites, will be experienced in each of the 
~100,000 daily heartbeats.  Although many groups have provided evidence of the 
beneficial effects of MTE in vitro and in vivo (animal models), the mechanism behind 
this functional improvement is yet to be elucidated.  In the meantime, it is important to 
overcome these obstacles and further improve our understanding of myocardial 
regeneration for the design and development of the most outstanding construct that will 
overcome one of the biggest causes of death.  
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3 Materials and methods 
 
3.1 Materials used for cell–related work 
All consumable and reagents and their product number, stock concentration, final 
concentration and company purchased from are listed in the appendix. 
3.1.1 Cells  
• Human embryonic stem cells (hESCs): H7 cell line (Thomson 1998) (obtained 
from Geron corp. Menlo Park, CA) 
• Mouse embryonic stem cells (mESCs) (ES-D3): Line D3 (Robbins et al. 1992), 
(ATCC-, LGC Standards, Middlesex, UK distributor) (CRL-1934) 
• Feeder cells for mESCs: STO fibroblasts carrying Neomycin resistance gene and 
LIF expression vector (SNLs) (Alan Bradley (Bongso et al. 1994)) and 
mitotically inactivated SNLs (iSNLs) 
• Feeder cells for hESCs: Mouse Embryonic Fibroblasts (MEFs) harvested from 
MF-1 (Harlan, UK) 
• Adult rat primary myocytes: Isolated from Sprague Dawley rats (Harlan, UK) 
3.1.2 Tissue culture media  
3.1.2.1 Growth medium for feeder cells  (SNLs, iSNLs, MEFs and iMEFs) 
Dulbeco’s Modified Eagles Medium (DMEM) (without glutamax) supplemented with 
10% fetal bovine serum (FBS), 1% Non-Essential Amino Acid (NEAA), 1% L-
glutamine (L/G), 1% Penicilline/Streptomycin (P/S). 
3.1.2.2 Growth and differentiation media for mESCs and hESCs 
Before inducing differentiation, it is important that cells are maintained in an 
undifferentiated state. Therefore different media was used for cultivation and 
differentiation of ESCs 
 
• Media for cultivating mESCs: 
Knock-Out DMEM (KO-DMEM), supplemented with 15% knockout 
serum replacement (KOSR), 1% NEAA, 1% L/G, 0.5% P/S, 0.1mM/L 
beta-mercaptoethanol (βME) and Leukemia inhibitory factor (LIF) (1 µl 
/ml) (added freshly before use). 
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• Medium for differentiating mESCs: 
DMEM+GlutaMax®, supplemented with 15% batch-tested FBS, 1% 
NEAA, 1% P/S and 0.1mM βME, without LIF. 
• Medium for cultivating hESCs: 
Mouse embryonic fibroblasts-conditioned medium (MEF-CM) plus 8 
ng/ml recombinant human basic fibroblast growth factor (rhbFGF) 
(added freshly for daily feeding). MEF-CM was prepared in house by 
making daily collections of media from MEF cultures, which were 
incubated for 7-10 days with ‘hESC’ medium to which basic fibroblast 
growth factor (bFGF) (4ng/ml) was freshly added each day.  
• ‘hESC’ medium was made up of KO-DMEM supplemented with 20% KOSR, 
1% NEAA, 0.5% L/G, 0.5% P/S, 0.1mM βME. 
• Medium for differentiating hESCs via embryoid body (EB) formation: 
Same as ‘hESC’ medium, except for 20% KOSR was replaced by 20% 
non-heat-inactivated FBS. 
3.1.2.3 Medium for adult rat myocytes: 
• 500 ml of M199 DMEM was supplemented with 1% P/S, 0.2% bovine serum 
albumin (BSA), 0.0088g ascorbic acid, 0.33g creatine, 0.313g taurine, 0.161g 
carnitine. Insulin was added to desired volume of medium freshly (82uL stock 
Insulin solution/500ml medium).  
 
3.2 Methodology for generation of ESC-CM 
3.2.1 Generation of mESC-CM from D3 line via embryoid body (EB) formation 
Derivation of cardiomyocytes from mESCs is a multistep process, requiring 1) the 
propagation of mouse fibroblastic SNL cells on gelatinized surfaces, followed by their 
mitotical inactivation with mitomycin C treatment, 2) propagation of mESCs on iSNL 
feeder cells grown on gelatinized flasks, 3) removal of the feeders and 4) induction of 
mESCs differentiation via EB formation by hanging drop technique.  
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3.2.2 Propagation and maintenance of SNL feeder cells 
3.2.2.1 Gelatinization 
T75 flasks were gelatinized with 0.1% gelatin to ensure SNL cells adhere to the surface. 
0.1% gelatin solution was pipetted into T75 flask and left in the incubator for a 
minimum of 15 minutes, after which time it was removed by suction to dryness. 
 
3.2.2.2 Recovery and maintenance of SNL cells  
A vial containing 1 ml of frozen SNLs (1.5x106) was hand-held in a water bath at 37°C 
and gently shook to mix the defrosting cells. Immediately prior to dissolution of the last 
crystals, the vial was removed from the water bath and sprayed outside with 70% 
ethanol. The contents of the vial was then transferred aseptically into a 15ml centrifuge 
tube containing 9ml of SNL medium and centrifuged at 300xg for 5 minutes at room 
temperature to remove the cryoprotectant, DMSO. The cell pellet was dispersed into 
single cells by finger–tapping, before resuspension of cells in 1 ml of fresh SNL 
medium.  The cells were then seeded into a T75 flask containing 14 ml of fresh SNL 
medium and incubated at 37°C in a humidified incubator containing 5%CO2 / 95% air 
mixture. Cultures were examined daily for microbiological contamination. 
3.2.2.3 Splitting/subculturing the SNL cells 
When near confluent, SNLs were sub-cultured into new gelatinized T75 flasks in a 1:6 
split ratio. For this, the, medium was aspirated from the flasks, washed twice with 10ml  
PBS without calcium and magnesium (PBS- -), and incubated for 5-6 minutes at 37°C in 
2 ml Trypsin/EDTA (T/E).  After a brief pipetting to release cells from clusters, the 
activity of trypsin was inhibited by serum added in 8ml SNL medium. The cells were 
then collected by centrifugation (5 minutes at 300xg) The cell pellet was dispersed into 
single cells by finger tapping prior to resuspension in 6ml SNL medim and split equally 
into six T75 pre-gelatinized flasks containing 14 ml medium for further culture. For this 
study, cells were split 1:6 twice a week. Once the desired number of cells was obtained 
for a particular application, the cells in excess were frozen down.  
3.2.2.4 Inactivating SNL cells 
Inorder to prevent SNL cells from overgrowing D3 ESC when they are co-cultured as 
feeders, the SNLs were mitotically inactivated with Mitomysin C (MITOC) prior to co-
culturing.  For this 1.5 ml of 10x MITOC solution was pipetted into each T75 flask 
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containing 13.5 ml SNL medium and left in the incubator for 2-3 hours to inactivate the 
SNL cells. Medium was then aspirated and cells were washed three times in PBS--, 
trypsinized (2ml/flask) for 5 minutes at 37°C and collected by centrifugation (5 minutes 
at 300xg). Cell pellet was broken up into single cells and an aliquot (20 µl) was counted 
using a hemocytometer. Cells were then frozen down or seeded onto pre-gelatinised 
T25 flasks a day before seeding the D3 cells onto them.  
3.2.2.5 Freezing down of SNL and iSNL  cells 
SNLs and iSNLs were frozen down at a cell density of 1.5x106 cells/ml/vial and 
1.5x106cells /ml/vial, respectively in freezing medium containing 10% dimethyl 
sulfoxide (DMSO). The seeding density used for iSNL ensured complete coverage of 
the surface of a T25 flask. Cell counts were made using a hemocytometer prior to 
freezing. For each vial, the cells were resuspended in 0.5ml FBS first and then 0.5ml of 
cold 2x concentrated freezing medium (2x freezing medium: 20% DMSO and 80% 
FBS) was added dropwise with mixing. As usually more than a single vial-worth 
number of cells were frozen down, this procedure was carried out in a 15ml centrifuge 
tube placed on ice. The vials were stored overnight at -70oC, either in a “Mr. Frosty” 
(www.vwrsp.com) or in a polystyrene box wrapped with tissues to protect from quick 
freezing. On the following day cells were transferred to a liquid nitrogen tank for long-
term storage. 
 
3.2.3 Propagation, maintenance and differentiation of D3 mESCs 
3.2.3.1 Propagation and maintenance of D3 mESCs in an undifferentiated state 
A day prior to starting the D3 cultures, iSNLs were plated out onto pre-gelatinized T25 
flasks (1.5-2 million iSNLs/flask). The most important part of cardiomyogenesis from 
ESCs is the maintenance of ESCs in the undifferentiated, pluripotent state in culture. 
The mESCs seeded onto iSNLs were maintained by cultivating them on feeders in “D3 
cultivation medium” (see section 3.1.3.2) supplemented by LIF (1000 U/ml). Cells were 
usually propagated for 2-3 passages on iSNLs. Before induction of differentiation  D3 
cells were ‘weaned off’ from the feeders, by subculturing (1:2 split ratio) twice onto 
gelatinized flasks. 
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3.2.3.2 Differentiation of D3 mESCs  
Cells were differentiated in ‘D3 differentiation medium’ in the absence of LIF (see 
section 3.1.3.2) and without feeder cells. 1ml of T/E was added to the D3 mESCs in 
T25 flasks and incubated at 37ºC for 5 minutes. Cells were then collected in a 15 ml 
tube containing fresh media and centrifuged for 5 minutes at 300xg. Supernatant was 
then removed and an aliquot of 20uL of the single cell suspension was counted using a 
hemocytometer. A dilution of cell suspension was made in differentiating medium so 
that 20 µl contained 400 D3 cells (i.e. 20x103 cells/ml). Using a multichannel pipetter, 
20 µl of cell suspension was pipetted onto the bottom part of a 10 cm x 10 cm Petri-
dish . The dish was then placed upside down to act like a lid, so that embryoid bodies 
(EBs) formed in “hanging drops” in each of the 20uL drop. The day of EB formation 
was referred to as d0 of differentiation. After two days (d2) the dish was reversed and 
the EBs formed in each drop were “flooded” with 25 ml of differentiating medium. EBs 
were left to grow in suspension culture for 5 days, with feeding once every 2 days. On 
d7 of differentiation EBs were plated out onto 0.1% gelatinized surfaces of 10 cm round 
culture plates (approximately 720 EBs/100x100mm petri dish). Beating  
cardiomyocytes (ESC-CM) appeared on day 7 and  ESC-CMs were isolated on day 8.  
3.2.4 Generation of hESC-CM from H7 line via EB formation 
This process also involves multiple steps, requiring 1) propagation and maintenance of 
undifferentiated H7 cells on Matrigel-coated surfaces in MEF-CM and bFGF, 2) 
removal of the spontaneously differentiated cells with 5-10 minutes treatment with 
collagenase, 3) induction of differentiation by mechanically breaking up H7 colonies to 
form EBs in low adherence plates, followed by plating out. All the procedures used 
were as described by Geron Corporation (http://www.geron.com/PDF/scprotocols.pdf) 
(Xu et al 2001)  
3.2.4.1 Propagation, maintenance, subculturing and mitotically  inactivating MEFs 
MEFs were isolated from day 13 mouse embryos (strain CF1) by the laboratory 
personnel. Cells were expanded over two days. On the third day they were counted and 
frozen down (20million/vial).  To produce MEF-CM, one vial of cells was further 
propagated in 10% FBS for up to 3 passages prior to inactivation by MITOC using same 
procedures as for SNLs. After a cell count, 1.88X107  inactive MEFs (iMEFs) were 
seeded onto pre-gelatinized (0.1%) T225 flasks and cultured in 40 ml feeder growth (see 
section 3.1.3.2) to allow cell attachment overnight. The following day medium was 
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replaced with 150 ml ‘hESC’ medium and bFGF (4ng/ml). Daily collections of 150ml 
MEF-CM was made for 7-10 days. Collected MEF-CM was filter-sterilized through low 
protein adherence 0.2µ filters and stored at -20ºC (was used within 7 days when at +4º 
C).  
3.2.4.2 Propagation, maintenance and differentiation of H7 hESC-CM 
Propagating and maintaining H7 hESCs under feeder-free conditions  
To maintain H7 ESCs in an undifferentiated state, cells were cultured on Matrigel 
coated 6 well plates (1 ml Matrigel per well of a 6 well plate) for a week. Cells were 
cultured in MEF-CM, which was further supplemented with 8 ng/ml of bFGF (added 
freshly before use). H7 cells were subcultured every 5-7 days by removing 
spontaneously differentiated cells with collagenase IV solution (1ml/well (200 
units/ml)); up to 10minutes at 37 ºC). After aspiration of collagenase, each well was 
washed with 2ml PBS- - . Undifferentiated human colonies were then broken up 
mechanically with a 5 ml pipette into smaller pieces and subcultured in 1:3 or 1:6 split 
ratio in Matrigel-coated wells. The volume of MEF-CM on day of splitting was 3ml (to 
allow to-and-fro movements of plate to be made inside the incubator without spillage; 
this would ensure equal distribution of colonies when adhering); 4ml when fed daily, 
with bFGF being added freshly each time. 
Differentiation of H7 ESCs via embryoid body (EB) formation in 20% FBS 
Before the induction of differentiation via EB formation, the spontaneously 
differentiated cells among the undifferentiated colonies were removed by collagenase 
IV treatment. After washing each well with 2 ml PBS- - ,colonies were broken up by 
scraping with a 5ml-pipette in 2 ml human differentiation medium (see section 3.1.2.3), 
and transferred to a well of low adherence 6-well plates (1well into 1well). After 4 days 
in suspension, EBs (between 1-3) were plated out onto pre-gelatinized (0.5%) glass 
cover slips in 24 well plates or 10cm dishes. 
 
3.2.4.3 Differentiation of H7 ESCs in ‘monolayer’ method without EBs, using activin 
A and bone morphogenic protein 4 (BMP4) as inducers 
Cells were propagated and maintained in an undifferentiated state in 6-well plates as 
described above (section 1.2.3.2). Total cell count was made using a hemocytometer on 
one well; this figure was then extrapolated to the other wells to determine 
approximately how many cells were present in each well of a 6-well plate, and hence 
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the grand total that was available to replate into 24well-plate for subsequent 
differentiation. The spontaneously differentiated cells were then removed and the 
undifferentiated colonies were broken up mechanically as described H7 colonies were 
then subcultured in 24 well plates at a density of 200 x 103  cells/cm2 (400 x 103 
cells/ml/well). Once cells had reached confluence and a high-density undifferentiated 
monolayer could be observed (usually at 6 days post subculturing) differentiation was 
induced by changing medium completely and culturing the cells with 0.5 ml RPMI/B27 
medium containing 100 ng/ml activin A for 24 hours. The following day medium 
containing activin A was aspirated and cells were cultured with RPMI/B27 medium 
containing 10ng/ml bone morphogenic protein 4 (BMP4) for 4 days without changing 
medium. After 4 days medium was completely replaced by 1 ml of RPMI/B27. Medium 
was changed every other  day and beating occurs on day 10 and onwards. 
 
3.2.5 Enrichment of ESC-CM 
3.2.5.1 Microdissection  
Beating clusters in large 10 cm dishes were marked under the dish with a fine felt tip 
while observing on an inverted light microscope. Once all the beating clusters were 
marked, a hypodermic needle tip (23G) was used to cut around each beating cluster 
under the light microscope. All clusters collected in a 15 ml falcon tube were then 
washed in PBS - - and treated with 0.5 ml T/E at 37 °C (in a water bath) for 4-5 minutes 
to disaggregate cells . To ensure single cell suspension, cells were triturated with a 1000 
µl pipette and passed through a 23G needle 3-4 times. The tryptic activity was stopped 
by the addition of serum-containing medium and cells were collected by centrifugation 
(5’; 300xg). 
 
3.2.5.2 Percoll  
Large 10 cm dishes containing beating clusters of cardiomyocytes were scrapped in the 
25 ml medium they were previously cultured in using a cell scrapper and collected in a 
50 ml falcon tube. Dishes were further washed with 10 ml PBS-- and added to the 50 ml 
falcon tube containing cells. Cells were then centrifuged at 1200 rpm for 2-3 minutes. 
Supernatant was removed and cells were washed by re-suspending in 25 ml PBS-- and 
centrifuged twice. Differentiating ESC in adherent EBs were dissociated with 
blendzyme for 2-3 minutes in water bath. Cells were further triturated using a 1000 µl 
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pipette for more complete dissociation and re-suspended in differentiation medium and 
loaded onto a percoll gradient for cardiomyocyte enrichment (Geron corporation 
proprietary confidential information). Percoll was diluted in 150 mmol/L NaCl and 20 
mmol/L HEPES. There are four different fractions, 40.5% percoll gradient is in fraction 
II while the more dense gradient, 58.5%, is below in fraction IV and this is where Geron 
claims 10-20% the differentiating cells are cardiomyocytes. Some cardiomyocytes are 
also present in fraction III. Cell layers were apparent after centrifuging at 1500xg for 30 
minutes at room temperature with no brake for stopping the centrifuge. Cardiomyocytes 
from fractions III and IV were collected, washed with 10 ml PBS - - twice and re-
suspended in differentiation medium and centrifuged again at 300xg for 5 minutes. Cell 
pellets for both fractions were broken up as previously done and then pooled together 
and counted. 
 
 
3.3 Methodology for isolation of adult rat myocytes 
 
Adult myocytes are routinely isolated from Sprague Dawley rats using the Langendorff 
perfusion method similar to that described previously (Jones et al. 1990). Briefly, the 
heart was perfused for 5 minutes with Krebs-Henseleit solution (composition in mM: 
NaCl 119, KCl 4.7, MgSO4 0.94, KH2PO4 1.2, NaHCO3 25, glucose 11.5 and CaCl2 1 
and equilibrated to pH 7.4 with 95% O2 and 5% CO2). Following this, a further 5 
minutes perfusion was carried out with low calcium solution (composition in mM: NaCl 
120, KCl 5.4, MgSO4 5, pyruvate 5, glucose 20, taurine 20, HEPES 10 and 
nitrilotriacetic acid 5 with a pH of 6.95 and calcium was added to give a final 
concentration of 12-14 µM as measured with a calcium electrode). This solution was 
equilibrated with 100% O2.  The heart was then further perfused for an additional 15 
minutes with a solution similar to that of the low calcium solution, except it did not 
contain nitrilotriacetic acid but with added collagenase (0.6 mg/ml), hyaluronidase (0.5 
mg/ml) and calcium to give a higher concentration of 200 µM. Left and right ventricles 
were separated, with the interventricular septum remaing with the left ventricle. 
Ventricles were then cut into pieces with a 1 mm wide razor array. Ventricular pieces 
were shaken at 35ºC under 100% O2 for 5 minutes with the same enzyme-containing 
solution followed by the passing of pieces through 300 µm mesh sized gauze and 
incubated for a further 5 minutes with enzyme solution. The supernatant was 
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centrifuged at 400 xg for 1 minute at room temperature. Cells were then washed and 
resuspended in Krebs Henseleit solution.  
 
3.4 Methodology for biomaterial processing  
 
All chemicals used were obtained from Sigma Aldrich® unless otherwise stated 
3.4.1 Material processing for PET/DLA, PET/DLA-0.2wt% TiO2 and PBT/PEG 
(PEE) 
 
The synthesis process was carried out in a stainless steel vacuum pressure reactor, 
which mainly consists of two reactors, one reactor for the transesterification process and 
the other for the polycondensation process. Figure 3.1 is an illustration of the reactor 
unit used to synthesis the biomaterials, the reactor was designed and constructed at the 
Technical University of Szczecin (collaborators in the present project, (El-Fray 2003c)). 
To calculate the amount of each substrate needed to be added for the reaction, the 
equations 1 and 2 were used. 
 
(DP x Mw DMT) + 2(DP + 1)EGl + (1 x Mw DLA)                   Equation 1 
DP = ((1 - % of SS) x Mass of SS) / (% of SS x mass of SH)                Equation 2 
DP = degree of polymerization, Mw = Molecular weight, DMT = dimethyl terephthalate, EGl = ethylene glycol DLA 
= Dileionic acid, SS = soft segment, SH = hard segment. 
 
During the transesterification stage a reaction mixture of ethylene glycol (EGl)(287.68 
g), dimethyl terephthalate (DMT) (ZWCh Elana Torun, Poland) (256.08 g) and zinc 
acetate catalyst (Zn(Ac)2) (0.208 g) was heated up to 180°C at a heating rate of 1.5 °C 
/min. The reaction was then terminated when more than 95% of the stoichiometric 
amount of the methanol by product evaporated and was collected in a cylinder (~ 124 
ml). Before the polycondensation step, DLA (Uniqema, The Netherlands; acid value 
196 mg KOH/g) with or without 0.2wt% (2.23 g) of TiO2 nanopowder (AEROXIDE ® 
P 25, Degussa, Germany) was added to the reaction mixture, then the pressure was 
decreased to 0.2-0.4 hPa and the temperature increased to 260°C. The catalyst in this 
step of the reaction was antimony trioxide (Sb2O3). The progress of polycondensation 
reaction was observed by power consumption of the stirrer motor as described in the 
literature (El-Fray & Slonecki 1999). The reaction mass (1115.76 g) was extruded by 
means of compressed nitrogen into water and pulled out of the machine as fiber strings. 
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The polymer obtained was then left to dry over night at 50°C. Multiblock (PEE) with a 
chemical structure as in Polyactive® (Du et al. 2002) biomaterial and containing 30 
wt% (PBT) as hard segments and (PEG) of molecular weight 1000 g/mol was 
synthesized in a similar way and used as a reference material. Thin films (0.5 mm thick) 
from polymer granules were prepared according to ASTM D 1897-77 obtained by press 
molding, under a pressure of approximately 10-20 MPa at 145 °C. Samples were then 
left to cool until the temperature in the hot press lowered to 35°C. Testing materials 
were cut in the required shapes, either micro-dumbbells (0.5 mm thick, 4mm2 cross-
sectional area and 25mm long) or circular discs (0.5mm thick, 10 mm2 or 13 mm2 cross-
sectional area), which were used for different characterization experiments. Figure 3.2 is 
a schematic diagram illustrating the steps involved in producing PET/DLA block 
copolymers. 
 
The intrinsic viscosity of polymers after processing was measured in 
phenol/trichloroethylene mixture (1:1 vol. %) as a solvent at 30ºC with an ubbelohde 
capillary viscometer in a water bath, to ensure that good degree of polymerization was 
obtained during processing. All polymers were dissolved at room temperature. Equation 
3 was used to calculate the intrinsic viscosity of the polymers.  
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Where ηreal = relative viscosity, ηref = reference viscosity = t1/t0 (t1 (s) = approximate time of polymer 
solution flow, t0 (s) average time of pure solvent flow (e.g. chloroform) c = polymeric solution 
concentration (for every 50 ml of clear solvent 0.25g of polymer)  
 
Values obtained for the polymers were as follows, PET/DLA = 0.413, PET/DLA-
0.2wt%TiO2 = 0.690 and PEE = 1.087, indicating good degree of polymerization and 
oligomers were not the end product of the synthesis.  
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Figure 3.1 A schematic diagram of the reactor unit used for the synthesis of 
biomaterials (El-Fray & Slonecki 1999). 
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Figure 3.2 Schematic diagram illustrating the steps involved in producing PET/DLA 
block co-polymers. 
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Figure 3.3 Chemical reactions that take place in both the transesterification and 
polycondensation step for the production of PET/DLA biomaterials, hard segment is 
PET and soft segment is DLA. 
 
3.4.2 Synthesis for PET/DLA/DLA biomaterials 
The transestrification and polycondensation steps were carried out in the same manner 
as for PET/DLA, PET/DLA-0.2wt%TiO2 and PEE (same temperature, catalyst etc, see 
section 3.3.1). However, after the polycondensation step the temperature was decreased 
to 155°C. A lactide segment was produced prior to the reaction by condensation 
between D,L-lactic acid (DLLA) and Priplast 3192 (it is DLA with hexanodiol on both 
ends). This segment was then added to the reactor with stannous octate catalyst. The 
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polycondensation step lasts for 6 hours at 165°C and a pressure in the range 0.4-0.6 hPa. 
The polymer solution was then cooled down to 120°C and obtained as fibres. The main 
hard/soft segments ratio was 30/70. The weight percentages in soft segments were DLA 
part 80 wt% and lactide part 20 wt%. 
3.5 Topography patterning on PET/DLA/DLLA biomaterials 
 
Micropatterned PET/DLA/DLLA sheets were fabricated using Phase Separation 
Micromoulding (PSµM) method, this part of the project was carried out in collaboration 
with the University of Twente (Netherlands), where the patterning was carried out 
following a published process (Papenburg 2007). Briefly, this involves the fabrication 
of a micropatterned silicon wafer (the master mold), in this project the wafers were 
10cm round circular moulds and had dimensions of 20 µm channel width, 30 µm ridge 
width and 25 µm ridge height. The micro-architecture of the mold is prepared using 
photolithography. The key requirement for the PSµM method is that the polymer needs 
to be dissolved in a solvent and then immersed in a non-solvent. For PET/DLA/DLLA 
material, chloroform (Merck, analytical quality) was used as the solvent to form a 
polymer solution at room temperature. Methanol and ethanol were used as the non-
solvents. Once the polymer solution was casted onto the mold it was then placed in a 
bath containing the non-solvents. It is at this stage that phase separation is initiated due 
to the liquid exchange between the solvent and non-solvent causing the polymer 
solution to be saturated with non-solvent precipitate, as described in the literature 
(Papenburg 2007). The inverse replica of the mold micro-pattern is imprinted onto the 
polymer sheet as it solidifies. The polymer sheet is then released from the mold and left 
in the non-solvent for 24 hours to ensure complete removal of the solvent. Figure 3.4 
illustrates the steps involved in the PSµM process. 
 
 
 
Figure 3.4 Schematic illustration of the phase separation micromolding 
(PSµM)technique, adapted from (Papenburg 2007) 
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3.6 Techniques for biomaterial characterization 
3.6.1 Surface Examination 
3.6.1.1 Scanning Electron Microscopy (SEM) 
Surface morphology and microstructural homogeneity of neat PET/DLA and 
PET/DLA-0.2wt%TiO2 composites were characterized using a JEOL JSM SEM. Small 
circular discs (9mm diameter) were mounted on stubs using carbon adhesive tape and 
sputtered (K550 sputter machine, Quorom Technologies Limited) with a fine (∼10nm) 
layer of gold coating. A 10kV accelerating voltage was used to observe surface 
morphology.  
3.6.1.2 Focused Ion Beam (FIB) 
Focused Ion Beam (FIB) (FIB 200SIMS) (FEI company, www.fei.com) system was 
used to prepare small cross-sections in the sample containing 0.2wt% TiO2 to assess 
whether or not NPs could be observed and with the aim of studying the distribution of 
particles in the polymer matrix. The Secondary Ion Mass Spectrometry (SIMS) (FIB 
200SIMS) (FEI company, www.fei.com), which is connected with the FIB system, was 
used to detect any traces of NPs.  
3.6.1.3 White light interferometry (Zygo®)  
The surface roughness of the samples was measured using white light interferometry, 
using a Zygo® (NewView 200) instrument (Zygo corporation, www.zygo.com). The 
instrument makes measurements at single points on the surface. To ensure a 
representative area of interest was tested, multiple measurements were made 
automatically from an area of 6mm x 6mm (36mm2). This was made possible by using 
the “pattern editor”which is a special function in the instrument that permits the user to 
create pattern files to direct the movement of a programmable stage based on a 
Cartesian coordinate system (X-Y). Graphpad Prism 4 software was used to calculate if 
there was any significant difference between the surface roughness of the samples from 
the same batch. Measurements were also taken for untreated samples. 
3.6.1.4 Scanning Ion Conductance Microscopy (SICM) 
A scanning ion conductance microscope (SICM) was used to scan the surface of the 
biomaterials (with and without TiO2 NPs) in collaboration with Dr. Gorelik (NHLI, 
Imperial College). The SICM setup has previously been described (Gorelik et al. 2006), 
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it was built at Imperial College London in Professor Yuri Korchev’s laboratory. Briefly, 
the system includes a sensitive glass nanopipette probe filled with electrolyte with an 
Ag/AgCl electrode (placed approximately 30-50 µm in the vertical direction from the 
surface of the biomaterial it intends to scan) plugged into it connected to a scanning 
piezoelectric translation stage, an electronic feedback generator and a computer which 
allows data processing (data acquisition hardware and software are produced by East 
Coast Scientific, Cambridge, UK).  
3.6.1.5 Transmission electron microscopy (TEM) 
Samples were prepared using cryo-ultramicrotone (Power Tome XL, RMC Products by 
Boeckeler) at -80°C and mounted on copper grids. Samples were then coated with 
carbon. The transmission electron microscope (TEM) (JEOL- JEM FX 2000) was used 
to observe thin sections (~90-200 nm). Acceleration voltage of 200 kV was used for 
these observations. 
3.6.2 Mechanical testing 
3.6.2.1 Tensile testing 
Dumbell samples (0.5mm thick, 4mm cross-sectional area and 25 mm long) were 
prepared for mechanical testing by press compaction according to ASTM D 1897-77 
and then stamped into required dimensions. Using an Instron TM-M tensile testing 
machine equipped with 500 N load cell at a crosshead speed of 100 mm/min, force-
displacement data was collected. Stress-strain curves were obtained from the raw data 
using equations 4 and 5, respectively. 
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The calculated stress at failure point, yield stress and elongation at break values were 
averaged over 3 measurements for each sample. 
 
3.6.3 Water contact angle 
To measure the degree of biomaterial hydrophobicity and hydrophilicity as a function of 
polymer composition a contact angle goniometer and optical system (HAAS SEO 
contact angle machine, Poenix-mini) was used. This instrument uses the sessile drop 
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method to capture the profile of a pure liquid (water) on a solid substrate (biomaterial of 
interest) to determine the contact angle.  
3.6.4 Thermal analysis by differential scanning calorimetry (DSC) 
Differential scanning calorimetry (DSC) scans were carried out in Szczecin University 
of Technology in Poland, using a DuPont apparatus. Samples were vacuum dried at 
70°C, and kept in a desiccator overnight. The temperature range used for this 
measurement was between -120°C (below the Tg of DLA) and 300°C (above the 
melting temperature of PET). The process was carried out in a triple cycle: first heating, 
subsequent cooling followed by final heating at a rate of 10°C/minute. During the first 
heating cycle the sample is only melted to eliminate thermal history from the sample, 
e.g. during extrusion from the reactor or during pressing and no data is analyzed, it is at 
this stage that polymer transition begins. Therefore in second cooling step sample 
crystallization is observed giving the Tg and crystallization temperature (Tc) for the 
hard segment. Finally, during the third step, heating the sample from -120°C to a higher 
temperature (300°C), the Tg and Tm for the soft and hard segment is obtained, 
respectively. The Tg was determined from the midpoint of the peak obtained in the 
scans. 
3.6.5  X- Ray diffraction (XRD) 
X-ray diffraction (XRD) analysis on biomaterials was performed on a Phillips PW1700 
Series automated powder diffractometer to confirm the presence of TiO2 NPs in 
PET/DLA-0.2wt%TiO2 biomaterials. Cu Kα radiation of 40kV and 40mA was obtained 
using a secondary crystal monochromator. The analytical parameters were: step size 
0.04º, scan step time of 1 second and a diffraction range of 5º -60º (2θ) 
3.6.6 Biomaterial degradation 
The degradation of biomaterials was studied up to 12 weeks. Biomaterial degradation 
was studied under three different conditions; PET/DLA, PET/DLA-0.2wt%TiO2 and 
PEE discs were immersed in PBS- - only, SNL fibroblast TCM (section 3.1.3.1) and 
finally biomaterials were also seeded with SNL cells cultured in fibroblastic medium. 
At given time points, e.g., 3, 6, 12, 18 and 24 weeks, the biomaterials were removed 
from wells and left to dry in a desicator for 24 h and then prepared for analysis. 
However, biomaterials that were seeded with SNL cells were trypsinized to ensure all 
cells were lifted off the surfaces of the samples, by treating them with T/E for 5 minutes 
at 37°C. The cells and T/E solution were then aspirated, followed by three washes in 
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PBS--. SEM and white light interferometry were used to visualize morphological 
changes on the surface of the material. Infra-red (IR) spectroscopy FTIR model Nexus 
by Thermo Nicolet) was used to study the change in chemical structure of the materials 
over a period of time. Gel permeation chromatography (GPC) was used to study the 
molecular weight of the polymer. Weight loss (%) and water absorption (%) of the 
biomaterials and the pH of media were also measured. Further details on these 
techniques are described below. 
3.6.6.1 Infra Red (IR) sample preparations 
Biomaterials immersed in PBS- -, TCM as well as seeded with SNL cells and cultured in 
TCM were taken out from the well and left to dry. Small circular discs of approximately 
5 mm were cut and placed in the IR apparatus. IR analysis was performed on a Nexus 
machine by Thermo Nicolet Co. 
3.6.6.2 Gel permeation chromatography (GPC) 
Polymer weight average molecular weight (Mw), number average molecular weight 
(Mn), average molecular weight (Mz) and the ratio of Mz/Mn were obtained using 
conventional gel permeation chromatography (GPC) (Spectra Physics 8800 pump) with 
polystyrene standards using chloroform as solvent and eluent. This testing was carried 
out by collaborators at the University of Szczecin (Poland).   
3.6.6.3 Water absorption, weight loss and pH 
The pH of culture media was recorded after each immersion time point at 37°C. 
Previously weighed biomaterials were extracted from culture mediums at 3, 6, 9, 12, 15, 
18, 21 and 24 weeks and weighed immediately to obtain the wet weight of the polymer 
to assess polymer water absorption (WA%). Biomaterials were then left to dry in a 
desicator for a week and re-weighed to obtain weight loss (WL %). WA (%) and WL (%) 
were calculated according to the following equations: 
WA (%) = ((Ww - Wo ) / Wo ) x 100                                                                                  Equation 6 
WL (%) = ((Wo - Wd ) / Wo ) x 100                                                                                   Equation 7 
 
where Ww is the biomaterial wet weight, Wd is the biomaterial dry weight and Wo is the original 
biomaterial weight. The results are presented as the mean of n = 3 samples ± standard deviation. 
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3.7 Techniques for characterizing cell-biomaterial interactions 
3.7.1 ESC-CM - biomaterial interactions 
All biomaterials were alcohol sterilized with 70% ethanol for a minimum of two hours 
before seeding cells onto them. 
3.7.1.1 Observation of cardiomyocytes by immunocytochemistry (ICC) 
hESC-CM cultured on pre-gelatinised glass cover slips, or in 96-well plates with and 
without biomaterials were fixed in 4% paraformaldehyde in PBS- - for 10 minutes, 
followed by two washes in PBS- - for 5 minutes each time. Cells were permeated with 
0.2% Triton-x 100 for 15 minutes followed by blocking with 1% Bovine Serum 
Albumim (BSA) for 1 hour. Positive controls were then subjected to primary cardiac 
MHC antibody (Ab15; 1:200 dilution, Abcam, Cambridge) for two hours followed by 
three washes in PBS--. Both the negative and positive controls were subjected to FITC-
conjugated secondary antibody (Ab5768; 1:800 dilution in BSA, Abcam, Cambridge) 
for 1 hour. As the materials had a green auto fluorescence, Alexa 546 (red) conjugated 
goat anti-mouse IgG secondary antibody (1:400; Invitrogen) was also used to visualize 
cardiomyocytes.  Samples were washed threes times with PBS-- at 5 minutes interval 
and mounted in “prolong” which contained nuclear stain DAPI, or DAPI was added to 
final PBS-- wash at a concentration of 5ug/ml. All steps were carried out in room 
temperature. Cardiac cells were visualized using a confocal microscope (Leica, SP2) or 
a Zeiss Axio Observer Z1 fluorescence microscope in wells, without mounting. 
3.7.1.2 Observation of viable cells by light microscopy 
The biomaterials were opaque making it difficult to observe the cells on the material 
two days post cell seeding. Neutral Red staining was therefore used as an indicator to 
show whether cells were alive. Neutral red stain was diluted 1:100 in culture medium of 
test samples and after 10 minutes of incubation cells were observed on an inverted light 
microscope. 
3.7.1.3 Examination of the adherence and spread of mESC-M and hESC-CM using 
SEM 
Once cells were ready to be examined under SEM 48 hours after seeding, they were 
rinsed with PBS-- and fixed with 2.5% Gluteraldehyde in 0.5M Sodium Cacodylate 
(CACOD) buffer for 48 h. Samples were then washed in sodium CACOD buffer twice 
and post fixed with 1% osmium tetroxide in 0.5M sodium CACOD for 30 minutes and 
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dehydrated through graded ethanol series (70% and 90% for 10 minutes each) to 100% 
ethanol (twice for 15 minutes each).The samples were then treated with 
hexamethyldisilazane (HMDS) twice for 15 minutes each time. They were left in excess 
HMDS overnight to ensure samples were fully dry before examined. Samples were 
sputter- coated with 10 nm layer of gold coating. SEM with 5kV accelerating voltage 
was used to observe surface topography. 
3.7.1.4 Effect of biomaterials on functional activity (rate of beating) of hESC-CMs 
To study the effect of  PET/DLA, and PET/DLA-0.2wt%TiO2 on the rate of beating, the 
isolated hESC-CM were cultured for 10 days in a 96-well plate containing either no 
material (controls) or  each of the two materials (in triplicate). To make measurements, 
the plate was placed onto an inverted microscope stage surrounded by an incubation 
chamber at 37°C (Nikon), and the moving images of beating areas were projected onto a 
screen. Contraction/relaxation was detected by changes in light intensity at a fixed point 
using the ‘time measurement’ function of Nikon Element Advanced Version software. 
Measurements at multiple sites within the same field of view were made on pre-
recorded images. 
 
3.7.2 Fibroblastic SNL – biomaterial interaction 
3.7.2.1 Effect of Biomaterials on SNL  proliferation   
 
Due to limited ability of cardiomyocytes to proliferate, SNL mouse fibroblastic cell line 
was used to study the effect of the biomaterials on cell proliferation. Gelatinized and 
non-gelatinised culture plastic (polystyrene), and samples of PET/DLA, PET/DLA-
0.2wt%TiO2 and PEE biomaterials were used for this experiment and results were 
compared to cell proliferation on tissue culture plastic (TCP) (control). To ensure 
samples did not float and all cells were seeded directly onto the biomaterials, cell 
crowns (Scaffdex®) were used as inserts in 24-well plates. Cells were seeded at a 
density of 25,000 cells/cm2. On days 2, 4 and 6 the medium was collected for testing 
lactate dehydrogenase (LDH) released into culture medium (taken as an index of cell 
death). The cells at these time points were trypsinized with 200 µl of T/E per well for 5-
6 minutes at 37°C. Tryptic activity was inhibited by adding 15% serum containing SNL 
medium. A 10 µl aliquot was counted using a haemocytometer and an average was 
taken from the three samples. Graphpad Prism 4 package was used to analyze the data.  
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Cell proliferation assay was carried out also with AlamarBlue assay kit (Invitrogen). As 
proliferating cells maintain a reduced environment, reduction in the redox indicator 
AlamarBlue caused a change in the color from the oxidized blue form to the reduced 
fluorescent red form.  SNLs at seeding density of 10,000  cells/cm2 were cultivated in 
300 µl of SNL medium in each well of a 96-well plate with and without biomaterials. 
On days 2, 4 and 6, a 30 µl aliquot of culture medium was removed from each culture 
and added to each test well containing AlamarBlue. After 4h of incubation, absorbance 
readings were taken on a spectrophotometer (BioTek, Synergy HT) at 570nm 
(absorbance of AlamarBlue is read at 570nm). At each time point tests were carried out 
in triplicate (n=3). 
3.7.2.2 Effect of Biomaterials on SNL  cell death   
LDH assay kit (Invitrogen®) was used to test for LDH released from cells into the 
medium to indicate cell death.  Supernatant from days 2, 4 and 6 were collected and 
stored at -4°C until ready for analysis. When ready to be analysed, eppendorf tubes 
containing the supernatant were thawed out and centrifuged to remove any debris that 
may have been collected. 1 x LDH assay cofactor was prepared by adding 25 ml tissue 
culture grade water to the bottle of lyophilized cofactors. LDH assay mixture was 
prepared by mixing equal amounts of LDH assay substrate, cofactor and dye solutions. 
Two times the volume of assay mixture was added to the supernatant removed from the 
testing samples and incubated at room temperature under aluminium foil for 30 minutes. 
The reaction was then terminated by the addition of one tenth the volume of 1M 
hydrochloric acid (HCl) to each tube. Contents were then transferred to appropriate 
sized cuvettes for spectrophotometric measurement. The medium collected on day 0 
was used as the blank sample (control). The absorbance was measured at a wavelength 
of 490 nm. 
3.8 Physicochemical characterization techniques for TiO2 NPs 
 
Commercial grade, nanosize TiO2 (Aeroxide® P25, Degussa, Frankfurt a. M., 
Germany) was used to produce PET/DLA-0.2wt%TiO2 composites without further 
treatment. According to the manufacturer the NPs consist of approximately 80% anatase 
and 20% rutile crystalline phases and have mean particle size of 21 nm and a specific 
surface area of 50 m2/g (El-Fray & Boccaccini 2005). The particle size was remeasured 
in the present study in the specific vehicles used to maintain and expose the cell cultures. 
These vehicles include Krebs Henseleit (1 L ionised water supplemented with 69.6g 
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NaCl, 3.5g KCl, 2.32g MgSO47H2O, 1.66g KH2PO4, 21.0g NaHCO3 and 20.8g 
glucose.), adult rat cardiomyocytes, hESC-CM and SNL fibroblastic cultivation 
medium (see section 3.1.3 for their compositions). All the above media are high ionic 
strength solutions with high concentrations of divalent cations that cause P25 TiO2 NPs 
to aggregate (Long et al. 2006). The particle size distribution of P25 TiO2 NPs was 
measured using a dynamic light scattering instrument (Zeta PALs, Brookhaven 
Instrument Corporation). Before making the TiO2 containing solutions, NPs were 
sterilized by autoclaving and an initial concentration of 1000 ppm (1g/L) stock solution 
was made followed by 1 hour sonication and then subsequently diluted to yield 
concentrations ranging from 0 to 150 ppm, before measuring the particle size 
distribution. These diluted suspensions were then left to settle to monitor the growth of 
the P25 NPs aggregates after 45 minutes. To calculate the particle size, the refractive 
index of the anatase form of TiO2 (2.49) (Long et al. 2006) was assumed.  The zeta (ζ) 
potential of P25 NPs was also determined in all the above vehicles from a 30 ppm 
suspension (Zeta PALs, Brookhaven Instrument Corporation). The determination of the 
ζ-potential was necessary for understanding the TiO2 particle behaviour in aqueous 
media in relation to their tendency to agglomerate.  
 
3.9 Techniques used for cell contraction 
3.9.1 Measurement contractility of freshly isolated rat cardiomyocytes and hESC-CM 
with TiO2 NPs 
A video edge detection cell-length recording system (IonOptix) was used to measure the 
continuous contraction amplitude (% shortening), time to peak (TTP) shortening or time 
from peak to 50% or 90% relaxation (R50/90) for adult rat myocytes and hESC-CM. 
Myocytes in suspension were placed onto a perspex bath with a glass floor and placed 
on the stage of a Nikon TE200 inverted microscope. Cells were left to settle for 20 
minutes and then superfused with Krebs-Henseleit solution containing 2 mmol/L Ca2+ 
equilibrated with 95% O2 and 5% CO2 at a rate of 2ml/min and maintained at 32 ºC by a 
heater placed next to the chamber inlet. Cells were paced electrically using a biphasic 
50V pulse at 0.5 Hz. Only the rod-shaped myocytes contracting along their longitudinal 
axis were selected with clearly defined edges were selected. Beating hESC-CM clusters 
on 0.5% gelatinized glass cover slips were tracked in the same way as rat myocytes. 
Measurements were made during spontaneous contractions. Once tracking was 
established on suitable cells, 20 minutes was allowed to elapse to ensure contraction 
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amplitude and relaxed length was stable and not fluctuating, before perfusing the cells 
with TiO2 containing Krebs-Henseleit solution with 2 mmol/L Ca2+. A 1000 ppm stock 
of TiO2 was made in adult myocytes TCM and hESC-CM TCM, the solution was 
further diluted in Krebs-Henseleit solution before exposing the cells with TiO2 solution. 
Adult rat myocytes were perfused with 10 and 100 ppm solution, while hESC-CM was 
only perfused with 10 ppm. IonOptix software was used to measure contraction 
amplitude, TTP shortening and R50/90 for both adult rat myocytes and hESC-CM. 
Beating rate of hESC-CM was also obtained in terms of beats per minute (b.p.m).  
3.9.2 Monitoring hESC-CM beating rate over 24 hours 
Beating hESC-CM on 0.5% gelatinised glass cover slips were cultured in human 
differentiation medium in the absence and presence of 10 ppm TiO2. The beating rate 20 
minutes, 2, 4 and 24 hours postinoculation was measured using a Nikon optical light 
microscope.  
3.10 Statistical analysis 
Results are expressed as mean± standard error mean, one-way and two-way ANOVAs 
(analysis of variances) were used to analyze data with Graphpad Prism 4 software. One-
way ANOVA was used to compare the means of different treatments used. Two-way 
ANOVA was used to compare the means of different treatments at different time points.  
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4 PET/DLA block copolymer characterization for a 
myocardial tissue engineered patch 
4.1 Introduction 
 
The work presented in this chapter was undertaken to develop and characterize new 
biocompatible poly(aliphatic/aromatic-ester) multiblock copolymers for potential use 
for engineering a myocardial patch. PET/DLA multiblock copolymers containing 30 
wt% hard segments of PET and 70 wt% soft segments composed of DLA were 
synthesized by a two step-process, namely transesterification and polycondensation 
from the melt (El-Fray 2003c) (see section 3.4.1). Additional TiO2 NPs were added at a 
low concentration of 0.2wt% to form nanocomposites (initially 0.4wt% was used to test 
the effect of TiO2 on bioactivity). The synthesized biomaterials, PET/DLA and 
PET/DLA-0.2wt%TiO2, will serve as substrates for ESC-CM in MTE. The cellular 
biology studies on these materials are presented in Chapter 5. Multiblock PEE made 
from 30% PBT and 70% PEG, similar to the commercially available Polyactive® 
biopolymer (Waris et al. 2008), was used as a control.  
 
This chapter focuses on a number of key issues as follows. Firstly, biomaterial 
characterization in areas where current biomaterials in MTE need optimizing, including 
mechanical properties, degradation behavior and surface morphology. The influence of 
0.2wt%TiO2 NPs on the biomaterial’s properties is also investigated. The degradation of 
the biomaterials was investigated under three different culturing conditions (PBS, TCM 
with and without fibroblastic cells) to study their effect on degradation compared to the 
method of immersing biomaterials in simulated buffer solution (SBF), which has been 
previously used to study the degradation of these biomaterials (Prowans, El-Fray, & 
Jursa 2005).  
 
Although multiblock copolymers have previously shown suitability for tendon 
regeneration (El-Fray 2003c), for the first time in this project, PET/DLA block 
copolymers have been investigated as potential myocardial engineering substrates, 
namely due to their elastic properties, resistance to deformation and biocompatibility in 
TE applications. Details on material fabrication can be found in chapter 3, section 3.4, 
and the techniques used for their characterization are given in section 3.5. In this chapter 
surface morphology, material bioactivity and mechanical properties are reported in 
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section 4.2.1 followed by degradation testing results in section 4.2.2. Finally, this 
chapter includes a thorough discussion of the results (section 4.3), followed by closing 
remarks, section 4.4. 
4.2 Results 
4.2.1 Biomaterial characterization 
 
Surface topography and microstructure  
As expected, SEM micrographs as shown in figure 4.1 and 4.2 revealed the roughened 
surface of TiO2 containing PET/DLA, compared with PET/DLA alone and PEE (Figure 
4.3), a commercial-like material, due to the incorporation of NPs. Further confirmation 
of changes on the surface due to the inclusion of TiO2 NPs was provided by white light 
interferometry, illustrating an increase in the surface roughness as indicated by an 
increase in peaks formed during scanning (Figure 4.4). Measurements of the root mean 
square (rms) value, as described in chapter 3 in section 3.6.1.3, of the biomaterials 
containing TiO2 indicated a significant increase (p<0.001) in rms values of 
PET/DLA0.2wt% TiO2 in comparison to PET/DLA. Furthermore, the roughness of the 
PET/DLA biomaterial was always significantly (p<0.05) greater, using ANOVAs 
statistical analysis,  than that of the commercially available PEE biomaterial (figure 4.5). 
 
 
  
Figure 4.1 SEM micrographs of PET/DLA at a) x 50 magnification, b) x1000 
magnification. 
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Figure 4.2 SEM micrographs of PET/DLA-0.2wt%TiO2: a) x 50 magnification (inset is 
an image of spherulites-like structures observed on the surface of the biomaterials), b) 
x1000 magnification. 
 
 
 
 
 
Figure 4.3 SEM micrograph of PEE biomaterial (x 50 magnification). 
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Figure 4.4 White light interferometry images of surfaces of untreated materials: a) 
PET/DLA, b) PET/DLA-0.2wt%TiO2 and c) PEE. 
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Figure 4.5 Root mean square, rms (µm), values of fabricated biomaterials n=36. 
(significant difference found: # p< 0.05 PET/DLA-0.2wt%TiO2 vs. PEE, *** p<0.0001 
PET/DLA-0.2wt%TiO2 vs. PET/DLA). 
 
As expected, the presence of TiO2 NPs, even at low concentrations, does influence 
surface morphology, as confirmed by SEM (figures 4.1 and 4.2) and white light 
interferometry (figures 4.4 and 4.5). It is evident from figures 4.1 and 4.2 for PET/DLA 
and PET/DLA-0.2wt%TiO2, respectively, that PET/DLA-0.2wt%TiO2 shows additional 
formation of small spherulites on the surface where this is absent in PET/DLA surfaces, 
*** 
# 
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these results suggest the TiO2 NPs may initiate the nucleation of a crystallization 
process on the surface of the biomaterials. To confirm that the changes in surface 
morphology observed by SEM were not an artifact due to gold coating, and that they are 
indeed a part of the polymer matrix, a FIB system was used to prepare images with low 
primary beam currents (∼5nm penetration). Figure 4.6 shows images of the two 
different block copolymers, figure 4.6 a) showing a smooth surface for PET/DLA, while 
figures 4.6 b) and 4.6 c) show the bulges formed confirming the addition of TiO2 NPs 
does alter surface morphology. Simultaneously, SIMS which is connected to the FIB 
system, was used to detect TiO2 NPs, however, this was not possible due to the small 
percent of particles present.  
 
      
 
Figure 4.6 FIB images of untreated a) PET/DLA (x2k magnification), b) PET/DLA-
0.2wt%TiO2 (x2k magnification), c) PET/DLA-0.2wt%TiO2 (x20k magnification). 
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SICM was used to study the morphology of the biomaterial surfaces when immersed in 
TCM without any additional coating. This method allowed visualization of the 
biomaterial surface without causing permanent damage to them by gold coating (as 
would be done for SEM and FIB) therefore making the surface usable again after 
scanning. Figures 4.7 and 4.8 further confirm that the addition of TiO2 NPs alter the 
morphology of the biomaterial by increasing the surface roughness. Figure 4.8 shows a 
line profile of a section of the biomaterial with 0.2wt% TiO2 NPs and it can be seen that 
roughness ranges between 100 nm to 200 nm.  
   
 
Figure 4.7 SICM micrographs of biomaterial surfaces for: a) PET/DLA and b) 
PET/DLA-0.2wt%TiO2 (Dr. Julia Gorelik, Imperial College). 
 
         
Figure 4.8 SICM micrograph for PET/DLA-0.2wt%TiO2 surface with a line profile 
illustrating the grooves and troughs introduced onto the surface of the biomaterials by 
the TiO2 NPs (Dr. Julia Gorelik, Imperial College). 
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Confirmation of TiO2 NPs 
XRD analysis was performed to determine whether TiO2 NPs or PET blocks could be 
detected by this technique. No sharp peaks were observed for the PET sample. However, 
typical anatase peaks were observed in PET/DLA biomaterials containing 0.4wt% TiO2 
only and not the biomaterial containing 0.2wt% TiO2, maybe due to the reducued 
content, as indicated in figure 4.9. Anatase is the main crystalline phase of the starting 
titania powder.  
 
Figure 4.9 X-ray diffraction (XRD) patterns for PET/DLA, PET/DLA-0.2wt%TiO2 and 
PET/DLA-0.4wt%TiO2 samples, peaks observed correspond to Anatase. 
 
 
TiO2 agglomerates could be seen during TEM imaging in samples containing NPs. 
PET/DLA film composites did not show any diffraction pattern confirming their 
amorphous structure. Figures 4.10 a) and 4.10 b) are TEM micrographs showing black 
“spots” which are TiO2 agglomerates. Both high and low magnification images were 
taken. Diffraction pattern and energy dispersive x-ray (EDX) analyses were carried out 
during TEM observations confirming the presence of the TiO2, as shown in figure 4.10 
c) and 4.10 d). 
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Figure 4.10 TEM images of untreated PET/DLA-02wt% TiO2 sample: a) x 30 K, b) x 
100K, c) diffraction pattern, d) EDX analysis confirming the presence of TiO2 NP. 
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Wettability of biomaterials 
The degree of water contact angle can be used as an indication of the biomaterials 
hydrophilic properties (Pouliot 2004). Figure 4.11 is a graph illustrating the water 
contact angle measured on the investigated biomaterials. 
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Figure 4.11 Water contact angle (degree) measured on PET/DLA, PET/DLA-
0.2wt%TiO2 and PEE biomaterials n=6 (* p < 0.05 PET/DLA vs. PEE). 
 
 
  
Figure 4.12 A picture taken to measure the contact angle of a water droplet on 
PET/DLA biomaterial (base line length i.e. yellow line is 10 mm).  
 
 
It can be seen from figure 4.11 that PEE biomaterial is the most hydrophilic material 
with the least degree of water contact (57º ± 2) while PET/DLA is the most hydrophobic 
(65.5º ± 0.5). One-way ANOVAs test shows a significant difference (p < 0.05) between 
PEE and PET/DLA. Results illustrate PET/DLA-0.2wt%TiO2 to have intermediate 
hydrophilic properties (63º ± 2), the effect of TiO2 NPs on wettability is addressed in 
* 
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detail in the discussion of this chapter, section 4.3. Figure 4.12 is a picture taken during 
the water contact measurements for PET/DLA biomaterial, illustrating the principle of 
the measurements carried out.   
Thermal properties of biomaterials 
Table 4.1 Summary of DSC results obtained during thermal analysis. 
 Soft segment Hard segment 
Soft and hard 
segment 
Sample 
TgS 
(°C) 
TgH 
(°C) 
TcH 
(°C) 
TmH 
(°C) 
TgS&H 
(°C) 
PET/DLA -52.8 n/a 59.73 130.60 -39.80 
PET/DLA-
0.2%TiO2 
-45.28 n/a 65.80 128.60 -37.60 
PBT/DLA -61.70 n/a 35.04 116.50 -54.00 
Tg- glass transition temperature, Tc-crystallization temperature, Tm-melting temperature, S-refers to soft 
segment, H-refers to hard segment  
 
Table 4.1 summarizes the thermal properties of the biomaterials obtained from the DSC 
scans. DSC was used to determine the effect of TiO2 on the thermal behaviour of PET, 
as well as to compare the effect of hard/soft segment content on thermal properties of 
poly(aliphatic/aromatic-ester) multiblock copolymers. These effects have been well 
documented in the literature (El-Fray 2003c). Heating polymers above the Tm of the 
hard segments (Tm of PET is 265°C, Tm of  PBT is 220-267°C) causes the 
rearrangement of the domains as they disassociate and become fluid, leading to the 
phase mixing of the hard and soft segments. Upon cooling, the hard/soft segments phase 
separate into nanostructured micro-domains causing them to become immiscible again, 
giving the crystallization temperature of the hard segment (TcH). However, due to the 
small amount of hard segments (30%) compared to soft segment (70%), the TcH was not 
observed until the second heating cycle. The Tg of the hard segments (TgH) was not 
available, again, due to the small content of hard segments in the block copolymer. 
Instead the TgS/H of the amorphous phase of the hard/soft segment was observed in the 
second heating curve after the polymer had mixed, and reformed its amorphous phase 
during cooling. The TgS for the copolymer containing PET appears to be in the low 
temperature region and shifts to an even lower temperature region with PBT hard 
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segment. In general, a decrease in TgS is associated with a higher degree of phase 
separation as well as higher degree of crystallization of PBT domains compared to PET.  
Mechanical properties 
Figure 4.13 shows the typical stress-strain curves in tension obtained for PET/DLA and 
PET/DLA-0.2wt%TiO2 biomaterials. It can be seen that the tensile strength for TiO2 
NPs containing material has increased by nearly 100% in comparison with the TiO2 NP-
free PET/DLA polymer, while the elongation at breaking point increased by 300%. This 
remarkable improvement of the mechanical properties indicates the reinforcing effect of 
TiO2 NPs in the polymer matrix and can have very positive effect on the long-term 
fatigue properties of the composites. PET/DLA copolymers have already demonstrated 
excellent fatigue resistance (El-Fray & Altstadt 2003). The effect of TiO2 NPs on 
mechanical properties of PET/DLA is further discussed in section 4.3. 
 
 
Figure 4.13 Stress-strain curves for PET/DLA, PET/DLA-0.2wt%TiO2 and PEE with 
Young’s modulus of 2.8 MPa, 26.7 MPa and 4.07 MPa, respectively. 
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Table 4.2 compares the mechanical properties of the biomaterials investigated here to 
the properties of myocardium of both rat and human origin. It can be seen that the 
Young’s modulus and tensile strength of the biomaterials is considerably greater than 
that of the native myocardium, this is further discussed in section 4.3. 
 
Table 4.2 Mechanical properties of investigated biomaterials and myocardium of rat 
and human.  
Biomaterial Young’s modulus 
(stiffness) (E) 
Tensile 
strength 
Reference 
PET/DLA 2.8 MPa 2.4 MPa Figure 1.14 
PET/DLA-
0.2wt%TiO2 
26.7 MPa 9.1 MPa Figure 1.14 
PEE 4.07 MPa 7.4 MPa Figure 1.14 
Myocardium of 
rat 
0.001-0.14 MPa 30-70 kPa (Bing et al. 1971; 
Takaoka et al. 2002) 
Myocardium of 
human 
0.02-0.5 MPa 3-15 kPa (Nagueh et al. 2004; 
Watanabe et al. 2006) 
 
 
4.2.2 Biomaterial Degradation 
Surface morphology using SEM 
The SEM results obtained for assessing  biomaterial degradation for PET/DLA, 
PET/DLA-0.2wt%TiO2 and PEE for 6 and 12 weeks of immersion in different media 
are shown in figure 4.14 – 4.16. Biomaterial degradation was carried out under three 
different conditions, PBS, TCM alone and finally with SNL cells seeded on the 
biomaterial surfaces cultured in TCM. The material degradation in the three media was 
studied and in turn compared to untreated biomaterials. In this section the surface 
morphology investigation by SEM of the biomaterials is reported (figures 4.14 - 4.16).  
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Figure 4.14 SEM micrographs of PET/DLA biomaterials a) untreated b) 6 wks in PBS 
c) 6 wks in TCM d) 6 wks in TCM and SNLs e) 12 wks in PBS f) 12 wks in TCM g) 12 
wks in TCM and SNLs (scale bar represents 50 µm). 
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Figure 4.15 SEM micrographs of PET/DLA-0.2wt%TiO2 biomaterials a) untreated b) 6 
wks in PBS c) 6 wks in TCM d) 6 wks in TCM and SNLs e) 12 wks in PBS f) 12 wks in 
TCM g) 12 wks in TCM and SNLs (scale bar represents 50 µm).
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Figure 4.16 SEM micrographs of PEE
 
biomaterials a) untreated b) 6 wks in PBS c) 6 
wks in TCM d) 6 wks in TCM and SNLs e) 12 wks in PBS f) 12 wks in TCM g) 12 wks 
in TCM and SNLs (scale bar represents 50 µm).
 
 
The results in this section focus on the qualitative investigation of the biomaterials 
surface degradation obtained from SEM micrographs, micrographs are a representation 
of 3 samples. It is possible to visualize some sort of crystal formation on the surface of 
the biomaterials immersed in PBS, these can be crystal depositions from the PBS 
solution which maybe the cause of increase in surface roughness, as these crystals, 
possibly phosphate crystals are not observed in biomaterials immersed in TCM with or 
without cells. 
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Surface roughness using white light interferometry 
 
In this section images obtained from white light interferometry after biomaterials were 
immersed in PBS, TCM alone and with SNL cells seeded are presented (figure 4.17 - 
4.19). This is followed by graphs (figure 4.20 – 4.22) obtained from measuring the 
roughness parameters rms (µm) of the biomaterials under each condition. Results are 
compared to untreated biomaterials. 
 
 
         
   
 
    
 
Figure 4.17 White light interferometry micrographs of PET/DLA biomaterials: a) 
untreated b) 6 wks in PBS c) 6 wks in TCM d) 6 wks in TCM and SNLs e) 12 wks in 
PBS f) 12 wks in TCM g) 12 wks in TCM and SNLs. 
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Figure 4.18 White light interferometry micrographs of PET/DLA-0.2wt%TiO2 
biomaterials: a) untreated b) 6 wks in PBS c) 6 wks in TCM d) 6 wks in TCM and SNLs 
e) 12 wks in PBS f) 12 wks in TCM g) 12 wks in TCM and SNLs. 
 
 
 
 
 
g f e 
d c 
a 
b 
123 
 
    
 
   
 
   
 
Figure 4.19 White light interferometry micrographs of PEE biomaterials: a) untreated 
b) 6 wks in PBS c) 6 wks in TCM d) 6 wks in TCM and SNLs e) 12 wks in PBS f) 12 
wks in TCM g) 12 wks in TCM and SNLs. 
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Figure 4.20 Root mean square (rms) (µm) values of biomaterials untreated and after 6 
and 12 weeks in phosphate buffer saline solution (PBS) for PET/DLA, PET/DLA-
0.2wt%TiO2 and PEE n=6 (** p<0.01, ***p <0.001 numbers 6 and 12 weeks versus 
untreated).   
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Figure 4.21 Root mean square (rms) (µm) values of biomaterials untreated and after 6 
and 12 weeks in tissue culture medium only (without fibroblastic SNL cells) for 
PET/DLA, PET/DLA-0.2wt%TiO2 and PEE n=6 (** p<0.01, *** p<0.001 numbers 6 
and 12 weeks versus untreated).   
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Figure 4.22 Root mean square (rms) (µm) values of biomaterials untreated and after 6 
and 12 weeks in tissue culture medium with fibroblastic SNL cells for PET/DLA, 
PET/DLA-0.2wt%TiO2 and PEE n=6 ( ** p<0.001 p numbers 6 and 12 weeks versus 
untreated).   
 
The studies of biomaterials degradation after 12 weeks of incubation in TCM with and 
without fibroblastic SNL cells showed that surface roughness changes depend on 
material composition. The PET/DLA polymer surface shows many cracks and irregular 
topography indicating deformation has occurred (figure 4.14), while for PET/DLA 
containing TiO2 NPs distinct heterogeneous surface topography could be observed 
(figure 4.15). On the other hand the PEE surface is uniform and smooth as seen in 
(figure 4.16). SEM observations were confirmed by measurements of rms values 
representing the surface roughness. Identified defects on the PET/DLA surface gave 
high numbers of rms under all conditions (figure 4.17 – 4.19), while PET/DLA-
0.2wt%TiO2 surface gave high numbers of rms only at some regions, probably rich in 
TiO2 NPs, due to poor distribution of the particles in the polymer matrix, as discussed 
above.  
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The surface morphology of the biomaterials degradation in this section was assessed 
using white light interferometry. After 12 weeks of incubation in PBS, rms values for 
all biomaterials showed a steady and significant (p< 0.01 and p< 0.001) increase. 
Biomaterial degradation with SNL fibroblastic cells showed similar trend of increase of 
rms (µm) value in comparison to the biomaterials immersed in TCM only, where there 
was no significant change in rms value to PET/DLA-0.2wt%TiO2 biomaterial. More 
interestingly, there was a significant change in rms value for PET/DLA biomaterial at 6 
and 12 weeks, while there was only a significant (p<0.01) decrease in rms at 6 weeks 
only for PEE. This could be due to the hydrophilic nature of the PEE and therefore the 
degradation occurred via bulk degradation mechanism, where the dimension of the 
biomaterial alters as opposed to the surface degradation in the more hydrophobic 
PET/DLA.  
 
Chemical bonding in biomaterials using infrared (IR) spectroscopy  
In this section the effect of degradation on the biomaterials chemical bonding as 
determined by IR spectroscopy is reported (figure 4.23 – 4.25). The faster the 
degradation rate of the biomaterial the more disruption occurs in its chemical bonding. 
Results here illustrate the change in chemical structure after immersing biomaterials in 
three different cultures for 12 weeks indicating biomaterial degradation was occurring. 
The change in chemical structure is compared to the untreated samples.  
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Figure 4.23 IR spectroscopy graphs for untreated PET/DLA and after 12 weeks in PBS, 
TCM with and without cells. 
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Figure 4.24 IR spectroscopy graphs for untreated PET/DLA-0.2wt%TiO2 and after 12 
weeks in PBS, TCM with and without cells. 
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Figure 4.25 IR spectroscopy graphs for untreated PEE and after 12 weeks in PBS, TCM 
with and without cells. 
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pH, weight loss and water absorption 
Graphs illustrating the measured pH value of the cultures where the biomaterials were 
immersed along with the change in weight (%) and the amount of water absorbed (%) 
for each biomaterial, as shown in figure 4.26. Details on the methods and calculations 
for these measurements can be obtained from chapter 3. The relevance of these results 
for the intended application of the biomaterials is discussed in section 4.3. 
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Figure 4.26 a) pH, b) weight loss (%) and c) water absorption (%)  graphs for 
PET/DLA, PET/DLA-0.2wt%TiO2 and PEE biomaterials after 3, 6, 9 and 12 weeks in 
TCM with cells n=6. (pH graph: 3 weeks ** p < 0.01 PET/DLA vs. PET/DLA-
0.2wt%TiO2, 12 weeks ** p < 0.01 PET/DLA vs. PEE) (Weight loss and water 
absorption graphs: ** p < 0.01 PEE vs. PET/DLA and PET/DLA-0.2wt%TiO2, *** p < 
0.001 PEE vs. PET/DLA and PET/DLA-0.2wt%TiO2) 
 
 
a 
b c 
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131 
Gel permeation chromatography (GPC) 
The results below are the measurements made for molecular weight of the samples 
cultured over a period of 12 weeks in PBS and TCM with cells conditions. 
 
Table 4.3 Number average molecular weight (Mn), weight average molecular weight 
(Mw) and polydispersity (Mw/Mn) for a) PET/DLA, b) PET/DLA-0.2wt%TiO2 and c) 
PEE before cultured (untreated), and after immersion in PBS and with SNL cells in 
TCM for different time periods. 
  
 
Untreated PBS Cells 
 
 6 wks 12 wk 18wks 6wks 12wks 18wks 
Mn 6,832 6,842 5,216 5,648 6,731 7,009 5,858 
Mw 22,382 19,712 16,904 15,552 20,097 18,248 17,197 
Mw/Mn 3.276 2.881 3.241 2.753 2.986 2.604 2.935 
 
 
 
As expected, PEE biomaterials absorbed the highest percent of water compared to 
PET/DLA through out the duration of the experiments. This could be due to the 
extremely hydrophilic PEG soft segment content compared to the more hydrophobic 
DLA soft segment in PET/DLA biomaterials. The polydispersity (Mw/Mn) as well as 
molecular weight (Mw) of PET/DLA and PEE biomaterials decrease after 12 weeks of 
incubation which is typical for a degradation process in the polymers. Corresponding 
 
Untreated PBS Cells 
 
 
6 wks 12 wks 18 wks 6 wks 12 wks 18wks 
Mn 9,375 7,602 8,989 8,805 10,98 10,036 11,29 
Mw 65,473 64,88 81,604 77,191 65,17 80,636 75,54 
Mw/Mn 6.997 8.534 9.008 8.776 5.934 8.035 6.687 
 Untreated PBS Cells 
 
 6 wks 12wks 18wks 6 wks 12wks 18wks 
Mn 5,005 5,733 9,358 4,904 5,037 6,169 - 
Mw 18,661 18,199 18,174 15,285 16,667 15,532 - 
Mw/Mn 3.728 3.174 1.942 1.116 3.304 2.517 - 
a 
c 
b 
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values for PET/DLA containing TiO2 are higher what can also be the result of 
subsequent degradation of polymer chains and release of NPs into the chloroform 
solution used for GPC to dissolve the polymer (0.45 µm filter was used). Also the IR 
spectroscopy observation suggests that PET/DLA containing NPs degraded (figure 
4.24), this can be concluded from the new peak formation at 3300 cm-1, which can be 
ascribed to OH- groups at the ends of the degraded polymer chains. 
 
4.3 Discussion 
 
The hypothesis that TiO2 NPs will alter the surface topography of the biomaterial was 
confirmed. Results obtained showed that NP addition of 0.2wt% increased the surface 
roughness of the biomaterials, which is in agreement with previous findings (El-Fray & 
Boccaccini 2005). Increased surface roughness should lead to better cell attachment and 
maintenance of cardiac cell phenotype (Polonchuk et al. 2000). SEM, SICM, FIB and 
white light interferometry images illustrated the topography to have altered upon 
addition of the NPs. However quantitatively, the significant difference between the 
biomaterial roughness varied with each batch, although TiO2 containing biomaterials 
did always have a rougher surface, the difference was not always significant. This could 
be due to TiO2 particle agglomeration that occurs during the preliminary 
polycondensation step when the NPs are added. The size of TiO2 NPs in polymer 
solution needs to be measured. However this proved to be difficult as the polymeric 
solution is very viscous and sticky during the measurement (Nano Zetasizer, Malvern 
Instruments) instrument and therefore it was decided to measure the TiO2 agglomeration 
using TEM. TEM micrographs (figure 4.10) confirmed that there is homogenous 
spreads of the NPs within the biomaterials, however some limited agglomeration had 
also taken place, which will cause intra- and inter- batch variance in the surface 
roughness. It is the alternating roughness on the surface that is hypothesized to act as 
anchorages for cells, to enhance cellular adhesion and spread. A scaffold or patch 
intended to be used in TE needs to have some surface resemblance of the ECM found in 
the human body (section 2.4.4) and the addition of TiO2 NPs also aimed at mimicking, 
to some extent, the natural matrix in the myocardium. The addition of TiO2 NPs to 
polymers has been extensively investigated in the literature for TE, as previously 
described in the literature review (chapter 2, section 2.4.3).  
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Results in this chapter show that the addition of as little as 0.2wt% TiO2 NPs has an 
affect on both the mechanical and morphological properties of the biomaterials. This is 
in agreement with previous studies where addition of 0.13 wt% TiO2 NPs to PET/DFA 
increased the tensile strength and elongation at breaking point by approximately 100% 
and 300%, respectively (El-Fray & Boccaccini 2005). Since the myocardium is thought 
to have limited regenerative capacity and the heart itself cannot compensate for the cell 
loss which occurs during MI eventually leading to maladaptive LV remodeling and 
possible end-stage heart failure (Akins 2002) (see section 2.1.2), acellular polymeric LV 
restraint devices have been suggested to control negative LV remodeling and dilation 
associated with MI to preserve ventricular geometry and cardiac function (Sabbah 2003; 
Walsh 2006) (see section 2.6.2). An expanded heart requires more effort to eject the 
same amount of blood as a normal (uninjured) sized heart would and therefore LV 
restraints use LaPlace’s law to improve the function of the dilated heart (Christman & 
Randall 2006). Briefly, LaPlace principle relates the pressure difference transmurally 
with the wall thickness, radius and tension build up inside the ventricle ((T=(P*R)/M), 
T = tension in the vessel walls, P= pressure difference across the vessel walls, R = 
radius of the vessel and M = vessel thickness). Upon dilation the radius of the ventricle 
wall increases, thus to maintain the same pressure inside the injured ventricles during 
ejection as an uninjured heart, the tension consequently increases. Therefore the aim of 
the investigated cardiac patch is not only to deliver cells to the diseased region but also 
to support the injured myocardium preventing LV expansion after myocardial infarct 
occurs. With the tensile strength increasing upon TiO2 addition, this is advantageous in 
that the patch can simultaneously act as support whilst delivering cells. Different 
approaches have been suggested, restraints could serve either as a ‘wrap’ for both 
ventricles (Schroder et al. 2006; Walsh 2006), solely for left ventricle (Enomoto et al. 
2005) or as a ‘patch’ which covers only the infarcted area (Kelley et al. 1999). The 
CorCapTM patch made from polyethylene terephthalate (PET-polyester) has a Young’s 
modulus between 2.8 and 3.1 GPa, whereas PET/DLA and PET/DLA-0.2wt%TiO2 have 
a lower modulus of 2.8 and 24.6 MPa, respectively. The fact that biomaterials 
investigated in this chapter are stiffer than the myocardium itself (0.14MPa and 0.2-
0.5MPa for myocardium of rat and human, respectively) indicates that they will support 
the heart and prevent dilation. However, it is essential for the elastic properties of the 
biomaterial to be close to the elastic properties of the native myocardium to prevent cell 
detachment from the patch; in this case the stiffness of the biomaterials investigated in 
this chapter is not greater than that of other biomaterials already tested in vivo, PLLA 
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for example has a stiffness of 1-4 GPa (Chen et al. 2008), suggesting that these 
biomaterials will not cause further problems in vivo.  
 
A further important factor to be considered when designing a suitable engineered 
construct for TE application is the hydrophilic nature of the biomaterial (van Dorp et al. 
2006). The amount of water uptake is related to the molecular weight of the polymer 
which depends on the soft/hard segment ratio as well as the nature of the two segments. 
PBT and PET are the hard segments while PEG and DLA are the soft segments in the 
Polyactive®- like (PEE) and PET/DLA biomaterials, respectively. PEE biomaterials 
have previously been reported to be very hydrophilic, the higher the water uptake by the 
polymer the more swelling occurs which in turn changes the surface characteristics of 
the biomaterials (van Dorp et al. 2006), hence affecting cellular attachment. Results 
show PEE to be significantly more hydrophilic than PET/DLA (figure 4.11), while TiO2 
containing PET/DLA was shown to have intermediate hydrophilic properties, similar to 
that reported for tissue culture plastic (~ 62 ± 3 degrees) (Pouliot 2004; Steele et al. 
1994). In previous findings, it has been reported that for the Polyactive® material, the 
lower the PEG soft segment and the higher the PBT hard segment, the more cell 
proliferation occurs (Pouliot 2004). However, because our PET/DLA material consists 
of PET and DLA, both hydrophobic materials, one can hypothesize cells may prefer to 
proliferate on these materials. The inclusion of TiO2 NPs increased the hydrophilic 
property of the material, compared to that without TiO2, because TiO2 is able to absorb 
water at the surface (Gerhardt 2007), for this reason PET/DLA-0.2wt%TiO2 polymer 
has intermediate hydrophilicity in comparison to the extremely hydrophilic PEE and the 
hydrophobic PET/DLA, which is the basic requirement for optimal adhesion of most 
anchorage dependent cell types (Lydon, Minett, & Tighe 1985; Papadaki et al. 
2001;Pouliot 2004; Van Wachem et al. 1985).  
 
Results presented in this chapter show PET/DLA biomaterials to be relatively stable, in 
terms of degradation, in comparison to the PEE biomaterial. A key advantage of 
PET/DLA is the high content of a natural fatty acid (DLA) (70 % DLA compared to the 
30% synthetic PET). Although fatty acids are hydrophobic and relatively stable in terms 
of degradation, they have been classified as non toxic by ingestion once broken down 
(El-Fray 2003c). All polymers are susceptible to degradation, however the conditions 
under which the polymers degrade vary depending on their compositions and in vivo 
conditions. In vitro conditions enable, to a certain degree, prediction of their 
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degradation characteristics. The rate of degradation was studied using three different 
solutions, PBS, TCM and TCM with cells. PBS was used instead of the more commonly 
used SBF which is preferred for bone application because of its ability to maintain a pH 
of approximately 7.4, which is essential for cell survival. Furthermore, since it is an 
isotonic (matches human body ionic concentration) buffer solution, it resists change in 
hydronium (H3O+) and hydroxide ions(OH-). SBF is more commonly used for bone TE 
to predict the potential bone-bonding behavior through apatite layer formation to assess 
the bioactivity of biomaterials (Renke-Gluszko & El-Fray 2004). Polymeric materials 
can degrade in two different ways; either by hydrolysis or oxidative scissions of 
polymer backbone, with the former being the degradation process of interest in this 
chapter. The aim of this study was firstly to understand whether or not PBS was a 
suitable solution to use to investigate the degradation of biomaterials. In the case of 
PET/DLA biomaterials, the immersion in PBS and in TCM with and without cells made 
no difference on the degradation rate for the duration of the experiment (3 months). 
However, this treatment significantly affected the degradation of PEE as the samples 
immersed in PBS were still in tact after 18 weeks, while materials in TCM had 
disintegrated completely and it was not possible to carry out any form of measurements 
on them. This could be due to the concentration of proteins found in the FBS contained 
in the TCM which closely resembles the protein concentration found in the human body. 
Visual observation of samples indicated that biomaterials were degrading by a bulk 
degradation mechanism, as the dimension of the samples did not change during the 
testing period, but there was a decrease in weight over a period of 12 weeks. Moreover, 
SEM and white light interferometry micrographs showed that structural material 
degradation was occurring on the surface of the biomaterials.  
 
In TE it is essential for the biomaterial to degrade once the cells have been delivered, 
however the biomaterial chosen for each particular application needs to match the 
regeneration rate of the tissue it intends to help regenerate. As mentioned earlier, the 
myocardium itself has limited regenerative capacity and therefore the degradation of the 
biomaterial needs to be slower than a scaffold used for skin or bone TE for example. In 
the case of the particular application being considered here, cardiac patch, where the 
biomaterial will also be used as a myocardial support to prevent remodeling (which 
often occurs 16 weeks after an infarct in rats) it is mandatory for the patch to not only be 
relatively stable over a longer period of time, but also maintain its mechanical integrity 
while the polymer is degrading to continuously provide support until the infarcted 
136 
myocardium has regenerated. Previously, the effect of SBF on the mechanical 
properties of poly(aliphatic/aromatic-ester) copolymers was studied (Renke-Gluszko & 
El-Fray 2004) and it was reported that the polymers containing a higher ratio of the soft 
segment did not lose their mechanical properties compared to the stiffer polymers 
containing 60 and 70 % hard segments. Thus the polymer with 30% PET and 70% ratio 
was used for this application.   
 
4.4 Closing remarks 
After thorough characterization of the PET/DLA and PET/DLA-0.2wt%TiO2 
biomaterials properties (surface morphology, degradation behaviour, wettability and 
mechanical properties), the proposed biomaterials seem suitable for MTE. The addition 
of TiO2 NPs positively affected the biomaterials for their intended application in cardiac 
patches. It can be concluded that PET/DLA biomaterials are slow degrading and are 
therefore suitable to be used for cell delivery vehicles while simultaneously supporting 
the left ventricle preventing remodeling. The addition of TiO2 NPs enhances the 
mechanical properties of the bone PET/DLA matrix without negatively affecting the 
degradation behaviour of the materials in relevant media. 
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5 Cell-biomaterial interactions 
 
5.1 Introduction 
 
The work in this chapter focuses on the investigation of the biocompatibility of the new 
elastomeric materials, i.e. PET/DLA copolymer and it’s TiO2 –enhanced form 
(PET/DLA 0.2wt%TiO2 NPs) for the intended application as heart patches in MTE. The 
main objective of this chapter is to report, for the first time, the cell-biomaterial 
interactions on these materials in terms of cardiomyocyte attachment and spreading and 
their functional activities with the aim to assess the materials suitability for cardiac TE. 
SNL fibroblast cell viability/cytotoxicity and proliferation were also examined. 
 
 In these studies ESCs are used as a cell source to produce cardiomyocytes. Initial 
investigations were carried out utilising the mESC line D3, but following the 
establishment hESC cultures in this Laboratory, most studies were carried out on hESC 
line H7, as indicated. Due to the opaque nature of the materials, visualisation of 
individual spontaneously beating cardiomyocytes was not possible, but when these were 
cultured as beating clusters, it was possible to see where they were located on the 
materials and hence to follow their beating activity for months. Cardiomyocyte 
attachment and spreading was examined by SEM. To confirm the identity of the ESC-
CMs on the biomaterials, cells were stained for cardiac specific protein MHC.  Due to 
limited potential of ESC-CM to proliferate, for this part of the study a mouse 
fibroblastic cell line was employed. Cell viability on the materials was examined 
qualitatively, by staining cells with a vital dye, and quantitatively by measuring LDH 
release into culture medium. As the enzyme LDH is normally found intracellularly, its 
presence in culture medium indicates release from dead cells, which lose their 
membrane integrity. The behaviour of cells on materials was examined without and 
with gelatin-coating as ESC-CM attachment is optimal on glass or plastic surfaces 
following gelatin-coating of the surfaces. The results were compared to tissue culture 
plastic (TCP) made of polystyrene which is routinely used for tissue culture in vitro, and 
commercially available PEE was used as a reference material. 
 
The details about the maintenance and propagation of SNL fibroblasts and generation of 
cardiomyocytes from mESC and hESC lines are described in detail in chapter 3, section 
3.2. Techniques used to characterize cell-biomaterial interactions are detailed in section 
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3.7 in chapter 3. In this chapter the visualization and confirmation of ESC-CM is 
documented in section 5.2.1. The morphology of ESC-CM on all biomaterials using 
SEM is reported in section 5.2.2. Section 5.2.3 represents results of investigation on the 
effect of PET/DLA biomaterials on the functional activity of beating hESC-CM. Finally, 
the effect of biomaterial on cell proliferation and death is reported in section 5.2.4. This 
is followed by a thorough discussion of the results in relation to MTE (section 5.3) and 
closing remarks are included in section 5.4. 
 
5.2 Results 
5.2.1 Visualization and confirmation of ESC-CM  
 
Figure 5.1 shows light microscopy images of vital dye (neutral red) stained 
differentiated mESC confirming that these cells survive and can be visualized on 
biomaterials by light microscopy. It is evident also that any release from biomaterials 
did not inhibit cell survival (at day 3). 
  
  
Figure 5.1 Light microscope images of mESC-derived cells seeded on PET/DLA 
biomaterial at day 8 of differentiation. a) 3 days after cell seeding without neutral red 
staining of cells, b) after 15 minutes of neutral red staining.  
 
 
Due to biomaterial auto florescence it proved difficult to carry out ICC for ESC-CM on 
biomaterials, therefore cells from the same cell suspension that were seeded onto the 
biomaterials, were also seeded on glass cover slips running parallel to the experiment 
(figure 5.2). Images obtained from staining ESC-CM with FIT-C conjugated secondary 
antibody which recognizes cardiac MHC are shown in figure 5.2, which is found only in 
cardiac cells. 
a b 
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Figure 5.2 hESC-CM on glass cover slips: Green stain: FIT-C labelled MHC (cardiac 
cells); Blue: DAPI stained nuclei (x 40 magnification) a) – d) confirming the presence 
of cardiomyocytes on four different glass cover slips. 
 
 
5.2.2 The adherence and spread of ESC-CM on biomaterials: SEM observations 
 
This section presents SEM micrographs of ESC-CM on biomaterials, with and without 
gelatin coating (figures 5.3 –figure 5.8). Cells were seeded onto biomaterials and fixed 
four days after seeding, to ensure that cell adhesion occurred. Thorough details of 
sample preparation are presented in section 3.7.1.3 in chapter 3.  
 
a b 
c d 
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Figure 5.3 SEM micrographs of differentiating mESCs showing adherence and spread 
on PET/DLA material pre-coated with 0.1% gelatin: a) Low magnification view and b) 
high magnification view. 
 
 
 
 
 
 
 
b 
a 
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Figure 5.4 SEM micrographs of hESC-CM on the neat PET/DLA material: a) with 
0.5% gelatin coating, b) without gelatin coating. 
 
 
 
 
 
a 
b 
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Figure 5.5 SEM micrographs of mESC-CM adherence and spreading on PET/DLA-
0.2wt%TiO2:a) on 0.1% gelatin coating, b) without gelatin coating.  
 
 
 
 
 
a 
b 
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Figure 5.6 SEM micrographs of hESC-CM on PET/DLA-0.2wt%TiO2:  a) with 0.5% 
gelatin coating, b) without gelatin coating.  
 
 
 
 
 
a 
b 
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Figure 5.7 SEM micrographs of mESC-CM on PEE: a) with 0.1% gelatin coating, b) 
without gelatin coating.  
 
 
 
 
                               
 
 
Figure 5.8 SEM micrographs of hESC-CM on 0.5% gelatinized glass cover slips. 
 
 
 
 
 
 
 
 
a b 
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5.2.3 Contraction measurements of ESC-CM cultured on biomaterials 
Results in this section illustrate the effect of PET/DLA and PET/DLA-0.2wt% on the 
functional activity of isolated hESC-CMs, as measured by beats per minute (b.p.m) in 
comparison to tissue culture plastic (figures 5.10 - 5.12, 5.14 - 5.16). These cells were 
then fixed for ICC with nuclear DAPI stain and Alexa 546 labeled MHC to confirm that 
the cells being measured were in fact cardiomyocytes (figures 5.9, 5.13 and 5.17). From 
the results in figure 5.13 and 5.17, it is evident that DAPI was taken up by the 
biomaterials and not the cells; however the uptake of Alexa 546 was not interrupted by 
the presence of the biomaterials.   
      
 
 
 
Figure 5.9 Visualisation of hESC-CM: Immunostained hESC-CM grown on TCP in a 
96-well plate for 10 days in the absence of materials: Red stain: Alexa 546 labelled 
MHC (cardiac cells); Blue stain: DAPI (nuclei) a) corresponding control from which 10 
antibody was omitted, indicating that red stain in b) was specific to cardiomyocytes.  
(- = without, + = with, 10=primary, 20=secondary, ab=antibody). 
-10ab +20ab 
+10ab +20ab 
+10ab +20ab outside 
well 
b a 
c 
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Figure 5.10 Light microscopic images of beating hESC-CM cultured on TCP and 
examined after 10 days following seeding. The rate of beating of hESC-CM at these 
locations was measured by placing a coloured circular probe around them. Probe 
surrounding a beating area marked as green and red, with their corresponding traces in 
two different areas are shown. Insets are the ICC images of these cultures, Red stain: 
Alexa 546 (cardiac cells), Blue stain: DAPI stained nucleus (+ = with, 10=primary, 
20=secondary, ab=antibody). 
ICC of hESC-CMs on TCP +10ab +20ab 
ICC of hESC-CMs on TCP +10ab +20ab 
outside 
well 
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Figure 5.11 Spontaneously beating isolated hESC-CM seeded onto PET/DLA and 
examined after 10 days following seeding: a) Light microscopic image showing the 
positions of some of the beating ESC-CM cultured on PET/DLA biomaterial, but which 
did not land on the material itself. b) Trace obtained from the coloured probes placed 
around the beating areas. c) Same trace as in b) but a closer view to show synchrony in 
contraction peaks obtained from different beating areas residing at some distance from 
each other.  
 
 
 
 
a 
b 
c 
148 
 
 
 
 
Figure 5.12 Light microscopic image of beating hESC-CM on PET/DLA for 10 days: 
a) showing beating of hESC-CM in four areas, with different coloured probes 
surrounding each beating point, b) the trace obtained from the four probes, showing all 
four areas beating in synchrony. 
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Figure 5.13 Spontaneously beating hESC-CM cultured onto PET/DLA: hESC-CM seen 
in the gaps between the wall of wells and the edge of material. Nuclear stain DAPI was 
absorbed by the material, causing it to fluoresce in blue. Red stain: Alexa 546 (cardiac 
cells) Blue stain: DAPI (nuclei) a) corresponding controls from which 10 antibody was 
omitted, indicating that red stains in c) and d) was specific to cardiomyocytes. Inset are 
the images obtained without DAPI staining (blue fluorescent channel switched off due 
to DAPI being taken up by the biomaterial, hence interfering with image). (- =without, 
+ = with, 10=primary, 20=secondary, ab=antibody). 
 
inside 
well 
outside 
well 
biomaterial 
-10ab +20ab +1
0ab +20ab 
+10ab +20ab 
biomaterial 
inside 
well 
outside 
well 
biomaterial 
inside 
well 
a b 
c 
150 
 
 
 
 
 
 
Figure 5.14 Spontaneously beating hESC-CM cultured on PET/DLA-0.2wt%TiO2: a) 
light microscope image showing positions of three different beating hESC-CM with 
different colored probes, surrounding each beating area, (b) the trace obtained from the 
three probes. Below the graph paper the enlarged traces are plotted closely together 
showing that at two areas beating is in synchrony.  
 
 
 
 
b 
a 
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Figure 5.15 Beating hESC-CM seeded onto on PET/DLA-0.2wt%TiO2 biomaterial: 
light microscope image showing three different beating hESC-CMs that have landed on 
the TCP. These beating areas were circled with different colored probes to obtain traces 
for their beating activity. Inset is the trace obtained from the three probes, showing all 
three areas beating in synchrony, as encircled by black rings. 
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Figure 5.16 Beating hESC-CM that were seeded in 96 well plates with PET/DLA-
0.2wt%TiO2 biomaterials. A light microscope image showing three different beating 
hESC-CM that have landed onto the TCP, with different coloured probes surrounding 
each beating area and the trace obtained from the three probes, showing all three areas 
beating in synchrony. 
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Figure 5.17 Spontaneously beating hESC-CM cultured onto PET/DLA-0.2wt%TiO2: 
hESC-CM seen in the gaps between the wall of wells and the edge of material. Nuclear 
stain DAPI was absorbed by the material, causing it to fluoresce in blue. Red stain: 
Alexa 546 (cardiac cells) Blue stain: DAPI (nuclei). a) corresponding control from 
which 10 antibody was omitted, indicating that red stain in b) and c) was specific to 
cardiomyocytes. Inset are the images obtained without DAPI staining (blue fluorescent 
channel switched off due to DAPI being taken up by the biomaterial, hence interfering 
with image). (- =without, + = with, 10=primary, 20=secondary, ab=antibody). 
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5.2.4 Effect of biomaterials on SNL proliferation  
 
Cell proliferation was followed for 6 days on materials with and without gelatin coating. 
Figure 5.18 illustrates the percentage increase of SNL cells after culturing 25,000 SNL 
cells per cm2 on non-gelatinised and gelatinised surfaces. From the graph it is evident 
that all three biomaterials supported cell proliferation with and without gelatin coating, 
figure 5.19 a) and b) respectively. However, there was a significantly (p<0.05) lower 
number of cells on gelatinized biomaterials compared to gelatinized plastic (figure 
5.19b). 
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Figure 5.18 Graphs illustrating SNL percentile increase of cell number on gelatinized 
and non-gelatinized a) plastic b) PET/DLA c) PET/DLA-0.2wt%TiO2 and d) PEE 
biomaterials. * p<0.05, ** p<0.01 gelatinized vs. non-gelatinized. (Nt/N0)x100 = 
percetage increase in number of cells, Nt = total number of cells, N0 = original number 
of cells. 
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 Figure 5.19 Results of fibroblast proliferation studies. Graphs illustrating SNL 
percentile increase of cell number on: a) non-gelatinized  and b)  gelatinized surfaces on 
days 2, 4 and 6.  Results are the mean ± sem of 3 separate experiments each performed 
in triplicate. * p<0.05, ** p<0.01, *** p<0.001 vs. plastic, #p<0.05 vs PET/DLA-0.2% 
TiO2. (Nt/N0)x100 = percetage increase in number of cells, Nt = total number of cells, 
N0 = original number of cells. 
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5.2.5 Effect of biomaterials on SNL cell death 
 
The amount of LDH release from the cells cultured on the biomaterials, with and 
without gelatin coating, was evaluated for days 2, 4 and 6 and used as an indication of 
cell death during the experiment (Figure 5.19).  
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Figure 5.20 LDH release by cells cultured on gelatinized and non-gelatinized a) plastic 
b) PET/DLA c) PET/DLA-0.2wt%TiO2 and d) PEE. 
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Figure 5.21 LDH release by cells cultured on plastic, PET/DLA, PET/DLA-
0.2wt%TiO2 and PEE on days 0, 2, 4 and 6 for a) non- gelatinized surfaces and b) 
gelatinized surfaces. Results are the mean ± s.e.m of 3 experiments each performed in 
triplicate. Results were not significantly different. 
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To confirm that the reduction in cell number on the biomaterials between days 4 and 6 
(Figure 1.3) is due to cell death as opposed to inhibition of cell proliferation, LDH 
release by SNL seeded onto the biomaterials between days 4 and 6 was normalized for 
the number of cells at day 4 (Figure 5.20). 
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Figure 5.22 LDH release by cells cultured on different materials, LDH release between 
days 4 and 6 normalised for number of cells at day 4 on a) gelatinized biomaterials and 
b) non-gelatinized biomaterials (* p <0.05 plastic vs. PEE) c) direct comparison 
between gelatinized and non-gelatinized biomaterials. Results are the mean ± s.e.m of 3 
experiments each performed in triplicate. 
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5.3 Discussion 
 
In these studies, both mouse and human ESCs were utilized as a cell source to produce 
cardiomyocytes for testing material biocompatibility for future MTE. This experiment 
was very challenging: not only the methods of culturing undifferentiated ESCs were 
different for cells from different sources, but also the methods of inducing them to 
differentiate were very dissimilar. Producing enough numbers of ESC-CMs for the 
intended applications was a further complication as the yield of ESC-CM is rather low, 
typically 1-5% (Kehat et al. 2001;Ling-Ling et al. 2006;Xu et al. 2002) when cells are 
induced via EBs. Production of enough number of cells was not possible until the 
‘single monolayer’ method (Laflamme et al 2007) was established in this laboratory. 
This meant that there was a lot of cell culturing to propagate undifferentiated ESCs, so 
that either enough beating clusters can be microdissected from differentiated cultures, or 
cells could be enriched via discontinuous Percoll gradient centrifugation (Ling-Ling et 
al 2006; Geron protocols). 
 
Under the light microscope, live cardiomyocytes can be identified as spontaneously 
beating cells. However, ESC-CM, especially hESC-CMs, are very sensitive to heat 
changes and stop beating when they are at temperatures below 37°C. Their presence in 
the cell suspension which was seeded onto different biomaterials was confirmed by 
routine analysis of an aliquot taken from the same cell suspension and culturing on glass 
coverslips to test for cardiac cell specific markers, such as cardiac MHC, after fixation 
and immunostaining, as shown in Figure 5.2. The fluorescent-labeled cardiomyocytes in 
this figure were obtained from micro-dissected beating clusters of cardiomyocytes. 
Twenty-four hours after micro-dissection 30% of cultured cells were MHC positive. 
 
Although single beating hESC-CMs could be seen easily and identified on transparent 
substrates, such as TCP or glass coverslips from their beating motion, it was not 
possible to detect their presence on the opaque biomaterials, unless they were in large 
clusters of spontaneously beating cells. These beating clusters continued to contract for 
up to two months in culture, as shown in Figure S1 in the supplementary material (on 
CD provided).   
 
SEM was used to qualitatively study the spread and adherence of mESC-CMs and 
hESC-CMs on the biomaterials. Initially mESC-CMs were used until hESC-CMs 
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became available. The mESC-CMs and hESC-CMs were isolated from spontaneously 
beating aggregates and seeded onto the biomaterials, with and without gelatin coating. 
Gelatin coating is routinely used as an adhesive matrix to encourage cells to adhere onto 
glass coverslips and TCP, at 0.1% and 0.5% concentrations for mESCs and hESCs, 
respectively. The aim of this study was to investigate whether or not cells would adhere 
onto the biomaterials without gelatin coating since gelatin is extracted from animal 
connective tissue found in skin, and that materials devoid of animal products are 
essential in future cell therapies.  Both mESC-CMs and hESC-CMs were found to 
adhere and spread well on the surfaces of PET/DLA, as shown in Figures 5.3 and 5.4a, 
but only when the material was pre-coated with 0.1 and 0.5% gelatin, respectively. 
Cells, exhibited cell surface features such as microvilli, suggesting good adaption to 
new culture conditions. However, compared to PET/DLA biomaterials, the adherence 
and spread of cells (mESC-CM) on PEE copolymer occurred with and without gelatin 
coating (figure 5.7). The inclusion of 0.2wt%TiO2 NPs in the neat PET/DLA material 
also resulted in cell adherence and spreading of both mESC-CM and hESC-CM with 
and without gelatin coating (Figure 5.5 and 5.6, respectively). This might have been due 
to several reasons; first the effect that NPs have on the surface topography of the 
biomaterials increasing roughness; second, the increase in hydrophilic properties upon 
inclusion of the NPs; third, the increase in bioactivity of the NP containing composites, 
and fourth the increase in biomaterial stiffness by inclusion of NPs may have also 
encouraged cell adhesion. The appearance of hESC-CM on PET/DLA-0.2wt%TiO2 and 
that on gelatinized glass coverslips (figure 5.8) were very similar, suggesting that the 
presence of TiO2 did not cause adverse effects on cardiomyocytes.  
 
Previously in chapter 4 it was evident that the addition of 0.2wt% TiO2 NPs 
significantly increased the rms value, i.e. the surface roughness of the biomaterial 
(figure 4.5) The particles were also observed to initiate nucleation of a crystallization 
process on the biomaterial surface forming spherulites (figure 4.3 a)), which could 
possibly act as anchorage sites for better cell adhesion, where this was absent in 
PET/DLA surfaces (El-Fray & Boccaccini 2005;Piegat et al. 2008). The fact that the 
PET/DLA biomaterial containing 0.2wt% TiO2 NPs has similar wettability properties to 
TCP (figure 4.11), which is the basic requirement for optimal adhesion of most 
anchorage dependent cell types (Lydon 1985;Papadaki 2001) (TCP θ ~ 62° ± 3 and 
PET/DLA-0.2wt% TiO2  θ ~ 63° ± 3) may also be the cause of good cell adhesion and 
spread in the absence of gelatin coating. Hydrophilic surfaces possess high surface 
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energies; while hydrophobic surfaces have lower surface energies (the water contact 
angle is large) i.e. the water minimizes the contact with the biomaterial. The 
intermediate values of TCP and PET/DLA-0.2wt%TiO2 between hydrophobic 
PET/DLA (θ ~ 65.5° ± 0.5) and hydrophilic PEE (θ ~ 57° ± 2) allows the surface of the 
biomaterial to be coated sufficiently with the proteins present in the tissue culture 
medium, encouraging cell adhesion (Tan & Teoh 2007). 
 
In previous reports the bioactivity of materials has been reported to increase 
significantly upon addition of TiO2 NPs for bone TE applications, where an increase in 
hydroxyapatite formation on the materials surface in contact with simulated body fluid 
(SBF) was reported (Gerhardt 2007). Furthermore, although chemical and topographical 
properties of biomaterials have been studied extensively, the mechanical properties have 
also received much attention recently. It has already been reported in chapter 4 that the 
stiffness of the PET/DLA polymer increased by 10 fold upon inclusion of TiO2 NPs 
(figure 4.13). The stiffness values of PET/DLA, PET/DLA-0.2wt%TiO2 and PEE were 
found to be 2.8, 26.7 and 4.07 MPa, respectively. It has been reported that fibroblasts 
proliferate better on stiffer materials
  
(Engler 2004;Tan & Teoh 2007;Wong 2004), 
hence the possible reason for better cell adhesion of the cardiomyocytes and cell 
proliferation on PET/DLA biomaterials containing 0.2wt% TiO2  NPs. A significant 
finding reported by Lo et al., was that fibroblasts have a tendency to guide their 
movement by probing the substrates rigidity and when cells sensed a rigid substrate they 
tend to it expanded their lamellipodia and lamella. However when fibroblasts sensed a 
more flexible and soft substratem cells changed their movement direction (Lo 2000;Tan 
& Teoh 2007). Furthermore, the morphology of chondrocytes was also reported to 
depend on substrate stiffness, where they remained rounded on softer substrates while 
on stiffer, more rigid substrates, chondrocytes exhibited a flattened de-differentiated 
fibroblastic morphology and were reported to have increased ability to spread, attaching 
much faster and to a greater degree (Lo 2000;Tan & Teoh 2007). Despite the above 
literature, one cannot conclude that cells always prefer stiffer materials, of course cell 
proliferation and adhesion is very material sensitive, and stiffness could be an additional 
factor as, presented here. 
 
The opacity of the materials investigated was a limiting factor for measurements of 
contraction of cells on biomaterials since only large clusters could be visualised. 
Contractile activity was tested in 2 ways. First by following the beating motion of 
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microdissected large myocyte clusters cultured on these materials for prolonged periods 
(over 2 months) (figure S1; see movie in supplementary CD); the beating rate after 2 
months was within the range normally demonstrated by clusters of that age kept on 
tissue culture plastic, as observed in the laboratory. The second method was to add 
enzymatically dispersed single cells (or very small clusters) to material disks occupying 
the majority of the well in a 96-well tissue culture plate. The functional activity of ESC-
CMs, measured as b.p.m, was recorded from hESC-CM which landed onto the small 
gap between the edge of the material and the well wall at the time of cell seeding onto 
materials (see movies in supplementary CD, figure S2 showing beating hESC-CM that 
landed onto the small gap between the edge of PET/DLA biomaterial, figure S3 
showing six hESC-CM clusters beating in synchrony near PET/DLA biomaterial, figure 
S4 showing beating hESC-CM that landed onto the small gap between the edge of 
PET/DLA-0.2wt%TiO2 biomaterial and figure S5 showing several hESC-CM clusters 
beating in synchrony near PET/DLA-0.2wt%TiO2 biomaterial). The cells were in 
culture for 10 days at the edge of and immediately adjacent to the material (see above 
figures section 5.2.3). Beating on or near PET/DLA (figures 5.11 and 5.12) or 
PET/DLA-0.2wt%TiO2 (figures 5.14, 5.15 and 5.16) continued, and it was not marked 
different from that on TCP (figure 5.10) (see movie in supplementary CD, figure S6 
showing beating hESC-CMs on TCP).  For the material samples, several areas were 
sampled for beating in the same well (figures 5.11, 5.12, 5.14, 5.15 and 5.16), and the 
inserted trace showed that contraction was synchronised between areas.  This behaviour 
indicates functional conduction of electrical impulses between cardiomyocytes within 
the well, suggesting attainment of normal cardiomyocyte function.  Subsequent ICC 
staining confirmed cardiomyocyte identity (figures 5.9, 5.13 and 5.17 for TCP, 
PET/DLA and PET/DLA-0.2wt%TiO2, respectively), where the Alexa 546 antibody 
(red stain) was specific to cardiac MHC, where no non-specific binding occurred in 
control sets (pictures with only DAPI stain labelled with -10ab +20ab), suggesting that 
all red stains were due to recognition of cardiac MHC. The apposition or juxtaposition 
of PET/DLA or PET/DLA-0.2wt%TiO2 materials does not therefore produce gross 
toxicity in hESC-CM. 
 
As previously mentioned, because of the limited and uncharacterised proliferative 
ability of ESC-CM, quantitative measures for biomaterial biocompatibility in terms of 
proliferation and cell death were obtained using SNL fibroblast cell line. SNL 
proliferation on materials was compared to TCP, which represent ideal conditions for 
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cell culture in vitro. Cell proliferation on gelatinised and non-gelatinised surfaces was 
also compared. SNL cells proliferated steadily up to day 4 of culture on both PET/DLA 
and PET/DLA-0.2wt%TiO2 biomaterials and the additional gelatin coating of 
biomaterial surfaces had no significant effect on cell proliferation (Figure 5.18 a). 
However, there was a significant decrease in cell number on gelatinised surfaces of 
PET/DLA copolymers and PEE from day 4 to 6 (p < 0.05, 0.01 and 0.001 Figure 5.18 
b)); this could have been due to inhibition of cell proliferation or cell death. This 
behaviour can be seen in the sharp increase in LDH released into culture media, which 
was taken as an index of cell death, from day 4 to 6 on all three biomaterials, where this 
increase in LDH release is less pronounced for TCP (Figure 5.19 b). Furthermore, one 
can argue that since this experiment was a stationary culture, cellular waste products 
could have accumulated until media changed every other day, and this might have 
caused further effect on cell proliferation. Although non-gelatinised biomaterials 
supported a linear cell proliferation,  none of the biomaterials seem to have encouraged 
cell proliferation similarly to that seen on TCPs (Figure 5.18), in which cell numbers 
were statistically different at days 2, 4 and 6 when comparing cell proliferation on 
biomaterials and TCP.  
 
When comparing the three biomaterials, cells on PET/DLA-0.2wt%TiO2 polymer 
yielded a more pronounced cell proliferation in comparison to the PEE material, serving 
here as a reference (p<0.05). However, no significant difference between the PEE and 
PET/DLA was observed. This might have been due to the incorporation of TiO2 NPs. 
As mentioned above, the addition of NPs to the polymer matrix had a significant effect 
(p < 0.05) on the surface topography (figure 4.5), where surface roughness was greater 
in TiO2 containing biomaterial, which may act as an anchorage site for cells to adhere to. 
This is in agreement with previous findings by other authors working on 
nanocomposites (Webster 2003). It is evident that the reference PEE material did not 
encourage cell proliferation as much as PET/DLA biomaterials. This is due to the 
hydrophilic nature of the polymer, as compared to the more hydrophobic PET/DLA (as 
previously discussed in great detail in chapter 4, see also Figure 4.11). In previous 
findings, it has been reported that for the PEE biomaterial, the lower the PEG soft 
segment and the higher the PBT hard segment, there is an increase in cell proliferation 
(Pouliot 2004). However, because our PET/DLA material consists of PET and DLA, 
both hydrophobic materials, could possibly be the reason why cells preferred to 
proliferate on these materials. 
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LDH is a cytoplasmic enzyme. It can be used either as an indicator of cell proliferation 
(when extracted from cells) or as an indicator of cell death when it is released from cells 
due to loss in cell membrane integrity. In this experiment LDH is used in the latter 
context. Assaying for LDH activity in culture medium is a convenient simple 
biochemical test to study the toxic effect of biomaterials on the cells. A similar trend 
was observed in LDH activity in medium for all cultures at each time point studied. 
Basically, that the amount of LDH release increased throughout the experiment as 
presented in figure 5.19. The LDH measurements for the neat PET/DLA and PET/DLA-
0.2wt%TiO2 steadily increased until day 4 (Figure 5.19), which is proportional to the 
cell number increase, Figure 5.18. Comparing to TCP, the trend is similar where LDH 
release increased steadily, however at a much lower rate, where LDH concentration 
with and without gelatin coating followed a similar trend with no significant difference 
between the two conditions. Interestingly, there was no significant difference in LDH 
release from the cells between the neat PET/DLA and TiO2 NP containing material, 
suggesting that TiO2 NPs are not the cause of cell death or inhibition of proliferation. 
When comparing the LDH release of cells on biomaterials to the LDH release from cells 
on TCP, similar trends are also observed until day 4. However, there was a sharp 
increase in LDH activity, that occurred concomitantly with a  66% and 64% decrease in 
cell number, suggestive of cell death, for PET/DLA and PET/DLA-0.2wt%TiO2, 
respectively, from day 4 to day 6. This phenomenon was not observed in the case of 
TCP, suggesting that the by-products of the materials were possibly affecting cell 
proliferation or causing cell death. As cell numbers in polymer cultures at day 4 were 
fewer, this would imply a proportionately greater LDH release for a given cell number. 
To demonstrate this effect, the LDH release between day 4 and 6 was normalized with 
cell number present at day 4, for both gelatinized and non-gelatinized cultures (Figure 
5.20): a one-way ANOVA correlation shows the difference to be statistically significant 
(p<0.05) only between TCP and PEE for gelatinized cultures. This result confirms that 
there is an increase in SNL fibroblast cell death when in contact with all tested 
biomaterials compared to TCPs, rather than simply an inhibition of cell proliferation. 
The low cell number on day 6 on all biomaterials compared to TCP is difficult to 
explain, but possible toxic release from the materials as they begin to degrade should 
not be ruled out (section 4.2.2). Whether or not cell number would have decreased 
further on subsequent days is yet to be determined. However, the PET/DLA-
0.2wt%TiO2 nanocomposite material showed to be superior as compared to the 
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PET/DLA copolymer (without nano- TiO2) and to PEE. Recently, Mummery et al 
(2007) reported that the overgrowth of proliferating cells may result in a decrease in the 
percentage of cardiomyocytes (Mummery 2007). Therefore, one must consider when 
introducing the heart patch in vivo, to what extent is the patch supposed to encourage 
fibroblast proliferation which in turn will affect the integration of the ESC-CMs with 
the native heart.  
 
 
5.4 Closing remarks 
Results presented in this chapter suggest that PET/DLA and PET/DLA-0.2wt%TiO2 
biomaterials encourage ESC-CMs to adhere and spread in the presence of gelatin 
coating. More importantly, the change in surface topography, increase in tensile strength 
and increase in hydrophilic properties of TiO2 containing biomaterials compared to the 
neat PET/DLA encourage ESC-CMs to adhere and spread onto the biomaterials in the 
absence of gelatin coating. The observation of continuous beating of hESC-CM on 
PET/DLA elastomer and nanostructured PET/DLA-TiO2 elastomeric composite for 
more than 2 months in culture suggests that the materials will support cardiomyocyte 
function.  These results suggest that PET/DLA and especially PET/DLA-TiO2 are 
promising for MTE purpose, and suitable to progress to the next stage of testing in in 
vivo animal models. 
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6 Cardio-toxicity of TiO2 nanoparticles (NPs) 
 
6.1 Introduction 
The results in this chapter aimed at investigating, for the first time, the toxic effect of 
TiO2 NPs on cardiomyocytes. Since the current investigated 13 mm in diameter 
polymeric substrate consists of approximately 145 parts per million (ppm) concentration 
of TiO2 NPs, it was essential to study the possible toxicity effect of TiO2 NPs on 
cardiomyocytes. This was a crucial point to investigate since the substrate is degradable 
(although having a slow degradation rate, see section 4.2.2) and eventually the particles 
will be leached into the body when in vivo. Therefore, there were two aspects that 
needed investigating, firstly the effect of TiO2 NPs on the heart that will have the 
cardiac patch sutured onto it and secondly the effect of TiO2 NPs on the hESC-CMs that 
will be seeded onto the substrate. In the case of the former, freshly isolated adult rat 
ventricular cardiomyocytes were used as they are considered to be a true cell culture 
model representative of heart tissue since they are fully differentiated and therefore 
retain many characteristics of the native heart’s cardiomyocytes. For the second part of 
the experiment, micro-dissected beating hESC-CM clusters were used. The effect of the 
TiO2 NPs on cell proliferation and death (LDH release) was also studied using SNL 
fibroblasts, due to limited cardiomyocyte proliferation.  
 
However, before studying the effect of the TiO2 NPs on cellular behavior, it was 
essential to investigate the size and aggregation potential (given by the ζ-potential) of 
the particles in different media that will be ‘vehicles’ when testing the effect of NPs on 
cellular behavior. Detailed description of the materials and methods used for the 
experiments can be found in chapter 3 (section 3.8). In this chapter the effect of various 
media (SNL, hESC-CM and rat myocyte TCM and Krebs-Henseleit solutions) on TiO2 
particle aggregate size and ζ-potential is reported (section 6.2.1). The effect on the 
contraction of both adult rat cardiomyocytes and hESC-CM as well as the beating rate 
of hESC-CM is documented in section 6.2.2. Finally, the effect of NPs on cell 
proliferation is reported in section 6.2.3. This is followed by a thorough discussion of 
the results (section 6.3) and closing remarks (section 6.4). 
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6.2 Results 
This section illustrates the variation of particle size of TiO2 NPs in various TCM at a 
range of concentrations (figure 6.2 - 6.6). Thus the aim of these tests is to understand 
the agglomeration behaviour of the NPs before exposing cells to TiO2. Initially, the ζ-
potential of the media was measured for all suspensions with 30 ppm concentration of 
TiO2 NPs as an indication of the medium potential to form agglomerates (figure 6.1).  
6.2.1 Particle size and zeta potential 
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Figure 6.1 ζ-potential of TiO2 NPs in various tissue culture medium at 30 ppm 
concentration. 
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Figure 6.2 TiO2 particle size at 1 – 150 ppm concentration in adult rat cardiomyocyte 
TCM, immediately after sonication and 1 hr after sonication (steady-state). 
 
168 
10 ppm 100 ppm
0
100
200
300
400
500
Immediately after sonication
1 hr after sonication
TiO2 concentration (ppm)
Pa
rt
ic
le
 
si
z
e 
(n
m
)
 
Figure 6.3 TiO2 particle size at 10 and 100 ppm concentration in hESC-CM TCM, 
immediately after sonication and 1 hr after sonication (steady-state). 
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Figure 6.4 TiO2 particle size at 1 – 150 ppm concentration in SNL fibroblast TCM, 
immediately after sonication and 1 hr after sonication (steady-state). 
 
 
 
169 
1 5 10 50 100 150
0
250
500
750
1000
1250
1500
1750
2000
Ti O2  concentrati on (ppm)
Pa
rt
ic
le
 
si
z
e 
(n
m
)
 
Figure 6.5 TiO2 particle size at 1 – 150 ppm concentration in BSA free adult rat 
cardiomyocyte TCM and Krebs-Henseleit solution (**p < 0.01 vs. 1 ppm). 
 
 
 
Figure 6.6 TiO2 particle size at 0 – 150 ppm concentration in adult rat cardiomyocyte 
TCM (with and without BSA, *** p<0.0001) and Krebs-Henseleit solution. 
 
Figure 6.1 shows the ζ-potential of TiO2 NPs in all vehicles used in this study to range 
between +15 mV and -15 mV. In this study the particle size and ζ-potential of TiO2 in 
the various vehicles that cardiomyocytes and fibroblasts will be cultured in was 
investigated. However, particles in the vehicles investigated have low ζ-potential (BSA 
free adult rat TCM with Krebs = -5.13±4.8, BSA adult rat TCM = 3.95±6.5, adult rat 
TCM = -3.61±8.8, human TCM = -1.27±5.3, SNL TCM = -8.55±9.4) hence there is 
dispersion instability and particles will be expected to aggregate. Increasing TiO2 NPs 
concentration in all media (except BSA free rat TCM, Figure 6.6) had no significant 
effect on the particle size (nm). The addition of BSA inhibited TiO2 agglomeration. 
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Both hESC-CM and SNL fibroblast TCM contain FBS and this may be the reason why 
agglomeration was inhibited. This is further discussed in section 6.3.  
6.2.2 Contraction experiments 
Results in this section illustrate the effect of TiO2 NPs on hESC-CM clusters  and 
freshly isolated adult rat cardiomyocytes. For further detail on hESC-CM differentiation  
and adult rat isolation, refer to sections 3.2 and 3.3, respectively. The aim of these 
experiments was to determine the effect of the NPs on the cardiomyocytes seeded onto 
the biomaterials and the NPs effect on native heart as the biomaterial degrades and 
releases TiO2 NPs in vivo. hESC-CMs were used for the former while adult rat 
cardiomyocytes were used for the latter. Figure 6.7 and 6.8 illustrate light microscope 
images of an adult cardiomyocyte and hESC-CM, respectively, during contraction 
experiment. Figure 6.9 illustrates how each peak was then analysed used IonOptix 
software, inset is an example of a peak obtained during measurements for hESC-CM. 
 
Figure 6.7 A light microscope image and the peaks obtained during exposure of 100 
ppm TiO2 NPs on freshly isolated adult rat cardiomyocyte during a contraction 
experiment. Below is the trace obtained during each myocyte’s contraction. 
 
 
 
 
Figure 6.8 A light microscope image and the peaks obtained during exposure of 10 ppm 
TiO2 NPs on a hESC-CM cluster during a contraction experiment. Below is the trace 
obtained during each myocyte’s contraction.  
171 
 
 
 
Figure 6.9 An illustration of the results obtained from each peak, each peak will give a 
value TTP, R50 and R90. Inset is an example of a peak obtained during contraction 
measurements for a hESC-CM exposed to 10 ppm TiO2 NPs. 
 
Effect of TiO2 NPs on adult rat cardiomyocytes 
Results below represent the effect of TiO2 NPs at 10 and 100 ppm on adult rat 
cardiomyocytes. Initially, contraction was recorded for 20 minutes to obtain a basal 
reading in Krebs-Henseleit solution. Cells were then exposed to NPs (10 or 100 ppm) 
for a further half hour. This was followed by a Krebs-Henseleit solution wash. 
Percentage shortening, TTP, R50 and R90 of cardiomyocyte were measured. Cells were 
also cultured in varying concentrations (0-150 ppm TiO2) for 24-hours to see whether 
NPs increase cell death. Amount of LDH leakage was used as an indication of cell death. 
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Figure 6.10 Percentage (%) shortening of adult rat myocytes in response to 10 ppm 
TiO2 NPs (n=6). 
Time to 
peak 
Time to 90% 
relaxation 
Time to 
50% 
relaxation 
Length 
Time 
172 
TTP R50 R90
0
25
50
75
100
125
Basal
10 ppm
Wash
Ti
m
e 
(m
s)
 
Figure 6.11 TTP, R50, R90 in adult rat myocytes before (basal) and after 10 ppm TiO2 
NP exposure (n=6) (* p < 0.05 vs. R90 basal). 
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Figure 6.12 Percentage (%) shortening of adult rat myocytes in response to 100 ppm 
TiO2 NP (n=6) (** p< 0.01 vs. basal). Inset are the traces obtained during contraction 
experiments i) before TiO2 ii) after TiO2. 
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Figure 6.13 TTP, R50, R90 in adult rat myocytes before (basal) and after 100 ppm TiO2 
NP exposure (n=6) (** p < 0.01 100ppm vs. basal, ***p < wash vs. basal). 
 
 
Figure 6.14 Effect of NPs on lactate dehydrogenase (LDH) in adult rat myocytes. Cells 
were treated with different concentrations of NPs for 24 h. After incubation period, the 
LDH assay was performed to assess the LDH leakage n=6. 
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Effect of TiO2 NPs on hESC-CM 
Due to undefined cell edges in hESC-CM clusters (Figure 6.8), it was difficult to carry 
out measurements for 100 ppm TiO2 NPs because some of the particles had a tendency 
to settle on the high contrast points that were used during for tracking contraction, hence 
interfering with the measurements. Therefore in this section, the effect of only 10 ppm 
TiO2 on hESC-CM percentage shortening, TTP, R50 and R90 is documented. The 
beating rate of hESC-CMs is also reported. 
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Figure 6.15 Percentage (%) shortening normalised to basal for hESC-CM in response to 
10 ppm TiO2 NPs (n=6) 
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Figure 6.16 TTP, R50, R90 (all data normalised to basal) in hESC-CM before (basal) 
and after 10 ppm TiO2 NPs exposure (n=6). 
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Figure 6.17 hESC-CM beating rate cultured in 10 ppm TiO2 a) 24 h using light 
microscope b) using video-edge recording system (* p < 0.05, ** p < 0.01 vs. basal) 
 
6.2.3 Cell proliferation and LDH (for both rat and SNL) 
 
Vascularization is an important factor for myocardial regeneration, therefore the effect 
of TiO2 NPs on cell proliferation and cell death up to six days was investigated, using 
SNL fibroblast cell line, since cardiomyocytes have limited proliferative capacity. The 
morphology of the cells at days 2, 4 and 6 was also examined using a light microscope. 
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Figure 6.18 Fibroblastic SNL cell proliferation (%) for cells cultured in TiO2 NPs (0 – 
150 ppm) on days 0, 2, 4 and 6 (n= 9) (** p<0.01, *** p < 0.001). 
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Figure 6.19 LDH release by SNL fibroblastic cells cultured on plastic with TiO2 NPs on 
days 0, 2, 4 and 6 (n= 9) (day 2: **p < 0.01 0ppm vs. 100 and 150 ppm, day 4: *p < 0.5 
0ppm vs. 150ppm, day 6: ***p < 0.001 0ppm vs. 10-150ppm). 
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Figure 6.20 Morphological characterization of SNL fibroblasts by optical light 
microscope. Cells were treated with 0 and 1 ppm TiO2 NPs in SNL TCM and incubated 
for 6 days at 37°C in a 5% CO2 atmosphere: a) control 0 ppm day 2, b) control 0 ppm 
day 4, c) control 0 ppm day 6, d) 1ppm day 2, e) 1 ppm day 4, f) 1 ppm day 6 (scale bar 
100 µm). 
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Figure 6.21 Morphological characterization of SNL fibroblasts by optical light 
microscope. Cells were treated with 5 and 10 ppm TiO2 NPs in SNL TCM and 
incubated for 6 days at 37°C in a 5% CO2 atmosphere: a) 5 ppm day 2, b) 5 ppm day 4, 
c) 5 ppm day 6, d) 10 ppm day 2, e) 10 ppm day 4, f) 10 ppm day 6 (scale bar 100 µm). 
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Figure 6.22 Morphological characterization of SNL fibroblasts by optical light 
microscope. Cells were treated with 50 and 100 ppm TiO2 NPs in SNL TCM and 
incubated for 6 days at 37°C in a 5% CO2 atmosphere: a) 50 ppm day 2, b) 50 ppm day 
4, c) 50 ppm day 6, d) 100 ppm day 2, e) 100 ppm day 4, f) 100 ppm day 6 (scale bar 
100 µm). 
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Figure 6.23 Morphological characterization of SNL fibroblasts by optical light 
microscope. Cells were treated with 150 ppm TiO2 NPs in SNL TCM and incubated for 
6 days at 37°C in a 5% CO2 atmosphere a) 150 ppm day, 2 b) 150 ppm day 4, c) 150 
ppm day 6 (scale bar 100 µm). 
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6.3 Discussion 
 
There is much concern due to the fact that NPs, found in air pollutants, are small 
enough to penetrate through the smallest capillaries throughout the body and could pass 
through biological cellular membranes, potentially affecting any cell type posing a 
serious risk on organs that are sensitive to calcium and oxidative stress (e.g. the brain 
and heart) and may cause worsening conditions for patients suffering from a heart attack 
due to disruption of the membrane-bound enzymes which in turn causes cardiac 
arrhythmias (Kukin & Fuster 2002). However, understanding the properties of TiO2 
NPs and their effects with regards to human health issues has proven difficult due to 
their strong ability to aggregate. The toxicity of NPs on biological species has been 
shown to correlate with several different factors such as their specific surface area, ζ-
potential and particle aggregate size (Long 2006). The larger the positive or negative 
potential the more the particles repel each other in the medium due to dispersion 
stability. Generally, in this study increasing the TiO2 NP concentration had no 
significant effect on aggregate size, this maybe due to the presence of BSA in the adult 
rat TCM and the presence of FBS in both the hESC-CM and SNL TCM media.  
 
However, aggregate size in adult rat medium without BSA increased significantly 
(p<0.05) compared to aggregate size in TCM containing BSA. This result agrees with 
previous findings, where aggregate size in DMEM alone is relatively high (Long 2006). 
Long et al. (2006) found P25 TiO2 NPs to increase in size approximately 30 minutes 
after sonication when left to reach their steady-state. However, the difference in findings 
between the two studies is that Long et al. (2006) measured aggregate size in reduced-
serum DMEM (1% FBS containing TCM) while particle size in this study was 
measured in medium containing 2% BSA or 15% FBS. Another observation during the 
experiment was that the NPs in medium without BSA settled rapidly and needed 
constant stirring to make the suspension homogenous. This is in agreement with 
previous findings, where NPs in PBS and deionized water (without any FBS or BSA) 
did not mix well with the solutions (Hussain 2005). The BSA and FBS are both proteins 
and when particles are suspended in a medium containing these proteins, they become 
coated with the proteins; particle surface coating alters the NPs surface chemistry by 
altering the charge on the particle (Suzuki 2007). This experiment shows a significant 
difference (p<0.0001) in particle aggregate size in medium with and without BSA 
(figure 6.6). 
182 
Although the TiO2 particle sizes measured in these media were larger than the expected 
size of approximately 23 nm, the general theory is that the smaller/finer the NPs the 
more toxic they are on biological components (Warheit 2007a) since particle maybe 
able to cross the cell’s membrane barrier. However, Warheit et al. provided some 
contradicting evidence to this theory; in that particle toxicity correlates better with 
surface activity rather than with particle size and surface area. Surface activity generally 
refers to the ability of the particle to generate free radicals and cause oxidative stress in 
biological systems (Warheit 2007a). The mechanisms in which NPs behave and 
disperse in media is still not known and there is a need for assessment of the 
toxicological properties of NPs (Hussain 2005). 
 
After suturing the patch onto the diseased heart, TiO2 NPs will eventually be released as 
a result of degradation of the polymer. As mentioned above, in this study the contractile 
effect of the NPs on both the native cardiomyocytes that will be in direct contact with 
the sutured patch and the hESC-CM that will be seeded onto the patch needed 
investigating. Throughout the experiments carried out each biomaterial is immersed in 1 
ml medium in a 24 well plate, weighing approximately 70 mg and containing 0.2 wt % 
TiO2; therefore (0.2/100) x 70 mg = 0.14 mg of TiO2 NPs in each 13mm circular patch 
(If 1 mg/ 1 ml = 1000 ppm). Therefore: 0.14 mg/ 1 ml = 140 ppm TiO2 NPs will be 
released from the patch if the whole patch degrades upon immersion, assuming 
stationary culture conditions. 
 
Because the culture medium was changed every two days in vitro and the biomaterial 
containing TiO2 NPs is a slow degrading material, as it is seen to still be intact after one 
month (30 days) at least (see chapter 4, section 4.2.2), it is possible to conclude that the 
whole of the sample is not degrading between solution changes and in 2 days there 
could only be less than 10 ppm (140/15 = 9.33) of TiO2 NPs released into the solution. 
However, local concentrations at which either the adult cardiomyocyte cells or hESC-
CM will be in contact with the patch may be considerably more. For this reason, a 
minimum and maximum concentration of 10 and 100 ppm, respectively, on cell 
contraction was investigated.  
 
Since adult rat myocyte contraction needs to be stimulated by external electrical pacing, 
the effect of the NPs on spontaneous beating rate cannot be determined. However, the 
effect of the NPs on the strength of contraction (% shortening), time to peak (TTP) and 
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time to 50% (R50) and 90% (R90) relaxation was measured. Results obtained illustrate 
that 10 ppm TiO2 NPs  do not significantly (p > 0.05) affect the % shortening, TTP, R90 
and R50 of adult rat cardiomyocytes in 2 mmol/l Ca2+ levels Krebs-Henseleit solution. 
Figure 6.10 and 6.11 illustrate a sustained response to the NPs throughout the 
experiment.  
 
Further increasing the concentration of the TiO2 NPs to 100 ppm did decrease 
contraction amplitude 20 minutes after exposure to TiO2 NPs (basal: 6.1 ± 0.7% 
shortening to 4.2 ± 2% shortening, n=6) although not significantly ( p > 0.05) (figure 
6.12). However, after TiO2 NP exposure and the wash period a further reduction was 
noticed, suggesting that there maybe a delayed toxic effect on the myocyte contraction. 
Contraction amplitude decreased significantly (p < 0.05) from 6.130 ± 0.73% 
shortening at the basal to 2.82 ± 1.76 % shortening during the wash period. In the 
present study there was a slight but not significant depressant effect on R50 and R90 
due to 100 ppm TiO2 NPs throughout the experiment. Adult myocytes TTP saw a non-
significant (p > 0.05) reduction in the TTP post TiO2 NP inoculation which was not 
reversed during the washout period (figure 6.13).   
 
Contraction measurement showed only the short-term effect of particles on the cardiac 
functionality as the experiment for each myocyte lasts no longer than 2 hours. It must be 
pointed out that even if there is no immediate effect on the contractile properties of the 
cells, this does not mean that there is no toxic effect of NPs on cells, but merely an 
indication that there is no instant effect and that a long-term investigation is necessary. 
Due to the common inability of adult rat myocytes to remain stable in culture longer 
than approximately 48 hours, because they rapidly dedifferentiate and lose their 
essential characteristics, they were cultured in TiO2 NPs at concentrations in the range 
0-150 ppm for a maximum of 24 hours (figure 6.14). It can be seen that culturing the 
myocytes with NPs did not significantly increase LDH release from the cells when 
compared to the cells cultured without NPs, indicating cell death was not affected by 
TiO2 NPs.  
 
Adult myocyte contraction is usually carried out by tracking the borders of a well 
defined cell. This however is virtually impossible with hESC-CM beating clusters as 
they lack well defined edges, but by altering the lighting on the amorphous clusters, 
high-contrast points could be used as tracking points. During the experiment it was 
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noticed that some of the NPs had a tendency to settle on the cell instead of washing over 
the cell. This made it difficult to measure the effect of 100 ppm TiO2 NPs. Therefore the 
effect of only 10 ppm TiO2 on hESC-CM % shortening, TTP, R50 and R90 is 
documented. In general, there was no significant effect of 10 ppm TiO2 NPs on hESC-
CM contraction (figure 6.15 and 6.16). Although TTP, R50 and R90 increased during 
NP testing, this effect was reversed during the wash out period (figure 6.16).  
 
Unlike adult myocytes, hESC-CMs were not externally paced and measurements were 
made during spontaneous contractions and therefore beating rate was investigated. 
During the course of the contraction experiment the beating rate was seen to decrease, 
and this was continued during the washout period (65 ± 14 b.p.m during basal, 55 ± 20 
b.p.m during 10 ppm TiO2 NPs, 48 ± 19 b.p.m during washout) (figure 6.18b). This 
result was further confirmed when hESC-CMs were cultured in 10 ppm TiO2 NPs for 
24 hours, without solution changes between measurements. Cells without any TiO2 NPs 
showed a sustained beating rate while beating hESC-CMs clusters showed a decreased 
rate in response to the particles, with a significant (p < 0.05) difference after 4 hours and 
an even greater reduction in beats per minute after 24 hours (initially =  137.2 b.p.m  
and at 24 hours = 78.4 b.p.m, p < 0.01, n = 6) (figure 6.18a). Figure S7 shows beating of 
a hESC-CM cluster on TCP without TiO2 NPs and figure S8 shows that hESC-CM 
clusters also on TCP continued beating for 4 hours after culturing with 10 ppm TiO2 
NPs (see movies in supplementary CD). 
 
Vascularization is an important factor for myocardial regeneration, therefore the effect 
of TiO2 NPs on cell proliferation and cell death up to six days was investigated to study 
the initial effect of nanoparticles on cell viability, using SNL fibroblast cell line. The 
morphology of the cells at days 2, 4 and 6 was also examined using a light microscope. 
It is possible that it may take longer than the investigated 6 days for cells to penetrate 
through the cell membrane and this requires further investigation. 
 
Figure 6.20 a)-c) shows the general morphology of control cells cultured without any 
TiO2 NPs. On day 2 it can be seen that cells are sparsely distributed and become more 
confluent on days 4 and 6. When observing tissue culture medium containing NPs under 
a light microscope, the NPs appear to exhibit a dark reddish or blackish color. At the 
low dose of 1 ppm TiO2 NPs, cells seem to be similar to that of the control with little or 
no evidence of the NPs (figure 6.20 d)-f)). It is evident from the micrographs that cells 
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were able to proliferate when cultured with 1ppm TiO2 NPs similar to the control cells, 
which is further confirmed using the AlamarBlue assay where no difference is cell 
number was found (figure 6.18). However, increasing the dose of TiO2 NPs to 5 ppm 
(figure 6.21 a)-c)) the cells showed similar morphology to that of the control cells but 
appeared to be less confluent on days 4 and 6 compared to the cells with 0 and 1 ppm, 
this is confirmed with AlamarBlue assay (figure 6.18, p < 0.01). Furthermore, there 
appears to be some brown color particles, which seem to have been taken up by the cells 
through their membranes.  
 
Increasing the TiO2 NPs dose to 10 ppm cells seemed to be more sparsely distributed 
and more brownish particles were seen to be taken up by the cells. They have also 
proliferated significantly less (p <0.001) than the cells cultured in 0, 1 and 5 ppm and 
become more irregular in shape with larger nuclei on days 4 and 6 (figure 6.21 d)-f)). 
This result is in agreement with previous findings, where fibroblasts cultured in 6 ppm 
and above saw a significant decrease in cell viability in comparison with the control 
group of cells that were not cultured in TiO2 NPs (Jin et al. 2008). Fibroblasts cultured 
at higher doses of 50, 100 and 150 ppm seemed to have taken up NPs into their 
membranes. The micrographs (figures 6.22 and 6.23) show a decrease in cell population, 
this is confirmed with the alamarBlue® assay (p < 0.001) as well as LDH leakage from 
cell membranes, shown in figures 6.18 and 6.19, respectively. It can be seen that cells 
proliferated linearly with 1 and 5 ppm TiO2 NPs. It is evident from the micrographs that 
the cells internalize some of the particles in a dose dependent manner. However, the 
mechanism by which NPs enter the cell is still unknown. NPs are likely to have an 
effect on cellular function, this can be seen in the amount of LDH leakage from the cells 
into the culture medium, for more detail on cellular structure, TEM would be required 
to ensure that the TiO2 NPs were in fact engulfed by the cell membrane or to confirm 
that these NPs were simply settling on the monolayer of fibroblasts. From figure 6.19 
there seems to be an increase in LDH release into the culture medium with increasing 
cell number. On days 2 and 4 cells cultured with 10-150 ppm TiO2 NPs were seen to 
have a higher amount of LDH in the culture medium relative to their respective cell 
numbers compared to the control cells and the cells that were cultured in 1 and 5 ppm 
TiO2 NPs. Moreover, a sharp increase in LDH released from control cells and from cells 
that were cultured in 1 and 5 ppm TiO2 NPs on day 6 was observed, although cell 
number continued to increase. However, for cells cultured in 10-150 ppm TiO2 NPs 
concentration, there was less amount of LDH released into the culture medium 
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correlating to the lower yield in cell numbers, indicating TiO2 NPs could induce cell 
death, either by apoptosis or necrosis. 
 
6.4 Closing remarks 
 
To study the effect of TiO2 NPs on human health, one needs to ensure that the NPs 
remain in their nano size range, because although commercial TiO2 NPs are generally 
less than 50 nm in size (23 nm according to the manufacturer), TiO2 NPs are known to 
have low solubility and therefore agglomerate or precipitate in solution, making it 
difficult to assess the true nanotoxicological impact of TiO2 NPs. However, studies have 
shown that 0.5 and 1 µm particles are able to penetrate through the human skin (Tinkle 
et al. 2003). More relevant to this investigation, since the NPs already agglomerate 
within the cardiac patch during polymer processing (Piegat et al. 2008), the particles 
will be released as agglomerates (not as single NPs) whilst the constructs degrades in 
vivo. Since the biomaterial (PET/DLA) is a slow degrading polymer not all the NPs will 
be released simultaneously. Results show that there is some potential for harm of cells 
by TiO2 NPs which could be released by biodegradable polymers used for cardiac 
patches upon in vivo applications. Depression of contraction was observed for both 
hESC-CM and adult myocytes, although only at extremely high concentrations in the 
latter case. Fibroblast numbers were reduced, which could potentially inhibit scar 
formation if the patch were to be applied just after the infarction.  After a week the scar 
will be stable, and less vulnerable to this effect.  However, the prevention of excess 
fibroblast proliferation is potentially beneficial for inhibition of adhesion formation 
(Laflamme et al. 2005).  Overall, it will be important to tailor the TiO2 NP level and the 
biodegradation rate to retain the desirable characteristics given by TiO2 NPs to the 
polymeric patch in terms of mechanical strength and hESC-CM adhesion, while 
controlling NP release to levels below those shown to have negative effects in the 
present study. 
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7 Advanced patch design and ex vivo and in vivo 
investigations of PET/DLA biomaterials 
 
7.1 Background 
This chapter presents results from two different investigations that took place towards 
the end of the project, i) advanced patch design and ii) in vivo investigations. The 
advanced design of the heart patch includes the tailoring of the surface roughness of the 
patch. Additional surface topographical changes could be introduced for two reason; 
firstly to try and mimic the topography of the ECM (see section 2.2.4) and secondly to 
introduce controlled surface topography that ESC-CMs reportedly prefer to interact 
with (McDevitt et al. 2002). Furthermore, the chemical composition of the polymer was 
also altered. Since some MTE scaffolds are aimed to solely act as delivery vehicles with 
no intention to prevent LV remodeling that occurs post MI, there is no need for slow 
degrading biomaterials like the investigated PET/DLA polymers. Therefore the 
incorporation of DLLA (as a third segment) to the PET/DLA polymer was sought to 
increase the degradation rate of the polymer. The results are reported and discussed in 
section 7.2.   
 
After thorough material characterization and in vitro investigation, the biomaterials 
were ready to be investigated ex vivo and in vivo, these experiments were carried out by 
Dr. Hikaru Ishii (NHLI, Imperial College London). PET/DLA and PET/DLA-
0.2wt%TiO2 patches were sutured onto rat hearts ex vivo using a Langendorff apparatus 
set up, after thorough ex vivo investigations, patches were then sutured onto healthy rat 
hearts. Some of the findings (unpublished data) kindly provided by Dr. Hikaru Ishii are 
shown and discussed in section 7.3, for completeness of the present research project.  
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7.2 PET/DLA-modified with lactide soft segment biomaterial and 
topographical changes 
7.2.1 Introduction 
The main hard/soft segment of the newly developed thermoplastic PET/DLA-modified 
with lactide soft segment biomaterial also comprised, similar to PET/DLA, of a 30 wt% 
soft and 70 wt% hard segment ratio. The main difference of this material to PET/DLA 
biomaterial is that the soft DLA segment weight percentage is 80% DLA and 20% 
lactide part (i.e. the biomaterial comprised 30% PET, 54% DLA and 14% lactide part). 
Details on the fabrication of this biomaterial can be found in chapter 3, section 3.4.2. 
Figure 7.1 show the chemical structure of the PET/DLA modified with lactide segment 
biomaterial. 
 
The advantage of thermoplastic block co-polymers is the ability to tailor the segment 
ratio to meet the requirements needed for the intended application e.g. to provoke a 
given degradation behaviour (see chapter 2, section 2.5). The aim of developing this 
new biomaterial was to increase the degradation rate for cardiac patches intended to be 
solely used for delivering cells to the myocardium with no intention for preventing LV 
remodeling. Moreover, a further modification was carried out, the developed patches 
were subjected to topographical surface changes at the micron level, this was carried out 
in collaboration with colleagues at the university of Twente (The Netherlands) using a 
Phase Separation Micromoulding (PSµM) method (Papenburg 2007). Details on the 
fabrication method and parameters are documented in chapter 3, section 3.5. In this 
section the main results obtained are shown and discussed in section 7.2.2, followed by 
a discussion of the results in section 7.2.3.  
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Figure 7.1 Schematic chemical structure of the PET/DLA-modified with lactide 
segment biomaterial. The lactide unit is reacted with Priplast (a polyester polyols 
derived from DFA). 
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7.2.2 Results 
7.2.2.1 Chemical bonding (IR)  
 
IR spectroscopy was carried out to analyze the chemical structure of the biomaterials. 
Figure 7.2 illustrates FT-IR spectra for PET/DLA and PET/DLA-modified lactide 
biomaterials, it is evident that there is only one significant difference between the two 
polymers; a new peak at 3406 cm-1 is observed in the new polymer, which describes –
OH groups at the end of polymer chains, as well as from hydroxyl groups in lactic acid 
and Priplast molecules. 
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Figure 7.2 IR spectroscopy for PET/DLA and PET/DLA biomaterial modified with 
lactide segment.  
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7.2.2.2 Surface characterization of PET/DLA biomaterial modified with lactide 
segment by surface topographical changes 
 
SEM images obtained for PET/DLA biomaterials modified with lactide segment that 
have undergone surface treatment by PSµM are shown in figures 7.3 (a-c). Figure 7.3 
shows an ordered topography on the biomaterials consisting of 20 µm wide channels 
with ridges of 30 µm and 25 µm width and height, respectively.  
 
   
 
 
 
Figure 7.3 SEM micrographs of PET/DLA-modified with lactide segment biomaterial 
that has undergone surface treatment by PSµM: a) air-side of biomaterial, b) substrate 
side,  c) side view of the biomaterial, the inset is an image at a lower magnification 
(scale bar 100 µm) (20 µm wide channels, ridges 30 µm in height and 25 µm in width) 
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7.2.2.3 Cell proliferation and LDH leakage 
 
SNL fibroblasts were seeded onto the PET/DLA-modified lactide segment biomaterials, 
with and without 0.5% gelatin coating. Figures 7.4 and 7.5 are SEM images showing 
SNL fibroblasts attached on the biomaterial. Cell proliferation (%) was assessed using 
alamarBlue assay (figure (7.6) and the amount of LDH leakage from the cells was used 
as an indication of cell death (figure 7.7).  
 
     
 
 
 
 
Figure 7.4 SEM micrographs of SNL fibroblasts cultured on PET/DLA-lactide 
biomaterials with topographical changes induced by PSµM, with no gelatin coating. 
Images taken 6 days after culturing: a) scale bar 800 µm, b) scale bar 100 µm and c) 
scale bar 40 µm.  
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Figure 7.5 SEM micrographs of SNL fibroblasts cultured on PET/DLA-lactide 
biomaterial with topographical changes induced by PSµM, with 0.5% gelatin coating. 
Images taken 6 days after cell seeding: a) scale bar 800 µm, b) scale bar 100 µm and c) 
scale bar 40 µm. 
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Figure 7.6 SNL fibroblast proliferation on gelatinized and non-gelatinized PET/DLA-
lactide biomaterials and plastic (TCP) at days 2, 4 and 6. Cell proliferation was assessed 
using alamarBlue assay kit, n=5 (days 4:**p < 0.01 non-gelatinized plastic vs. non-
gelatinized biomaterial, ***p < 0.001 gelatinized plastic vs. non-gelatinized biomaterial, 
p < 0.001 gelatinized plastic vs. gelatinized biomaterial and day 6: ***p < 0.001 
gelatinized plastic vs. non-gelatinized plastic). 
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Figure 7.7 LDH release by cells cultured on gelatinized and non-gelatinized plastic 
(TCP) and biomaterials (PET/DLA-modified with lactide segment) on days 2, 4 and 6, 
n=3 (day 6: ***p < 0.001 gelatinized plastic vs. non-gelatinized biomaterial, **p < 0.01 
gelatinized plastic vs. gelatinized biomaterial, *p < 0.05 gelatinized plastic vs. non-
gelatinized plastic).  
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7.2.2.4 Biomaterial degradation 
 
The graphs in this section compare the degradation of PET/DLA and PET/DLA-
modified with lactide segment, in terms of weight loss (%) and water absorption (%) 
(figure 7.8). Biomaterial degradation was assessed under two conditions, upon 
immersion in PBS and with SNL fibroblasts cultured in TCM. 
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Figure 7.8 Weight loss and water absorption graphs comparing PET/DLA and 
PET/DLA-modified with lactide segment cultured in PBS or with cells in TCM: a) 
weight loss of biomaterials cultured in PBS, b) weight loss of biomaterials cultured with 
cells in TCM, c) water absorption of biomaterials cultured in PBS, d) water absorption 
of biomaterials cultured with cells in TCM (* p < 0.5, ** p < 0.01, *** p < 0.001 
PET/DLA vs. PET/DLA-modified with lactide segment) 
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7.2.3 Discussion 
 
Results from IR spectroscopy showed that the chemical structure of the polymer is, as 
expected, altered upon the addition of the lactide segment due to an increase in –OH 
groups from the addition of the Priplast polyester, hence the detection of the extra –OH 
peak at 3406 cm-1. An ordered topography was achieved using the PSµM procedure, 
however the effect of this topography on ESC-CM (in terms of their maturation for 
example) needs further investigation. It is possible to speculate that this topography will 
encourage the cells to align within the ridges of the channels, elongate and eventually 
mature. SEM images show cells to adhere onto the substrate with and without gelatin 
coating (figures 7.4 and 7.5). However, it is evident from the micrographs that SNL 
fibroblasts also adhere onto the ridges of the patterned biomaterials with the addition of 
the gelatin coating (figure 7.5), where this is absent in figure 7.4 as no cells were 
visualized on the ridges of the polymer. However, no significant difference (p > 0.05) in 
cell proliferation (%) was detected using the alamarBlue assay (figure 7.6). Moreover, 
there was no increase in LDH levels for the cells cultured onto the biomaterials, 
compared to the cells cultured on the plastic, as seen in figure 7.7). Biodegradation tests 
showed that the addition of the lactide segment did increase the degradation rate of the 
polymer, this is evident from figure 7.8 where the weight loss (%) was significantly 
higher for the PET/DLA-modified with lactide segment compared to the neat PET/DLA 
polymer. The fact that the biomaterials are seen to degrade faster, will enable this newly 
developed biomaterial to serve as a MTE scaffold where there is no need for long term 
LV support.  
 
The work presented in this section is still at infancy and requires further investigation. 
The biomaterial needs to be characterized more extensively, for example the mechanical 
properties, water contact angle (indication of hydrophobic properties) and further 
surface analysis are key requirements. The mechanism in which the biomaterial 
degrades also needs to be investigated as well as the deterioration of mechanical 
strength of the biomaterial as it degrades needs thorough investigations. Furthermore, 
there is a need to investigate the effect of the induced topographical changes on ESC-
CMs, in terms of functional activity and maturation. This is further discussed in chapter 
8 (further work).  
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7.3 Ex-vivo and in vivo work (Dr. Hikaru Ishii, NHLI, Imperial 
College London) 
7.3.1 Introduction 
 
After extensive in vitro characterization of the PET/DLA biomaterials (described in 
chapters 4 and 5), the PET/DLA and PET/DLA-0.2wt%TiO2 patches were sutured onto 
normal isolated hearts by Dr. Hikaru Ishii (NHLI, Imperial College London). Since 
these are normal hearts, there can be no rescue from failure, so these experiments are 
designed only to test whether the patch itself has any deleterious effects on the heart. To 
study the effect of biomaterial patches on cardiac contractile function (e.g. left 
ventricular systolic and diastolic pressures as well as pressure-volume relationships) the 
Langendorff constant pressure heart perfusion system was used for ex-vivo analysis, 
figure 7.9 is a schematic illustration of the Langendorff setup. Briefly, this apparatus 
consists of a reservoir, gas distributor, perfusion cannula, heart chamber and pacemaker. 
All parts of the system are water-jacketed with water at 37°C to ensure heart remains at 
body temperature. Intraventricular pressure was then measured using a hand made 
balloon (made of polyvinyl plastic transparent film) inserted into the left ventricle. The 
main reason for using a Langendorff setup before carrying out in vivo work is that the 
data can be acquired quickly, in large numbers and at a relatively low cost in 
comparison to in vivo experiment.  It is also important from an animal welfare 
perspective, as it enables us to ensure the measure will not produce unnecessary 
suffering because of compromise of heart function when transferred to the in vivo 
setting. Following thorough ex vivo investigation, the patches were then transplanted 
into healthy rat heart for in vivo study for a period of two weeks. 
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Figure 7.9 Schematic diagram of a Langendorff apparatus setup. Adapted from 
(Sutherland & Hearse 2000) 
7.3.2 Results 
Ex-vivo and in vivo results showed the biomaterial patches (PET/DLA, with and without 
TiO2 NPs) to have no significant effect on cardiac function of healthy rat hearts (figure 
7.10). This is a positive results showing that TiO2 NPs do no affect healthy rat hearts 
contractile functions. Figure 7.11 shows PET/DLA-0.2wt%TiO2 patch intact two weeks 
after patch transplantation. 
 
 
 
 
 
 
Figure 7.10 Graphs illustrating the change in pressure ex vivo  (using the Langendorff 
apparatus): a) control group heart (with a biomaterial sutured onto it), b) PET/DLA-
0.2wt%TiO2 sutured on rat heart ( p > 0.05 n=5) (unpublished data, kindly provided by 
Dr. Ishii). 
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Figure 7.11 A picture taken two weeks after a PET/DLA-0.2wt%TiO2 patch was 
sutured on a healthy rat’s heart (experiment carried out by Dr. Ishii (image kindly 
provided by Dr. Ishii). 
7.3.3 Discussion 
In further investigations PET/DLA and PET/DLA-0.2wt% TiO2 patches have been 
stitched onto healthy rat hearts in vivo (Sprague Dawley rats (Harlan, UK)) (figure 7.11) 
to investigate the effect of these patches on cardiac functionality two weeks after 
implantation (work carried out by Dr. Ishii, NHLI). To date, results (unpublished data) 
show no significant effect due to patch transplantation on cardiac function, indicating 
that the patch properties are benign.  However, the PET/DLA patches did tear in five 
out of the six animals, whereas the PET/DLA-0.2wt%TiO2 patches were always found 
to be intact.  This is likely due to the increase in tensile strength of the biomaterials 
upon addition of the TiO2 NPs (as discussed in chapter 4). Furthermore, an increase in 
fibroblastic vascularization on the TiO2 containing PET/DLA patches was observed 
(communication by Dr Ishii) this was expected since in vitro SNL proliferation tests did 
show an increase in cell proliferation on the TiO2 NP containing biomaterials compared 
to the neat PET/DLA (as reported in chapter 5). Although vascularization is required for 
cell integration of TE construct (Rouwkema, Rivron, & van Blitterswijk 2008), it has 
been found that the resulting adhesions made removing the heart difficult 
(communication by Dr Ishii), as the patches had a tendency to stick to the chest wall.  
The surgeon therefore suggested the use of a Seprafilm, made from hyaluronate 
carboxymethylcellulose to act as an adhesion barrier. In conclusion it was reported that 
PET/DLA-0.2wt% TiO2 NP patches have no effect on healthy rat hearts, they are easier 
to handle as the patches did not tear during surgery and they are relatively more stable 
in vivo compared to the neat PET/DLA. 
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8 Conclusions and further work 
 
8.1 Conclusions 
 
Two novel biomaterials, namely PET/DLA elastomer and nanostructured PET/DLA-
0.2wt%TiO2 NP elastomeric composite have been fabricated for intended use in MTE 
for the development of myocardial patches and combined with ESCs for myocardial 
regeneration.  
 
Addition of 0.2wt% TiO2 NPs proved successful in terms of improvement of the 
polymer mechanical properties. Results obtained from the extensive biomaterials 
characterization showed the addition of as little as 0.2wt% TiO2 NPs had important 
effects on the biomaterials properties. Significant changes observed on the surface of 
the PET/DLA-0.2wt%TiO2 NP biomaterials proved to encourage ESC-CM and 
fibroblastic cellular adhesion in the absence of gelatin coating. This is an important 
factor since no additional xenogenic products are required to encourage 
biocompatibility in terms of cellular adhesion. The cells (hESC-CMs and fibroblasts) 
appeared to adhere and spread on the PET/DLA-0.2wt%TiO2 biomaterials in a similar 
way as that on gelatinized glass coverslips, suggesting that the presence of TiO2 did not 
cause adverse effects on the cells. Cell proliferation was always greater (with and 
without gelatin coating) in number for fibroblasts cultured on PET/DLA-0.2wt%TiO2 
compared to proliferation on neat PET/DLA and the commercially available PEE, 
possibly due to the increase in surface roughness of the PET/DLA-0.2wt%TiO2 
biomaterial. This is an important finding since vascularization aids myocardial 
regeneration. Cell death (indicated by LDH levels) was significantly less in PET/DLA-
0.2wt% TiO2 biomaterials compared to PET/DLA and PEE. The addition of TiO2 NP 
also improved the hydrophilic properties of the PET/DLA block copolymer, ideal for 
cellular adhesion.  
 
More importantly, the adherence and functional activity of microdissected hESC-CM 
clusters cultured on these biomaterials for prolonged periods was not affected since the 
beating rate after two months was within the range normally demonstrated by clusters of 
that age kept on tissue culture plastic as the cells did not detach from the surface. 
Furthermore, functional activity (in terms of b.p.m) of smaller microdissected hESC-
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CM clusters was not different from that on plastic, hESC-CMs appeared to contract in 
synchrony. 
 
Impressive improvement in tensile strength and elastic modulus of the PET/DLA 
biopolymer was achieved upon the addition of TiO2 NPs, so far thought to be 
advantageous for several reasons. Firstly, the increase in tensile strength prevented the 
patch from tearing after being sutured onto the rat heart in vivo. It is essential the patch 
remains intact until cells have fully integrated with the host myocardium so as not to 
disrupt myocardial regeneration. Secondly, the increase in elastic modulus enabled the 
patch to accommodate each heart beat without causing complications, such as 
arrhythmia, to the hearts contractile functions. Since the surgeon found it easier to 
handle the stiffer patch without problems occurring during suturing the addition of TiO2 
NPs offers a further advantage. However, it is worth mentioning that whilst poking the 
needle through the PET/DLA patch, no tearing was observed. The problem with the 
PET/DLA tearing was observed two weeks post implantation. Since the intention of the 
myocardial patch, in this investigation, is to deliver cells to the injured heart as well as 
prevent left ventricular remodelling its slow biodegradation rate is beneficial for this 
application.     
 
Although the addition of TiO2 NPs into the patch had no adverse effect on hESC-CMs 
cultured onto the biomaterials, it was also important to test the possible toxic effect of 
TiO2 NPs directly on the hESC-CMs functional activity since TiO2 NPs will eventually 
be released upon degradation of the polymer matrix. The effect of TiO2 NPs on the host 
myocardium also needed investigation as these particles will be released close to the 
injured heart. Results from this investigation found no significant effect of TiO2 NPs on 
cardiac functionality at various concentrations (<100 ppm).  
 
Results from this investigation suggest that PET/DLA and especially PET/DLA-0.2wt% 
TiO2 biomaterials are promising for delivering ESC-CM to the injured heart to aid 
myocardial regeneration and prevent left ventricular remodeling. After thorough 
investigations, these biomaterials are suitable to progress to the next stage of testing in 
in vivo animal models with induced infarcts.  
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8.2 Further work 
In this section suggestions for further work are listed.  
 
Although PET/DLA and PET/DLA-0.2wt%TiO2 biomaterials have been characterized 
thoroughly, there is a need for long-term degradation (over one year) testing to know 
precisely the time it takes for these biomaterials to fully disintegrate in relevant 
conditions for their application as cardiac patches. 
 
Currently in vivo experiments where the patches have been sutured onto the 
biomaterials have only been carried out on healthy rat hearts. The effect of these patches 
on infarcted hearts needs thorough investigation. 
 
The new polymer developed (PET/DLA-modified with lactide segment) towards the 
end of the project needs further characterization, for example in terms of the 
biomaterials mechanical properties, wettability, long-term degradation and 
cardiomyocyte compatibility for a more comprehensive understanding of the new 
polymer developed and eventually take this biopolymer to in vivo trials. 
 
The effect of surface topography on ESC-CM maturation and functional activity needs 
to be investigated; other dimensions and methods for introducing topographical changes 
onto the biomaterial surface should also be investigated to better understand the 
implication of topography on ESC-CM maturity. 
 
It is essential to increase the yield of ESC-CMs, while many groups are working 
towards this; there is also the need to know the effective cell dose for myocardial 
regeneration.   
 
Further investigation is required regarding the number of cell types that need to be 
introduced into an infarcted region to understand whether cardiomyocytes alone are 
sufficient or other cell types, such as fibroblast, are required to enhance vascularization. 
 
Finally, addition of the functionalities to the base PET/DLA and PET/DLA-0.2wt% 
TiO2 biomaterials, for example an electric conductivity function should be considered in 
advanced design of the cardiac patches. 
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Appendix 
Reagents and consumables for cultures 
 
All tissue culture materials were obtained from Gibco/Invitrogen (Paisley, Scotland 
UK) unless stated otherwise.  
• Dulbecco’s modified Eagle’s medium (DMEM, 11995-065)    
• Dulbecco’s modified Eagle’s medium with GlutaMax® (DMEM + GlutaMax®, 
31966021) 
• Knock-Out Dulbecco’s modified Eagle’s medium (KO-DMEM, 10829018) 
• Mouse embryonic fibroblast (MEF)-conditioned medium (CM) (MEF-CM) 
(made in house) 
• M199 Dulbecco’s modified Eagle’s medium (M199-DMEM 12350039) 
• Heat inactivated fetal bovine serum (HI-FBS; batch tested) (for mESC-CM 
differentiation) 
• FBS non-heat inactivated (for hESC differentiation) (10106-169) 
• Knock-Out Serum Replacement (KOSR) (10828-028) 
• Phosphate Buffered Saline (PBS) PBS++ (with Ca2+and Mg2+) and PBS-- (without 
Ca2- and Mg2-) (14190-094) 
• Non-Essential Amino Acid (NEAA) (11140-035) 10 mM (100x concentration 
stock) 
• Penicilline/Streptomycin (P/S) (15140-122) stock =10,000U of Pen/10,000µg of 
Strep per mL (diluted 1:100 or 0.5:100 in culture media supplemented by FBS 
and KOSR, respectively (final concentration of antibiotics in media with FBS: 
100U pen/100 µg strep per mL; in media with KOSR: 50U pen/50 µg strep per 
mL)  
• L-glutamine (L/G) (25030-024) 200mM stock: diluted 1:100 in culture media 
(final concentration: 2mM.) 
• Beta-mercaptoethanol (βME) (Sigma-Aldridge; www.sigmaaldrich.com, M7522) 
(14.3M stock: diluted 1:10 in PBS (working stock) which was stored in 40uL 
aliquots at -20°C. 35µL was added to 500mL culture media (final 
concentration:0.1mM) 
• Leukemia inhibitory factor (LIF) (I3769-50UG) 106 U/mL Stock. Diluted 1:1000 
in culture medium (final concentration: 1000U/mL)  
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• Recombinant human basic fibroblast growth factor (rhbFGF) (13256-029) 
(prepared as 10µg/mL Stock solution in 0.1% BSA/PBS--, sterilized through 
200µ low-protein-binding filter pre-wetted with 10% BSA; stored at 4°C up to a 
month; at -20°C (for 6 months) or at -80°C (for > 6months). Used at a final 
concentration of 4ng/mL (during daily collection of MEF-CM) or 8ng/mL during 
daily feeding of H7 cells 
• Mitomysin C (MITOC) 2mg stock (www.sigmaaldrich.com, M4287). 10X 
concentrated stock was prepared by dissolving 2mg in 2mL PBS-- and the volume 
was increased to 20mL with culture medium (used for mitotically inactivation of 
feeder cells)  
• Trypsin/EDTA (T/E) (www.sigmaaldrich.com, T4299) 1 ×, 500 BAEE units 
porcine trypsin and 180 µg EDTA, 4Na per ml in Dulbecco's PBS--, sterile-
filtered, cell culture tested   
• Blendzyme (www.roche-applied-science.com, 11988468001, Roche, Germany) 
• Gelatin (www.sigmaaldrich.com, G1393) (stock 2%). Diluted in PBS 1:20 for 
coating surfaces at 0.1% (for adhering mouse feeder cells, MEFs, mESCs and 
mESC-CM) or 1:5 for coating surfaces at 0.5% (for adhering hESC-CM) 
• Matrigel, growth factor reduced (Marathon Laboratory Supplies, London, UK, 
354230). Obtained as a 10mL frozen solution. Thawed overnight at 4°C. Diluted 
1:1 in cold KO DMEM and 1mL aliquots were kept frozen at -20°C. Each aliquot 
was thawed out overnight at 4°C and the volume was further diluted to 15mL on 
ice with cold KO DMEM (working Matrigel solution). Each well of a 6-well plate 
was coated with 1mL of this solution. 
• Collagenase IV (17104-019) (final concentration 200 units/ ml) 
• Basic fibroblast growth factor (bFGF) (13256-029) (stock concentration 10ng/ml, 
final concentration 8ng/ml) 
• Cell culture flasks (T25, T75 and T225) (Fisher Scientific UK, Loughborough, 
UK) 
• 10 mm glass-bottomed 35 mm dishes (MatTek Corp., Ashland, MA, USA) 
• Pipetters (Fisher Scientific UK, Loughborough, UK) 
• Pipette tips and pipettes (from 10 µl – 50ml) (Fisher Scientific UK, 
Loughborough, UK) 
• 15ml and 50ml centrifuge tubes (Fisher Scientific UK, Loughborough, UK) 
• Ascorbic acid (www.sigmaaldrich.com, G002722) 
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• Creatine (www.sigmaaldrich.com, C3630)  
• Taurine (www.sigmaaldrich.com, T0625-1KG) 
• Carnitine (www.sigmaaldrich.com, C0158) 
• Bovine serum albumin (BSA) (www.sigmaaldrich.com, A6003-100G) 
• Insulin (www.sigmaaldrich.com, I9278) (stock concentration 10mg/ml) 
• Sodium Chlordie (NaCl) (www.vwrsp.com, 102414J)  
• Potassium chloride (KCl) (www.vwrsp.com, 101984L) 
• Magnesium sulphate (MgSO47H2O) (www.vwrsp.com, 25165.260) 
• Potassium dihydrogen orthophosphate (KH2PO4) (www.vwrsp.com, 102034B) 
• Sodium hydrogen carbonate (NaHCO3) (www.vwrsp.com, 102475W) 
• Glucose (www.vwrsp.com, 101174Y) 
• Calcium chloride (CaCl2) solution (VWR/Merck, 19046 4K) (stock concentration 
of 1M solution). 
• Deionised ‘Milli Q’ water  
• Krebs Henseleit Buffer: Made as 10X and stored at 4°C. Diluted on the day of use 
and supplemented by CaCl2 solution (1mM for mESC-CM; 2mM for hESC-CM; 
4mM for adult ventricular myocytes 
 
